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Abstract
It is now known that external stimuli such as hoimones, neurotransmitters, 
growth factors, light and drugs initiate their biological actions by interacting with 
receptor macromolecules which are located in the cell membranes. Many 
transmembrane receptors are coupled to specific effector molecules via G proteins. 
These trimeric 'receptor-G protein-effector’ systems play a primary role in cellular 
signalling.
Molecular cloning techniques have revealed the presence of cDNA species 
encoding many receptor isoforms or splice variants as well as many G protein 
subunits. In this study, cDNA species either the long or the short isoforms of the rat 
TRH receptor were expressed stably in Rat 1 fibroblasts, and clones expressing 
specific binding of [^H]TRH were detected and expanded. Clones expressing each of 
these receptors at levels up to 1 pmol/mg of membrane protein were selected for 
analysis. Reverse transcriptase-PCR on RNA isolated from these clones confirmed 
that each clone expressed the expected splice variant. Both receptor splice variants 
bound [3H]TRH with an approximate Kd of 80 nM.
In the presence of TRH, both receptor subtypes were able to stimulate inositol 
phosphate generation in a pertussis toxin-insensitive manner with similar EC50 
values. However, despite reports that TRH receptors can also interact with the G 
proteins Gg and Gi2, neither receptor splice variant was able to modulate adenylyl 
cyclase activity in either a positive or negative manner. These data indicate that the 
long and short isoforms of the rat TRH receptor have similar affinities for TRH and 
display similar abilities to interact with the Gq-like G proteins, but show no ability to 
regulate adenylyl cyclase in this genetic background.
Although downregulation of signal transducer, G protein a  subunits, is a
well-documented phenomenon the mechanism has been unclear. Maintained 
exposure of Rat 1 fibroblasts transfected to express the molecularly defined « ia/D. 
aiB  , and a ic  adrenergic receptors resulted in a large downregulation of receptors 
and also a marked downregulation of cellular levels of both of the phosphoinositidase 
C-linked G proteins, Gqct and G n «  when exposed to the a i  adrenergic agonist 
phenylephrine.
In order to examine the mechanism of phenylephrine-induced downregulation 
of Gqa and G n a, pulse-chase 35s-amino acid labelling experiments were performed 
with each of the oia /d? «IB , and a ic  adrenergic receptor expressing cell lines. The 
rate of degradation of Gqa and G n a , which was adequately modeled by a 
monoexponential with half-life between 33 and 40h in each of the cell lines in the 
absence of agonist, was accelerated about 4 fold in the presence of phenylephrine. 
Each of the aiA/D, «IB , and a ic  adrenergic receptor expressing cell lines prelabelled 
with myo-[^H]inositol were shown to generate high levels of inositol phosphates 
when exposed to phenylephrine. Additionally, the degree of Gqa and G n a  
downregulation in Rat 1 fibroblasts transfected to express either the wild type 
hamster aiB adrenergic receptor or a constitutively active mutant (CAM) foim of this 
receptor was examined. The sustained presence of phenylephrine resulted in 
substantially greater downregulation in cells expressing the CAMaiB adrenergic 
receptor compared to the wild type at all concentrations of agonist. The enhanced 
capacity of agonist to stimulate second messenger production at the CAMaie 
adrenergic receptor and to regulate cellular levels of its associated G proteins by 
stimulating their rate of degradation is indicative of an enhanced stoichiometry of 
coupling of this form of the receptor to Gqa and G n a.
Treatment of cells expressing the CAMaip adrenergic receptor with a i 
adrenergic antagonists phentolamine, HV-723, corynanthine, YM-12617, 5-methyl 
urapidil and WB4101 resulted in upregulation (2-3 fold in 24h) in levels of this
11
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receptor. Pretreatment of the CAMaiB adrenergic receptor expressing cells with i
'phentolamine caused greater maximal output (about 2 -fold) from the Gqa and G n a  
to the phosphoinositidase C pathway as well as phospholipaseD pathway than the 
untreated cells upon addition of phenylephrine. However, the potency of 
phenylephrine was unchanged. By using this system in which the increased receptor 
levels in response to treatment with phentolamine caused an increase in the basal 
level of phospholipase D activity, screening of potential inverse agonists was 
performed. All of the above named a i  antagonists appeared to be capable of acting as 
inverse agonists at the CAMaip adrenergic receptor.
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Chapter 1. Introduction
Chapter 1. Introduction
1.1. Historical perspectives of cellular signalling
It is now apparent that external stimuli including hormones, neurotransmitters, 
growth factors, light and most drugs initiate their biological actions by interacting with 
receptor macromolecules which are located in the plasma membranes of cells. Many 
transmembrane receptors are coupled to specific effector molecules via intermediary 
coupling guanine nucleotide binding proteins (G proteins) and it is known that these 
trimeric "receptor-G protein-effector" systems play a major role in defining the ability 
of cells to respond to and process information from external stimuli as shown in 
Figure 1.1
Two signalling systems are primarily responsible for the production and 
amplification of intracellular signals resulting from specific extracellular stimuli. These 
are the receptor tyrosine kinases (RTKs) and the G-protein-coupled receptors (GPCRs) 
which will mainly be discussed in this introduction.
Since the first "second messenger" hypothesis for hormone action in cellular 
signalling based on the observation that the actions of adrenaline on canine liver could 
be mimicked by the heat stable factor, cAMP, it has been proposed that adrenaline 
bound to specific cell surface receptors could cause a conformational change in the 
catalytic moiety of adenylyl cyclase resulting in an activation of the enzyme [Rail et a l, 
1957; Sutherland et a l, 1962]. The requirement of GTP in glucagon-mediated 
regulation of adenylyl cyclase [Rodbell eta l, 1971], the effect of GTP in the enhanced 
dissociation of glucagon from its receptor [Rodbell etal., 1971 ; Harwood et a l, 1973] 
and the action of non-hydrolysable analogues of GTP in the activation of adenylyl 
cyclase without any agonist stimulation [Schramm & Rodbell, 1975] suggested that a
Figure 1.1. Schematic diagram for transmembrane signal 
transduction
General signalling pathways for the generation of second 
messengers are shown. Upon stimulation by external stimuli 
(agonist) G protein-coupled receptors are activated and transmit 
the signal to the effector enzymes via G proteins. Gg and Gi 
represent stimulatory and inhibitory Ga subunits which stimulate 
and inhibit adenylyl cyclase activity, respectively. G q/G na 
subunits activate phophoinositidase C (PIC) which hydrolyses 
phosphatidyl-4,5-bisphosphate (PIP2) and generates two second 
messengers, diacyl glycerol (DAG) and inositol-1 ,4,5-trisphosphate 
(IP3). DAG and Ca^+, which is released from an internal Ca^+ 
store, the endoplasmic reticulum (ER), stimulate protein kinase C 
(PKC) which in turn causes many cellular responses including cell 
growth, transformation, secretion, muscle contraction, sensory 
perception, and neuronal signalling.
Figure 1.1.
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guanine nucleotide binding site was invovled in the regulation of adenylyl cyclase and 
the role of ligand-bound receptor was to facilitate the guanine nucleotide mediated 
activation of the enzyme.
The more specific role of GTP in regulating receptor-effector interactions was 
demonstrated by high affinity GTPase activity associated with p-adrenergic stimulation 
of adenylyl cyclase, and GTP hydrolysis appeared to terminate the activation of the 
enzyme [Casel & Selinger, 1976]. Therefore, two states, an active GTP-bound state 
and an inactive GDP-bound state were suggested, and receptor activation was believed 
to cause the exchange of GDP for GTP. The ability to reconstitute this activity in
receptor was coupled to a GDP liganded G protein in the resting state and agonist
membranes of the murine S49 lymphoma mutant, eye, which is deficient in adenylyl 
cyclase activity [Ross etal., 1978] lead to the purification of this element which is 
known as Gg for its stimulatory effect on adenylyl cyclase [Northup etal., 1980].
By the 1980's, it was known that the G protein-mediated receptor signalling 
cascade could be controlled by turning on and off the signal [Gilman, 1984]. The
activation of the receptor caused a conformational change in both proteins leading to the 
exchange of GDP for GTP which promoted dissociation of the G protein from its 
trimeric form into a free active a  and a Py complex. The GTP-bound a  subunit could
then interact with the final executor effector system before its intrinsic GTPase activity
'hydrolysed the GTP to GDP promoting reformation of the holomeric protein and 
reassociation with the receptor causing deactivation of the cascade [Gilman, 1984; 
Gilman, 1987].
Many variants of the three (a , p, and y) subunits of G proteins have been 
identified by the advent of molecular cloning techniques. The functional roles for 
individual G proteins has been revealed, and it is now known that both the GTP- 
binding a  subunit and the py subunit complex are able to influence the activity of 
effector systems including adenylyl cyclase, phosphoinositidase C, phospholipase A2 ,
phospholipase D, various ion channels and MAP Kinase activity independently or 
simultaneously, either synergistically or in opposition [Hepler & Gilman, 1992; 
Clapham & Neer, 1993; Sternweis, 1994; Inglese etal, 1995].
More recently, the studies of crystal stucture of G ila revealed that crystals of 
the GDP-bound G ila monomers were linked, head-to-tail, in endless polymers [Mixon 
e ta l, 1995]. Determination of the crystal structure of transducin [Noel et a l, 1993] 
and of the transducin Py dimer [Sondek etal, 1996] has allowed the mechanism of the 
nucleotide-dependent engagement of the a  and py subunits that regulate their 
interaction with receptor and effector molecules to be understood at the molecular level. 
The interaction involves two distinct interfaces and alters the conformation of the a  
subunits but not of the py subunits. The sites for post-translational modification on 
Gta and Gty combined with the receptor-binding region of Gta suggested a plausible 
orientation with respect to the membrane surface and an activated heptahelical receptor, 
rhodopsin [Lambright et a l , 1996].
1.2. G protein-coupled receptors (GPCRs)
The first step in the transfer of signals from the outside to the inside of the cell 
is the binding of a hormone, neurotransmitter or growth factor to a transmembrane 
receptor on the plasma membrane. The superfamily of G protein-coupled receptors, 
with hundreds of members, is known to recognize a vast array of substances, including 
protein and peptide hormones, nucleotide and amino acid neuromodulators, biogenic 
amine neurotransmitters, lipid autacoids, sugar and alkaloid tastants, volatile organic 
odorants, calcium ions, and photons of visible and ultraviolet light.
The effect of guanine nucleotides on ligand binding to a receptor was first noted 
by Rodbell and coworkers [1971], with the demonstration that the affinity of glucagon 
binding to the plasma membrane of rat liver, was decreased by the presence of guanine
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Table 1.1. G protein-coupled receptors
Numerous hormones and neurotrasmitters are linked to a number of 
interwoven second messenger cascades via various receptor subtypes and G 
proteins. Abbreviations; ACTH, adrenocorticotropin I CRF, corticotropin- 
releasing factor; FSH, follicle stimulating hormone; GHRH, growth hormone 
-releasing hormone; hCG, human chorionic gonadotropin; LH, leuteinizing 
hormone; MSH, melanocyte stimulating hormone; PGE1&2 , prostagladin Ei & 
Ei; PHI2 , prostagladin I2 ; PTH, parathyroid hormone; 5-HT, 5-hydroxy- 
tryptamine; TSH, thyroid stimulating hormone; TRH, thyrotropin-releasing 
hormone; VIP, vasoactive intestinal peptide; CCK, cholecystokinin ; fMLP, 
fMet-Leu-Phe; NAF, nerve-activating factor; GnRH, gonadotropin-releasing 
hormone; IgE, immunoglobulin E; TXA2 , thromboxane A2 ; GAB A, y-amino- 
butyric acid.
* denotes the existence of subtypes of the receptor.
Table 1.1
Effectors Receptors
Adenylyl cyclase stimulation
ACTH LH*Adenosine A2 MSH 
Adrenergic pi, p2 Olfactory* Calcitonin PGEi, PGE2 
CRF PGI2 Dopamine Di PTH*FSH Secretin 
GHRH 5 -HT2 
Glucagon G2 Taste hCG* TSH* Histamine H2 Vasopressin V2VIP
Adenylyl cyclase inhibition
Adenosine A1 Opioid ô, y, p,
Adrenergic (%2A, oc2B PAF Angiotensin II PGEi, PGE2 Bradykinin* Thrombin*Dopamine D2 5-HT ia, 5-HT ib, 5-HT id Histamine H3 Somatostatin 
Muscarinic M2 , M3 Vasopressin V ia
Phospholipase C 
stimulation
a i  adrenergic* Muscarinic Mi, M4 , M5 Angiotensin II Neurokinin B 
Bombesin Oxytocin 
Bradykinin PAF, TXA2 
CCK Purinergic P2Y, P2X fMLP*, NAF 5-HTic, 5 -HT2 Glucagon G% Substance K*
GnRH Substance P* 
Histamine Hi Thrombin 
IgE* Vasopressin V ia , Vib TRH* VIP*
Phospholipase A2 stimulation
« 1  adrenergic* Histamine Hi Bradykinin* Leukotriene C4 , D4 
GnRH
Calcium channel
Opening Closing
Angiotensin II 0 2  adrenergic* 
Pi adrenergic GABAb GnRH Opioid*Somatostatin
Potassium channel
Opening ClosingAdenosine A 1 Muscarinic Mi 
Bradykinin*
Dopamine D2 
GABAb Muscarinic M2 
5-HTia, 5-HTic Somatostatin
6nucleotides. Later, the binding of p-adrenergic agonists but not antagonists were 
shown to be reduced by the presence of the GTP analogue, Gpp[NH]p [Maguire etaL,
1976]. Further studies on p-adrenergic receptors revealed that competition curves for 
antagonist versus radiolabelled antagonist had pseudo Hill coefficients close to 1 , 
competition curves for agonist versus radiolabelled antagonist were shallower with 
pseudo Hill coefficients less than 1 [De Lean etal., 1980]. These data suggested the 
existence of two affinity states for agonist. A low affinity state of receptor for agonist 
was seen in the presence of guanine nucleotides, whereas the receptor adopted a higher 
affinity for agonist when guanine nucleotides were absent.
In an attempt to account for the effects of guanine nucleotides on the ligand 
binding a ternary complex model was proposed. In the unstimulated state the inactive a  
subunit, coupled to py subunit, may interact with the receptor (R), leading to the 
agonist (H) promoted formation of a high affinity ternary complex (H>R>G protein). 
In the presence of guanine nucleotides which activate the a  subunit, the ternary 
complex is destabilized and both agonist and a  subunit can dissociate from the 
receptor.
A large number of individual G protein-coupled receptors (GPCRs) have now 
been cloned and sequenced, and the structure and function of these receptors has been 
the subject of much research in recent years. GPCRs have been subdivided into several 
classes including those for dopaminergic [Vallai’ and Meldolesi, 1989], muscarinic 
cholinergic [Birdsali & Hulme, 1983], serotonergic [Schmidt and Peroutka, 1989],
adrenergic [Gilman, 1987] and olfactory [Jones & Reed, 1987] receptors according to 
their ligands which are capable of activating several effector systems as shown in 
Table 1.1.
These GPCRs have in common a putative seven transmembrane spanning 
architecture as shown in Figure 1.2. When the amino acid sequences of the various 
cloned GPCRs were compared, the greatest homology was found in seven
Figure 1.2. Topographical representation of a typical G protein
coupled receptor
G protein coupled receptors (GPCRs) have an amino terminus and three 
loops (EL-I, EL-II and EL-III) that have an extracellular orientation, seven 
hydrophobic transmembrane a  helices (TM I through TM VII), and a carboxy 
terminus and three loops with an intracellular orientation (IL-I, IL-II and IL- 
III). The a  helical structure may extend into the extracellular or intracellular 
spaces. Each circle represents a single amino acid.
Proposed glycosylation sites are represented by a cross based upon the 
consensus amino acid sequence, N-X-S/T, with N being Asn and X being any 
amino acid residue. The proposed disulphide bond is shown between cysteine 
residues in EL-I and EL-II. A hook (Cys) in the proximal portion of the 
cytoplasmic tail is the proposed site for palmitoylation in some systems, forming 
a fourth intracellular loop [O'Dowd etal, 1989; Morrison etal, 1991; Kennedy 
& Limbird, 1993; Kawate & Menon, 1994].
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hydrophobic regions each consisting of between 20-25 amino acids. Each of these 
hydrophobic regions is thought to comprise a seven transmembrane helix. The regions 
of greatest diversity are at the extracellular N-terminus and at the intracellular C-
1.2.1.1. Functions of the N-terminus
8
terminus and cytoplasmic domains. Both the ligand bound and the G protein activated 
by the receptor determines the specific cellular response mediated by it. These two 
structural features of the GPCRs have been studied in great depth and will be discussed 
below.
1.2.1. Structural and functional features of GPCRs
It is now known that GPCRs have many structural adaptations to their
extracellular domains to allow them to respond to diverse signals. The present 
understanding of the structure of GPCRs is based on the structure of the photoactivated 
proton pump of Halobacterium halobium. This protein, termed bacteriorhodopsin, is 
folded in such a way that the N-teiminus is located on the extracellular surface of the 
cell and the C-terminus is intracellular. Between these two aieas are seven hydrophobic 
regions which electron microscopy and high resolution electron diffraction indicate as 
being transmembrane spanning domains arranged in a bundle perpendicular to the plane 
of the lipid bilayer [Henderson & Unwin, 1975; Engleman etal., 1980; Henderson et 
al, 1990]. Protease digestion studies and detailed immunological mapping have also 
provided supporting evidence for the existence of seven transmembrane spanning 
domains linking an extracellular N-terminus and an intracellular C-terminus [Dohlman 
eta l, 1987].
_ _
1.2.1.2. Functions of the C-terminus
1,2.1.3. Functions of the extracellular disulphide bonds
It has been shown that the N-terminus of GPCRs is extracellular and the length 
of amino acid sequence is variable from receptor to receptor. N-terminal Asn residues 
of this region are considered to be sites for N-linked glycosylation. Endoglycosidase 
treatment of many GPCRs decreases their molecular mass. For example, such 
treatment of the purified P2 adrenergic receptor resulted in a reduction of molecular 
mass from 65 kDa to 49 kDa [Rands etal, 1990]. Glycosylation is not thought to play 
a role in defining agonist binding activity since mutations of the two Asn residues in the 
P2 adrenergic receptor had little effect on agonist/antagonist binding or on the coupling 
of this receptor to adenylyl cyclase [O'Dowd e ta l ,  1989]. However, this post- 
translational modification may function in determining receptor location within the cell 
[O'Dowd et a l , 1989].
The presence of one or two cysteine residues in a similar position in most G 
protein coupled receptors suggests that this may be a common structural feature. 
Among the most well-studied and well-known GPCRs are the p~adrenergic receptor 
and rhodopsin. They have one and two cysteine residues, respectively, in their C- 
terminal sequence which have been shown to bind palmitate (Cl4:0) via a thioester 
linkage [O'Dowd et a l, 1989]. It is believed that the covalently bound palmitate 
becomes intercalated into the membrane bilayer, thereby creating a fourth cytoplasmic 
loop. Removal of the cysteine residue in the p2 adrenergic receptor uncouples the 
receptor from its associated G protein, Ggcc [O'Dowd et a l,  1989; Moffett et a l ,
1993], but equivalent mutations caused no functional effect in rhodopsin [Kamik e t a l , 
1988] and in the 012A adrenergic receptor [Kennedy eta l, 1993].
T  - .i ; .  i -A'
Members of the GPCR family contain a cysteine residue in the putative first 
extracellular loop (EC-1) near the top of the third transmembrane domain (TM3) and 
another cysteine in EC-2. It has been assumed that this pair of Cys residues forms a 
disulphide bond in most GPCRs [Strader eta l, 1994]. This linkage has been proposed 
to be important to allow the receptor to attain a normal conformation during synthesis, 
for normal expression on the cell surface or to maintain normal function, in particular, 
with respect to binding and activation. Data consistent with the presence of a disulphide 
bond between these two conserved Cys residues have been reported for rhodopsin 
[Davidson et a l, 1994], p2 adrenergic receptors [Dixon eta l, 1987; Dohlman et a l ,
1990], muscarinic acetylcholine receptors [Savarese e ta l, 1992], thyroid stimulating 
hormone receptors [Kosugi e ta l,  1992; Gustavsson e ta l ,  1994] and thyrotropin 
releasing hormone receptors [Perlman et a l, 1995; Cook eta l, 1996].
Evidence in support of this disulphide linkage has been primarily of two types. 
Firstly, it has been shown that the binding affinity of a number of GPCRs is decreased 
under reducing conditions. This effect, however, may involve reductions of 
disulphides other than the proposed bond. Secondly, substitution of one or the other of 
these Cys residues has led to decreased binding affinity, expression, or activation.
1.2.1.4. Importance of transmembrane domains for ligand binding
Although GPCRs share the same basic structure, differences exist in the 
method of agonist binding. The seven transmembrane (7TM) domains are known to 
participate in the formation of the ligand binding pocket. The receptors for small 
molecules such as light using 11-cis-retinal as a chromophore ligand [Khorana, 1992], 
small hormone and neurotransmitter molecules such as catecholamines, acetylcholine, 
histamine and serotonin [Strader a/., 1989; Dohlman etal, 1992; Savarese & Fraser,
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1992] bind these agonists in a cleft formed by the folding of the transmembrane 
helices.
The P2 adrenergic receptor has been used for many years as a model system for 
studying the function and regulation of these receptors in transmembrane signalling. 
Large parts of the intracellular and extracellular domains can be deleted without 
appreciably altering the ligand binding properties of the receptor. Studies using 
alkylating agents [Dohlman cïa/., 1988], photoaffinity labels [Wong etal., 1988] and a 
fluorescent antagonist [Tota & Strader, 1990] have shown that the ligand binding 
pocket, formed from the seven transmembrane helices, is located approximately one 
third of the way down into the core of the protein.
The carboxyl group of the aspartate residue in TM-III (Asp 113) was postulated 
to act as a counter-ion for the catecholamine nitrogen in the presence of an agonist or an 
antagonist containing a protonated amine group, like isoprenaline and propranolol. 
Two conserved serine residues (204 and 207) in TM-V were found to form a hydrogen 
bond with the para- and meta-hydroxyl group of isoprenaline, respectively [Strader et 
al, 1989]. This gives a model of isoprenaline binding to the P2 adrenergic receptor 
through a carboxylamine salt bridge at aspartate 113 and hydrogen bonds at serines 204 
and 207.
Receptors for peptide agonists appear to recognize these agonists on their 
exofacial surface [Fong e ta l ,  1992a & Fong et al., 1992b] whilst glycoprotein 
hormones such as thyrotropin bind to the N-terminal tail [Moyle et a l ,  1991; 
Nagayamae?a/.,1991] of the receptor causing a conformational change which leads to 
the tail binding to the extracellular loops of the receptor. A unique ligand-receptor 
interaction is described by the thrombin receptor, in which the thrombin molecule acts 
as a protease which binds to the N-terminal tail of the thrombin receptor and cleaves the 
first 25 amino acids of the receptor to create a shortened amino terminus which then 
acts as a "tethered ligand" causing activation of the receptor [Vu eta l, 1991a; Vu e ta l ,
11
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1991b]. The metabotropic glutamate receptors and parathyroid Ca^+ sensing receptor
utilize yet another mechanism to detect their ligands (Tanabe et al., 1992; Brown et al. ,
1993]. These receptors contain extremely large N-terminal regions which have stretches
.resembling bacterial transporters for small molecules such as amino acids [O'Hara et 
al., 1993]. Studies on these bacterial periplasmic binding proteins suggest that 
glutamate and Ca^+ binding to these domains induce a conformational change in the 
metabotropic glutamate receptors and Ca^+ sensing receptors {Oh etal., 1993]. This 
conformational change may then form another tethered ligand which binds to the 
exofacial surface of the receptor.
1.2.1.5. Importance of cytoplasmic domains for receptor-G protein 
interactions i
The first and second intracellular loops are relatively well conserved among G 
protein coupled receptors, but the third intracellular loop and the C-terminal tail are
quite divergent, possibly reflecting a molecular basis for variable ligand and G protein 
binding specificity. Most work in this area has focused on the third intracellular loop 
and the C-teiminal tail of the receptor.
Mutagenesis studies and the use of chimeras have been used to define the 
regions of GPCRs thought to comprise the site of G protein coupling. Mutagenesis 
studies of the adrenergic receptor show that a large portion of the third intracellular 
loop is important in activation of Ggoc and then adenylyl cyclase. Deletion of residues 
239-272 of the adrenergic receptor produced a receptor which could not activate 
adenylyl cyclase [Dixon et al., 1987]. Deletion of residues 222-229 and 258-270 both 
greatly reduced the activation of adenylyl cyclase by the receptor [Strader etal., 1987] 
and deletion of the residues at the C-terminal end of the third intracellular loop of the
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human p2 adrenergic receptor also resulted in stimulation of adenylyl cyclase to only a
fraction of the level produced by the wild type receptor {Hausdorff etal., 1990].
By constructing chimeric receptors where by a portion of TM V, all of TM VI
and the intervening third intracellular loop of the human p2 adrenergic receptor was 
introduced into the corresponding regions of the human « 2  adrenergic receptor, it was 
found that the chimera could stimulate adenylyl cyclase to approximately one third the 
level of that produced by the wild type P2 adrenergic receptor [Kobilka etal., 1988]. If 
only a portion of the third intracellular loop of the receptor was introduced, however, 
then the ability to activate adenylyl cyclase was lost. These results indicate that the third 
intracellular loop of the p2 adrenergic receptor plays an important role in governing the 
interaction of the receptor and GgCt and thus stimulation of adenylyl cyclase, but also 
that this loop is insufficient on its own to fully activate the G protein.
A highly conserved Asp residue at the junction of TM III and the second 
intracellular loop may be one of these additional determinants for G protein binding. It 
is thought that the conformational changes which occur upon receptor activation may 
mask or umnask this residue, as it is located in or near the cytosol. Mutagenesis of this 
residue and corresponding residues in bovine rhodopsin, the rat m l muscarinic 
receptor and the human adrenergic receptor either prevent receptor-G protein 
interaction or reduce affinity of receptor for G protein [Fraser etal., 1988; Fraser etal. ,
1989; Franke e ta l, 1990; Wong eta l, 1991].
Chimeric experiments with and P2 adrenergic receptors were performed to 
delineate the regions of G protein interaction. Such experiments showed that the 
cytoplasmic tail as well as the carboxyl-terminus of the third intracellular loop are 
important in G protein binding and in the agonist induced conformational change of the 
receptor which activates G protein [Cotecchia e ta l, 1990].
In addition to the importance of the third intracellular loop, the C-terminal tail 
may be involved in governing the fidelity of interaction of receptors and G proteins.
. 3
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The splice variants of the EP3 prostanoid receptor which have different C-terminal tails 
display a marked infidelity in G protein coupling and show remarkable promiscuity in 
coupling to G proteins [Namba etal., 1993]. Of the 4 splice variants of the EP3 
receptor isolated, EP3a coupled to Gia, EP3b coupled to GgO and EP3c coupled Ggct 
and Go«, whilst EP3d coupled to Gia, Gga and Gqa [Namba et ah, 1993; Negishi et 
al., 1993].
1.2.2. Functional regulation of GPCRs
One of the salient features of GPCRs is that their functions are subject to 
dynamic regulation by a number of mechanisms such as phosphorylation and 
phosphorylation associated desensitization which will be discussed in the following 
sections. I:
1.2.2.1. Phosphorylation of GPCRs
One of the most intensively studied modification mechanisms involves
phosphorylation by a family of G protein-coupled receptor kinases (GRKs). GRKs are 
a family of serine/threonine protein kinases that specifically recognize agonist- 
occupied, activated G protein-coupled receptor proteins as substrates. Phosphorylation 
of an activated GPCR leads to attenuation of receptor-G protein coupling since 
receptors phosphorylated by a GRK become targets for the binding of an arrestin 
protein. An arrestin bound to a GRK-phosphorylated receptor prevents coupling of that 
receptor to its cognate G protein, effectively reducing the level of functional receptor in 
the cell membrane. Since activation or agonist-occupancy of a receptor is a prerequisite 
for phosphorylation of a receptor by a GRK, this GRK-arrestin pathway results in the 
specific or homologous desensitization of receptor responses following agonist
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exposure. A role for GRKs and arrestins has been implicated in only a few model 
GPCR systems. Nevertheless, these model systems provide a framework for 
understanding the role of receptor regulation in diverse signal transduction pathways 
[Lefkowilz, 1993; Inglese a/., 1993].
Six distinct mammalian GRKs are known, which differ in tissue distribution
.and in regulatory properties [Premont etal., 1995]. The intracellular localization of 
GRKs to membrane-bound receptor substrates is the most important known regulatory 
feature of these enzymes. Among them rhodopsin kinase (GRKl) requires a post- 
translationally added farnesyl isoprenoid to bind to light-activated rhodopsin
■
(metarhodopsin II) [Hargrave etd ., 1993]. The p adrenergic receptor kinases (GRK2 
and GRK3) were named as an activity that phosphorylated the agonist-occupied P2 
adrenergic receptor. They are targetted to the membrane by associating with 
heterotrimeric G protein Py subunits released upon receptor activation of G proteins, 
and their substrate specificity is not limited to adrenergic receptors [Benovic et al. ,
1986; Benovic 1989].
Within the past few years, a novel subfamily of the GRKs has emerged from 
molecular cloning studies. This subfamily includes the mammalian GRK4 [Ambrose et 
al., 1993], GRK5 [Kunapuli & Benovic, 1993], and GRK6  [Benovic & Gomez,
1993; Haribabu & Snyderman, 1993], as well as the Drosophila GPRK2 sequence 
[Cassill eta l., 1991]. These kinases utilize distinct mechanisms for membrane 
localization, which are just beginning to be defined. GRK5 is the most extensively 
charaterized of these new kinases and has been shown to phosphorylate rhodopsin, « 2- 
and p2 adrenergic receptors, and m2-muscarinic receptors [Premont et al., 1994; Pei et 
al., 1994; Kunapuli etal., 1994]. All GRKs appear to play the same general cellular 
role of desensitizing activated GPCRs, but utilize distinctly individual means to the 
same end. More recently, Fredericks etal. [1996] have identified the sites of GRK2- 
and GRK5~mediated P2 adrenergic receptor phosphorylation which reside exclusively
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in residues of Ser and Thr in a 40-amino acid peptide located at the extreme caboxyl 
terminus of the receptor.
1.2.2.2. Mechanisms of desensitisation of GPCRs
Many GPCR systems are known to undergo some form of desensitization or 
adaptation to repeated or prolonged stimulation. The activity of an effector enzyme 
produced by a particular dose of a hormone is dependent on the previous activity of the 
system. Desensitization refers to the rapid attenuation of responsiveness to a drug or 
hormone in the continued presence of the agent. Many distinct mechanisms play a role 
in the overall desensitization of G protein coupled systems, including protein 
trafficking of receptors and G proteins among cellular membranes, second messenger- 
regulated protein phosphorylation, and enhanced degradation or removal of intracellular 
messengers.
Several distinct phosphorylation patterns have been correlated with different 
aspects of receptor desensitization. Among GPCRs, desensitization has been studied 
in the P2~adrenergic receptor [Hausdorff etal., 1990], cholinergic receptors [Menniti, 
et al., 1991; Nakahata etal., 1987; Eva etal, 1990], the a i  adrenergic receptor [Leeb- 
Lundberg eta l, 1987; 'LdXXion e ta l, 1994], the serotonin 5 HT2 and 5HTia receptors 
[Pauwels et al., 1990; Raymond, 1991], the receptors for thrombin [Paris et a l ,
1988], platelet activating factor [Morrison & Shikla, 1987], histamine [Dickenson et 
al., 1993], substance P [Menniti et a l, 1991; Sugiya et a l,  1987], bradykinin 
[Wolsing & Rosenbaum, 1993], and bombesin [Walshi et a l,  1993]. However, 
despite the large amount of information about the adenylyl cyclase-linked receptors, 
much less is known about the molecular mechanisms involved in desensitization of the 
receptors coupled to the phospholipase C signalling pathway.
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Several mechanisms have been delineated which are associated with the
.diminished response to agonist. Upon agonist occupation, the first event appears to be 
phosphorylation of the receptor at specific sites by the PARK and the cAMP-dependent 
protein kinase (PKA), which leads to rapid attenuation of receptor-G protein 
interaction. The sites required for phosphorylation by PARK have been localized to
serine and threonine residues in the carboxyl-terminal tail of the p2 adrenergic receptor 
[Dohlman gra/., 1987; Bouvier efa/., 1988]. More recently, Fredericks e td .  [1996] 
have identified the sites of GRK2- and GRK5-mediated p2 adrenergic receptor 
phosphorylation which reside exclusively in a 40-amino acid peptide located at the 
extreme caboxyl terminus of the receptor.
Phosphorylation of P2 adrenergic receptor by PKA occurs at one or both of the
?consensus sequences located in the third intracellular loop or the cytoplasmic tail 
[Benovic 1985; Hausdorff 1989]. p adrenergic receptors phosphorylated 
by either process couple poorly to Gg. Removal of the above-mentioned site of the p% 
adrenergic receptor by mutagenesis significantly alters the patterns of agonist-induced 
desensitization [Bouvier 1988; Hausdorff et d.,l9W>\. Similarly, p2 adrenergic 
receptor desensitization can be selectively altered by the use of specific inhibitors of 
PARK (heparin) or PKA (PKl) [Lohse etal., 1990]].
A second component of agonist-induced desensitisation of the receptor is 
sequestration (also referred to as an internalisation or com par tmental i sati on) of the 
receptor away from the cell surface to an intracellular location where it is presumably 
unavailable for interaction with G protein. p2 adrenergic receptors can eventually be 
recycled to the cell surface without the need for new protein synthesis. Finally, after a 
more prolonged (h) exposure to agonist, the total receptor numbers may become 
dramatically decreased, a process termed receptor down-regulation. This refers to the 
mechanisms that remove receptors from the cell membrane, leading to their 
internalisation and ultimately their degradation. Replacement of such down-regulated
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receptors generally requires new protein synthesis. The exact molecular determinants of 
this process are not well defined, it does appear that Gg coupling is an important 
component in the down-regulation process of p2 adrenergic receptor [Campbell et al.,
1991].
1.2.3. Mechanisms of multifunctional signalling by GPCRs
A number of GPCRs have recently been shown to regulate multiple effector 
pathways both when expressed endogenously and in heterologous systems. This signal 
bifurcation can be explained by three different models [Milligan, 1993]. Firstly, each of 
multiple receptor subtypes is able to interact with a separate G protein and each G 
protein is able to regulate a separate effector species. An example of this mechanism is 
the splice variants of the EP3 prostanoid receptor as described in section 1 .2 .1.5. 
Isoforms of this receptor are predicted to differ in the C-terminus and while they show 
identical ligand binding properties, they appear to interact with distinct members of the 
Gi family [Sugimoto etal., 1993].
Secondly, a single receptor activates multiple G proteins, each of which is able 
to regulate a separate effector. For example, in NG108-15 cells, both a ô-opioid 
receptor and an «28 adrenergic receptor are able to inhibit adenylyl cyclase and voltage- 
dependent Ca2+ channels in a pertussis toxin-sensitive manner. Opioid-mediated 
inhibition of adenylyl cyclase is abolished by antibodies that selectively interact with 
Gj2a  and (X2 adrenergic receptor inhibition of Ca2+ currents is attenuated by antibodies 
which identify splice variants of GqO. [McKenzie & Milligan, 1990; McFadzean etal. ,
1989]. Thirdly, a single receptor interacts with a single G protein and bifurcation of 
signal is subsequently produced by the regulation of different effectors by the G protein 
a  and py subunits. As certain phospholipases of the C and A2 classes are activated by 
Py subunits, it is possible that a receptor expressed at sufficiently high levels could
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activate sufficient G protein to allow the a  subunit to regulate one effector while the 
associated py subunits could regulate another [Camps eta/., 1992; Katz etal., 1992].
1.2.4. Constitutively active mutant (CAM) receptors
The unusual property of activating cellular signalling pathways in the absence 
of agonist have been reported in several GPCRs including the thyrotropin receptor 
[Parma etal., 1993], the luteinizing hormone receptor [Shenker et al., 1993], the 
dopamine Di & D5 receptor [Tiberi & Caron, 1994], 5HTiDa,5HTiDp and 5HT2C 
[Barker etal., 1994; Thomas et al., 1994] and in vitro mutants of various receptors. 
They are termed, consititutively active mutant (CAM) receptors. Recent studies of the 
properties of several mutationally activated receptors has led to a more detailed 
understanding of mechanisms by which GPCRs function.
1.2.4.1. The revised ternary complex model
Classic theories of receptor activation [Del Castillo & Katz, 1957] hold that 
agonist binding by receptors leads to a conformation that is productive for effector 
activation. Antagonists, on the other hand, are considered to be able to bind effectively 
with the receptor without requiring an induced conformational change and, thus, to 
inhibit rather than stimulate receptor signalling.
The ternary complex model [De Lean eta l, 1980], which is the most widely 
accepted model describing the activation of a G protein coupled receptor, relates the 
active form of the receptor to a ternary complex that involves the interaction of the 
hormone (agonist), the receptor and the G protein. However, based on recent analyses 
of ligand binding and activation of many GPCRs, this ternary complex model of 
receptor activation has been revised [Samama et a l, 1993]. Central to this revised
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model is the finding that mutated receptors can exist in a constitutively active state, that 
is, a state that can initiate productive signalling in the absence of agonist.
Analysis of in vitro model CAM and wild-type receptor systems indicates that 
receptors exist in an equilibrium of inactive and active states or conformations. 
Agonists [H] or CAM mutations shift the receptor toward the activated conformation 
[R*] ; neutral antagonists bind without shifting the equilibrium between inactive [R] and 
active [R*] conformations, and inverse agonists or negative antagonists shift the 
equilibrium toward the inactive conformation [R] as shown in Figure 1.3. 
Accordingly, it has been proposed that similar to channels that spontaneously isomerize 
between a closed (or resting) and open (or active) conformation, receptors resonate 
between a basal state [R] and an active state [R*], and that only the active [R*] state can 
productively interact with G protein to allow effector activation by the [R*G] complex 
[Bond etal., 1995]. Furthermore, agonists bind with higher affinity to the active state 
and trap the receptor in the [R*] conformation. Antagonists, on the other hand, can 
bind with similar affinity to both [R] and [R*].
I.2.4.2. Constitutive activation of receptors
It was discovered that interchange of a short homologous stretch of amino acids 
between the C-teiminal regions of the third cytoplasmic loops of the Gq-PLC-coupled 
a  IB adrenoceptor and the Gg-adenylyl cyclase-coupled p2 adrenergic receptors 
resulted, in both cases, in a pattern of constitutive activity [Cotecchia et al., 1990]. The 
basal agonist-independent signalling activity of the mutant receptors was greatly 
enhanced to levels comparable to that of a fully agonist-stimulated wild type receptor in 
the case of the P2 CAM [Samama et al., 1993]. Comparable mutations in the « 2A 
adrenoceptor also led to constitutive activation [Ren et al., 1993]. More recently the 
constitutive activity of GPCRs by mutation has been shown not limited to the third
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Figure 1.3. The ternary complex model.
This model was originally developed to explain several features of ligand 
binding to the adrenergic receptor. First, agonists but not antagonists were able 
to distinguish between a high- and a low- affinity state of the receptor. Second,the 
proportion and relative state of affinity of ligands for these two states of the 
receptor was observed to vary with the intrinsic activity of the agonist. Third, 
guanine nucleotides appeared to convert receptor from a high to low affinity state. 
[H] represents hormone; R for receptor; G for G protein.
a) shows the classical form of the model : M, the affinity of R for G; a , the 
molecular efficacy of the ligand; K, the receptor affinity of the ligand.
[HR] [RG] [HRG] [R]K = -------------- M =   cc = -[H] [R] [R][G] [HR] [RG]
b) shows the extended version of the model or allosteric ternary complex 
model. This model introduces an explicit isomerization step regulating the 
formation of the state of the receptor from R to R*, which is capable of binding to 
the G protein. J represents an equilibrium constant in receptor isomerization.
[R*] [HR] [R*G] [HR*G][R*] [HR*][R]T--------— K= ---------- M =   ct = ---------------  6 = -------------[R] [H][R] [R*][G] [HR*][R*G]  ^ [HR] [R*]
c) shows how the position of the equilibrium between an inactive state R 
and an active state R* varies with individual receptors and is altered by the presence 
of receptor ligands. Agonists function by stabilising R* while inverse agonists 
preferentially stabilise R. A continuum of ligands between full agonists and full 
inverse agonists is expected to exist, with antagonists having no effect on the 
position of the equilibrium at all.
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cytoplasmic loop but can be observed in mutations in the C-terminus as well as in the 
ligand binding domain (TM-III) [Matus-Leibovitch etal 1995; Perez etal, 1996].
Analysis of CAM P2- and « 2  adrenergic receptors indicates that the CAM 
receptors are also constitutively desensitised and phosphorylated since the CAM 
receptors are constitutive (agonist independent) substrates for GRK2 in vitro [Ren et 
d., 1993; Pei et d., 1994]. Furthermore constitutive GRK2 phosphorylation of CAM 
p2 adrenergic receptor can be partially inhibited by addition of an inverse agonist, 
which reduces the amount of receptor in the activated, GRK substrate state [Samama et 
al, 1994].
1.2.4.3. Inverse agonism
In constitutively active systems containing mutant receptors [Samama et al. ,
1994], heterologous expression systems with receptor over-expression [Chidiac etal. , 
1994; Tian etal., 1994], over-expressed receptor systems from transgenic animals 
[Milano et al., 1994], and in disease states associated with receptor mutations 
[Coughlin, 1994; Raymond, 1994] antagonists that were previously thought to lack 
intrinsic efficacy have been shown to actually depress constitutive receptor activity in 
vitro.
Drugs acting at GPCRs display a spectrum of efficacies from what has 
routinely been defined as zero for full antagonists to one for full agonists [Stephenson, 
1956]. Antagonists inhibit the binding of agonists to receptors, and the physiological 
effects of the former usually are attributed to their ability to prevent activation of 
receptors by endogenous hormones and neurotransmitters. In general, it is thought that 
antagonists do not modulate the activity of unliganded receptors, but a growing body of 
evidence contradicts this notion. Certain antagonists have been reported to produce
22
effects opposite to those of the corresponding agonists at GPCRs [Schütz & 
Freissmuth, 1992].
The direct, agonist-independent modulation of receptor activity by these 
antagonists has been referred to variously as inverse agonism, negative or reverse 
intrinsic activity, and negative antagonism [Schütz & Freissmuth, 1992; Ehlert, 1986; 
Costa & Herz, 1989; Costa etal, 1990]. This property gives ‘negative efficacy‘ due to 
its ability to actively destabilise spontaneous complexes of receptor and G proteins
Drugs displaying inverse agonism were postulated to have a higher affinity for 
[R] compared with [R*l, resulting in a decrease in the proportion of [R*] and a 
reduction in the basal regulation of the effector system as shown in Figure 1.3c 
[Milligan a/., 1995]. Therefore, the characteristics of inverse agonists tends to be 
more apparent in systems that express relatively high receptor levels with associated 
higher basal effector activity.
Much of the detailed early analysis of inverse agonism at GPCRs was derived 
from the ability of the ô-opioid receptor ligand ICI 174864 to inhibit basal high affinity 
GTPase acivity in membranes of NG108-15 cells [Costa & Herz, 1989; Costa et al. ,
1990]. Recent studies have examined this phenomenon directly at a range of receptors, 
including p2 adrenoceptor [Adie & Milligan, 1994; Chidiac etal., 1994; Samama eta l.,
1994], « 2 adrenoceptor [Tian e?a/., 1994], 5HT2C [Barker gW., 1994], SHTioa and 
5HTidp [Thomas etal., 1994], Dib dopamine receptor [Tiberi e?a/., 1994], and the ô- 
opioid receptor [Mullaney etal., 1996].
1.3. Guanine nucleotide binding proteins (G proteins)
1.3.1. Structure, function and mechanism of action
23
In all eukaryotic organisms, a family of heterotrimeric GTP-binding and 
hydrolysing proteins (G proteins) plays an essential signal transducing role in linking 
many cell surface receptors to effector proteins at the plasma membrane. Structurally, 
the heterotrimeric G proteins are composed of distinct a, p and y subunits of molecular 
masses 39-52, 35-36 and 7-8 kDa, respectively. G protein coupled signalling cascades 
include the regulation of various intracellular second messenger generating effector 
systems such as adenylyl cyclase, phosphoinositidase C, phospholipase A2, 
phospholipase D and ion channels.
The a  subunit has a single high affinity binding site for GDP or GTP and 
possesses intrinsic GTPase activity which results in hydrolysis of the terminal 
phosphate of bound GTP to yield bound GDP and free inorganic phosphate. The GDP- 
bound fonn of the a  subunit binds tightly to py forming an inactive complex, whereas 
the GTP-bound form dissociates from Py and can then interact with an effector protein 
causing an intracellular response. The p- and y subunits exist as a tightly associated 
complex which can itself activate effector molecules.
1.3.2. Ga subunits
Molecular cloning techniques have allowed identification of 21 distinct 
mammalian G protein a  subunits which are derived from 16 genes. These can be 
classified into 4 major subclasses based on structural homology at the amino acid 
sequence level. These are termed the Gg, Gj, Gqand G%2 families as shown in Figure 
1.4 [Simon et aL, 1991]. All a  subunits share sequence homology to a greater or 
lesser degree which reflects the similar function of these proteins.
Although the length of the polypeptide sequence does not show the homology 
between the a  subunits, regions of high and low homology exist between all a  
subunits. The regions of highest homology occur in four non-continuous regions that
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Figure 1.4. G protein a  subunit amino acid identity
The relationship among mammalian G a subunits is displayed. The a  subunits are grouped by amino acid sequence identity and define four distinct classes of 
G a subunits. The splice variants of Gga are not shown [Simon etal., 1991].
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1.3.2.1. Gs family
form the GTP-binding and hydrolysis domains. Regions of greatest diversity represent 
areas of functional differences in coupling to py subunits, receptors or effectors thereby 
conferring specificity upon the individual a  subunits [Simon etal., 1991]. Î
GgO subunit, named for its stimulatory effect on adenylyl cyclase, was first 
identified by evidence suggesting that a hormone sensitive GTPase was required for the 
stimulation of adenylyl cyclase [Cassel & Selinger, 1977 & 1978; Ross & Gilman,
1977]. Further studies demonstrated that disruption of hormone stimulated adenylyl 
cyclase in the cyc" mutant of S49 lymphoma cells was due to the absence of a GTP 
binding protein. Ross etal. [1978] found that reconstitution in vitro of cyc  cells with 
adenylyl cyclase-free plasma membrane detergent extracts resulted in restoration of the 
adenylyl cyclase activity. The latter findings permitted the purification of Gg by 
Northup etal. [1980]. This protein was shown to be a heterotrimer of a , p and y 
subunits which could be a mixture of two oligomers made up of two distinct a
i
subunits and indistinguishable Py dimers. The relative concentrations of these a  
subunits of molecular masses, 45k and 52kDa, varies between cell types and any 
functional differences between the two have yet to be identified.
Alternative splicing of a single GgO gene results in the production of four 
polypeptides comprising 380,381,394 and 395 amino acids [Bray etal., 1986]. The 
gene consists of 13 exons and 12 introns covering about 20kb [Kozasa e ta l,  1988].
GgCt-l and Gga-2 are identical except for a single 45 nucleotide stretch absent in Gga-3 
and Gga-4. Gga-2 and Gga-4 have an additional 3 nucleotides located 5 'end of exon 4,
This is due to the alternative splicing of exon 3 of the gene such that 
Gga-l and Gga-2 have exon 3 and Gga-3 and Gga-4 do not [Bray et a l,  1986;
Kozasa et a l, 1988; Kaziro et a l, 1990]. The production of an additional serine
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residue in Gs«-2 and -4 by this differential splicing may represent a potential
phosphorylation site on Gga for protein kinase C and indeed this GgCt has been shown
to be the target of phosphorylation by PKC in vitro [Pyne etal., 1992].
GgO is ubiquitously expressed in all cells although the relative levels of
expression of the splice variants vaiy from each cell and tissue type. The exact purpose
of this differential expression is not yet clear at present as there has been no evidence of
any functional difference between the splice variants.
1.3.2,2, G; family
The pertussis toxin-sensitive 40kDa G a subunit was first purified from bovine 
brain, and has been shown to couple to the inhibition of adenylyl cyclase. Gja has 
subsequently proved to be a mixture of three a  subunits termed G iia, Gi2a  and Gj3a 
[Jones & Reed, 1987].
Gjla: G ila is one of the largest members of the Gi family with a moleculai' 
mass of 41 kDa and is a substrate for ADP-ribosylation by a bacterial secretory 
endotoxin produced by Bordetella pertussis (PTX). This covalent modification occurs 
via the transfer of an ADP-ribose group, donated by NAD+, to a cysteine residue 4 
amino acids from the C-terminus of the a  subunit. Such transfer occurs most 
efficiently when the G protein is in its holomeric form complexed to its receptor 
[Gilman, 1987; Milligan, 1988]. PTX-mediated A DP ribosylation results in a 
stabilization of the trimeric form of the protein and causes the release of the inactive G 
protein from the receptor thus preventing transduction of the hormone signal to the 
appropriate effector system as described in section 1.3.5,1. The tissue distribution 
is limited to in neuronal tissues and certain other tissues, which indicate a likely role in 
regulating ion channels as opposed to adenylyl cyclase.
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G i2 a: Gi2a  is the smallest of the three Gi proteins, is a substrate for pertussis 
toxin catalysed ADP-ribosylation and shares around 8 8 % amino acid identity with 
Gila. Although other members of the Gia family have been shown to cause inhibition 
of adenylyl cyclase [Taussig & Gilman, 1995], there is greater evidence suggesting that 
Gi2a  is the main physiological regulator of this process. For example, it was 
demonstrated that Gi2a  was responsible for the inhibition of forskolin-stimulated 
adenylyl cyclase activity in NG108-15 neuroblastoma x glioma hybrid cells by using 
Gi2a  specific antisera to selectively uncouple Gi2a  from receptor regulation of 
adenylyl cyclase [McKenzie & Milligan, 1990].
Another system which Gi2a  may interact with is the MAP kinase cascade [van 
Corven eta l., 1993; Alblas e ta l ,  1993]. Flormonal stimulation of G^  a-coupled 
receptors causes activation of a series of protein kinases which ultimately leads to the 
phosphorylation and activation of MAP kinase which in turn catalyses the 
phosphorylation of a variety of cellular proteins to cause entry into the cell cycle and 
stimulation of transcription. It is probable, however, that this stimulation of MAP 
kinase is also mediated by Py [Grespo et a l, 1994].
G j3a: Gi3a is the third of the Gj family and is thought to stimulate various ion 
channels in the plasma membrane. It has been shown that a Gi protein purified from 
human erythrocyte membranes was capable of stimulating receptor activated K^ ' 
channels in atrial and pituitary membrane patches [Yatani et a l, 1987]. This protein 
was subsequently found to be G{3a. Furthermore, an amiloride sensitive Na+ channel 
was identified in renal epithelial cell line A6  which could be activated via Gi3a 
[Cantiello et a l, 1989], apparently via stimulation of phospholipase A^ [Cantiello et 
al., 1990]. Ausiello e ta l  [1992] also suggested that the stimulation of this channel 
proceeds via phospholipase A2 and generation of second messengers. It was also
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reported that Gi3a stimulated a large conductance renal apical Cl" channel [Schwiebert 
etal, 1990].
The involvement of Gi3a in trafficking of proteins from the Golgi to the plasma 
membrane has also been implicated since secretion of the heparin sulphate proteoglycan 
from LLC-PKl epithelial cells was inhibited upon overèxpression of Gi3a and location 
of this G protein to the Golgi complex [Stow e ta l,  1991]. Pertussis toxin treatment 
reversed this inhibition of secretion of heparin sulphate proteoglycan indicating a role 
for Gi3a in Golgi trafficking of a contitutively secreted protein.
Go«: Named for G 'other', was first identified as a 39kDa pertussis toxin 
substrate purified from bovine brain [Neeref a/., 1984; Stemweis & Robishaw, 1984; 
Milligan & Klee, 1985] and is distributed mainly in neuronal and electrically excitable 
cells. It was demonstrated that this a  subunit could inhibit the opening of a voltage 
sensitive N-type Ca2+ channel as well as a K+ channel [Heschler e ta l,  1990; van 
Dongen et a l, 1988]. Three GqO proteins has been identified [Hsu et a l,  1990; 
Strathmanngf 1990; Nürnberg e ta l ,  1994]. These Goa splice variants display 
differential tissue distribution; Gola being primarily restricted to neuronal cells whilst 
Go2a  is found in peripheral tissues such as pituitary, lung and testis. Unlike the splice 
variants of G^a, those of Goa have been shown to possess distinct functions [Kleuss 
e ta l, 1991; Man-Song-Hing etal, 1992; Numberg eta l, 1994].
G ta: Vertebrate visual transduction is known to be mediated by G^a. 
Transducin was first identified as the transducing entity between activated rhodopsin 
and the phosphodiesterase responsible for lowering levels of cGMP causing influx of 
Na+ from the outside of the cell, depolarization and thus initiation of nerve impulses to 
the brain. Two Gta subunits, named G tla and Gt2a , were cloned [Lochiie et d . , 
1985; Tanabe et a l,  1985; Yatsunami & Khorana, 1985; Medinski e ta l ,  1985],
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former being distributed in retinal rod membranes as well as in non-retinal taste tissue, 
whilst the latter was found only in retinal cone membranes [Grunwold et al., 1986; 
Ruiz-Avilaera/., 1995; Lerea e ta l,  1986]. The two types share 80% amino acid 
sequence identity.
G ustducin a: Gustducin a  , found on the inside face of the membrane of 
taste receptor cells, is the most recent a  subunit to be identified. This subunit was 
obtained from a taste tissue cDNA library and belongs to the Gj family since it contains 
a consensus amino acid sequence for pertussis toxin catalysed ADP-ribosylation 
[McLaughlinera/., 1992]. Rat gustducin shows 79 % , 81 % and 90 % identity with 
rat Gtla, bovine G tla and Gt2a , respectively [McLaughlin e ta l, 1992; Ruiz-Avila et 
al, 1995]. Hoon e ta l [1995] have suggested that baculovirus expressed gustducin a  
could interact with bovine rhodopsin and both bovine brain and retinal Py stimulate 
bovine retinal cGMP phosphodiesterase activity.
Taste transduction is initiated when taste stimuli interact with receptor sites or 
channels, causing membrane depolarisation and release of transmitter from receptor 
cells onto gustatory afferent neurons. Ionic stimuli such as salts and acids interact 
directly with apically located ion channels to depolarise taste-receptor cells, but sugars, 
amino acids and most bitter-tasting compounds bind to specific receptors on the outside 
of the cell membrane, most of which are coupled to gustducin and relay the signal to 
the second-messenger systems via phosphoinositidase C, phosphodiesterase or 
adenylyl cyclase [Wong eta l, 1996].
Gga: G%a, cloned from human brain and retina, is unique as it is the only Gi 
family member that lacks the cysteine residue which serves as the acceptor for PTX- 
mediated ADP ribosylation. G%a shares only 62 % amino acid identity with other 
members of the family [Matsuokag/ a/., 1988; Fong e ta l,  1988; Casey et al., 1990].
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It has a limited tissue distribution, being mainly restricted to neurones, and has a very 
slow guanine nucleotide release rate and a slow intrinsic GTPase activity [Hinton et a l ,
1990]. As yet, however, G^a has no clear function in signal transdution, although it 
may inhibit type I and type V adenylyl cyclases and allow pertussis toxin-insensitive 
inhibition of adenylyl cyclase [Taussig & Gilman, 1995].
1.3.2 .3. Gq family
cDNA cloning techniques have allowed identification of a family of G proteins 
involved in coupling receptors to the phospholipid hydrolyzing enzyme, 
phosphoinositidase C. This family comprises 5 isotypes namely, Gq, G n , G14, G15, 
and G i6* One member of this subclass, termed Gqa, was predicted to encode a protein 
of 359 amino acids, equivalent to approximately 42kDa under SDS-PAGE [Strathmann 
& Simon, 1990; Exton et at., 1990; Pang & Sternweis, 1990]. This ct subunit is not a 
substrate for pertussis toxin catalyzed ADP-ribosylation since it lacks the necessary C- 
terminal cysteine residue and is ubiquitously distributed.
Another isotype of the Gq subfamily is G n a , contained 359 amino acids, 
which shares 8 8 % amino acid sequence identity with Gqci [Strathmann & Simon,
1990; Simon e ta l,  1991]. G n a  is also pertussis toxin-insensitive and shows no
- ■functional difference to Gqa. Purified G qa/G na from brain was shown to activate 
phosphoinositidase Cpi in a reconstitution assay suggesting that the two a  subunits 
may have identical abilities to activate phosphoinositidase Cpi [Blank e ta l ,  1991].
Although they have similar function in the activation of phosphoinositidase C, the 
tissue distribution of the two proteins shows some variation, i.e., G n a  is not present 
in human haematopoietic cells and the relative amounts of the two subunits are different 
in both brain regions and peripheral tissues [Milligan eta l, 1993].
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The differences in primary structure between Qcft and G n «  are mostly 
clustered near the N-terminus of the proteins in regions concerned with py binding and 
the relative rate of GDP-GTP exchange and hydrolysis, perhaps indicating that Gqa 
and G n a  couple differently to different combinations of p and y [Simon etal., 1991].
G 14a  shares approximately 80% identity with Gqp and G n «  at the amino acid 
level. According to analysis of mRNA distribution, this protein was found primarily in 
stromal and epithelial cells [Wilkie et d., 1991] as well as in liver, lung and kidney 
[Nakamura e/a/., 1991]. G 15a  shares 57% amino acid identity with Gqa, G n «  and 
G 14a  and is found in murine B cells and myeloid cells [Simon et al., 1991 ; Amatruda 
etal., 1991]. Giga shares approximately 83% amino acid identity to G i^a and is 
distributed mainly in haematopoietic cells such as T cells and myeloid cells [Amatruda 
etal., 1991]. It has been shown that Gi^a and/or G i60t was involved in the signalling 
processes of chemokines and chemoattractants such as interleukin-8  and the 
complement-derivedC5aanaphylatoxin [Wuera/., 1993; Amatruda e/a/., 1993; Buhl 
etal., 1993]. More recently, Gi^a and Giea have been suggested to be a universal G 
protein adapter since they interact with a variety of GPCRs which are known to couple 
distinct Ga subunits [Milligan eta l, 1996].
The structure of these proteins shows differences from other a  subunits with 
two inserts near the C-terminus and a divergent N-terminus. The first insert (a.a.317- 
323) is similar to the corresponding region in G^a while the second insert (a.a.331- 
337) contains several shared residues which are not found in other a  subunits 
[Amatrudag/ d., 1991]. An additional aspect is a proline residue resides at position 50, 
a region involved in GTP binding and hydrolysis, where an alanine resides in G^a and 
G i a  or a threonine resides in G q a . This might indicate an impaired GTP binding and 
hydrolysing capacity [Pang & Stemweis, 1990; Casey eta l, 1990].
1.3.2.4. G j2 family
3 2
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Two isotypes, Gi2cc and G isa , have been cloned and are expressed 
ubiquitously. They share relatively little primary sequence homology with other a  
subunits, approximately 45%, and have less than 70% identity with each other 
[Strathmann & Simon, 1991].
Possible roles for these a  subunits have recently been reported in the activation 
of arachidonic acid metabolism [Xu etal., 1993] as well as in the regulation of Na+/H+ 
exchange [Voyno-Yasenetskaya e/a/., 1994]. G 12a  and G^ga were also shown to be 
activated by the thrombin and thromboxane A2 (TXA2) receptors in platelet membranes 
using photoreactive azidoanilide GTP analogues [Offeimanns et al., 1994]. These 
polypeptides display a slower basal GDP-GTP exchange rate than GgCt and most Gi« 
subunits [Pang & Sternweis, 1990; Casey et a l,  1990; Wange et al., 1991; 
Offermannse/a/., 1994]. »r:
1.3.3. Gpy subunit
The p and y subunits of heterotrimeric G proteins are a tightly associated dimer 
complex in the plasma membrane. Four distinct p subunits isotypes, ranging in 
molecular mass from 35 to 36 kDa, have been identified sharing around 80% amino 
acid homology with the differences spread throughout the sequence [Gao etal., 1987; 
Simon etal, 1991; von Weizsacker eta l, 1992], at least 10 y subunits ranging in size 
from 8  to lOkDa have been reported, sharing relatively little sequence identity, for 
example, y 1 being only 38% identical to y2 [Clapham & Neer, 1993].
The p and y subunit combination shows certain allowed association in cells. 
Theyl subunit associates with only the p i subunit. Conversely, complexes can be 
made of the p i subunit with yl, y2, y3, y5 and y7; p2 with any of y2, y3, y5 or y7.
.. ..................
however p3 does not associate with either y 1 or y2 [Pronin & Gautam, 1992; Schmidt 
etal, 1992; Iniguez-Lluhi era/., 1992; Ueda e/a/., 1994].
The roles of the Py subunits in membrane signalling are now considered to be 
many and include such membrane anchoring of a  subunits, activation of phospholipase 
A2 [Jelsema & Axelrod, 1987] and phosphoinositidase Cp isoforms [Camps et al. , 
1992; Smrcka & Stemweis, 1993; Lee etal., 1993], modulation of the activities of K+ 
channels [Logothetis etal., 1987; Wickman eta l, 1994; Reuveny e ta l,  1994], N- and 
Q-typeCa^+ channels [Ikeda, 1996; Herlitze e ta l, 1996], stimulation or inhibition of 
the activity of adenylyl cycase isoforms [Tang & Gilman, 1991; Gao & Giman, 1991; 
Cooper et a l,  1995] and modulation of the activities of kinases including GRKs 
[Pitchercra/., 1992; Kameyamaera/., 1993], MAP kinase [Crespo e/a/., 1994], and 
phosphatidylinositoL3-kinase [Stephens e/a/., 1994].
1.3.4. Mechanism and structural determinants in G protein action
The heterotrimeric G proteins undergo a series of steps leading to interaction 
with effector systems upon activation of GPCRs as shown in Figure 1.5. Activated 
receptor causes a conformational change in the G protein a  subunit such that the bound 
GDP is released and exchanged for GTP in the nucleotide which triggers two events; 
the G protein has a lower affinity for receptor in its GTP bound state and thus is 
released from it, and the trimer dissociates into free a  subunit and Py dimer. The GTP- 
bound a  subunit and/or the py complex liberated can then interact with an effector 
protein causing an intracellular response. The GDP-bound a  subunit has a lower 
affinity for effector and is released to reassociate once more with Py forming a 
quiescent GapyGDP complex. The system returns to a basal state when the holoenzyme 
associates with a neighbouring unoccupied receptor [Gilman, 1987].
34
Figure 1.5. G protein-mediated transmembrane signalling cycle
Step A) Basal state : In the basal state of receptor (R), G protein (a , 
p, y) and effector (E), G proteins exist as heterotrimers with GDP bound tightly 
to the ct subunit. The receptor is unoccupied and the effector is inactive.
Step B) Receptor activation : When hormone (H) binds to 
thereceptor (R), [HR] complex interacts with the heterotrimeric G protein 
(inactive form) to promote a conformational change and dissociation of 
GDPfrom the guanine nucleotide-binding site. GTP replaces GDP, and induces 
a conformational change in the a  subunit.
Step C) Subunit dissociation : G protein dissociates from the [HR] 
complex, reducing the affinity of hormone for receptor and, in turn, freeing the 
receptor for binding with a neighboring quiescent G protein. GTP binding also 
reduces the affinity of a  for Py, and subunit dissociation occurs.
Step D) Effector activation : Dissociated [a-GTP] fulfills its 
primary role as a regulator of effectors. The freed Py subunit complex may also 
interact directly with an effector (Ei) thereby modulating the activity of the 
complex, or it may act independently at another effector (E2) in some systems.
Step E) GTPase activity : The a  subunits possess an intrinsic 
GTPase activity. The rate of this GTPase determines the lifetime of the active 
species and the associated physiological response. The a-catalysed hydrolysis of 
GTP leaves GDP in the binding site and causes dissociation and deactivation of 
the active complex. The GTPase activity of a  is an internal regulator that 
controls an on/off switch. The GDP bound form of a  has high affinity for py, 
and subsequent reassociation of a  GDP with py dimer returns the system to the 
basal state.
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The guanine nucleotide binding site on the a  subunit is composed of 5 separate 
streches of amino acid sequence spread throughout the protein. These 5 repeated 
regions share significant homology to those of p2 1 ras and other members of the 
GTPase superfamiiy [Conklin & Bourne, 1993]. The C-terminal region of the a. 
subunit which is thought to be the contact site for the receptor forms a mobile region 
that prevents release of bound GDP. Upon agonist activation of a receptor, this C- 
terminal domain moves aside to allow GDP to leave the binding site and allow GTP to 
enter [Denker et al., 1992a; Noel etal., 1993]. The N-teiminal region of the a  subunit 
is important for interaction with py such that the N-terminus of G tia can compete for 
Py binding with monoclonal antibodies directed against the N-terminus [Mazzoni &
Hamm, 1989; Mazzoni 1991; Kokame aW/., 1992; Denker a/., 1992b].
It has been suggested that several regions of the a  subunit contact G protein 
coupled receptors. In particular, several lines of evidence suggest that the a  helix at the 
C-terminus of a  subunits is a contact site for GPCRs. PTX-catalysed ADP- 
ribosylation of Gja in a cysteine four residues from the C-terminus prevents interaction 
with the receptor as discussed in section 1.3,5.1 [West etal., 1985]. Mutations in 
the C-terminal tail and antibodies directed specifically against it can also cause 
uncoupling of the receptor-G protein complex [Sullivan et d., 1987; Simonds et a l.,
1989; Gutowski eta l, 1991; Hirsch eta l, 1991; Shenker eta l, 1991].
Substitution of three amino acids at the C-terminal end of G q a  to those of G |2 a  
caused a change in the receptor specificity of Gqa to that of Gi2a . From this work it 
was postulated that a C-tenninal p-tum, centred on glycine residue played a critical role 
in specifying receptor interaction of G  protein in the G j subfamily [Conklin et a l.,
1993]. Moreover, following the crystallisation of Gta, Noel e?a/.[1993] proposed that 
the C-terminal 5-10 amino acids of Gta undergo a conformational change upon binding
.
GTP, which may lead to functional dissociation of Gta from photoactivated rhodopsin.
"1 ^I
The N-tei*minal region of Ga subunit has also been postulated as a possible
receptor contact site because the N- and C-termini lie in close proximity in three
1.3.5. Covalent modifications of G proteins
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dimensional space. It has been demonstrated that a peptide corresponding to the N- 
terminus of Gt« inhibited interactions of Gta with rhodopsin without affecting 
interaction with p Y [Hamm etal., 1988; Conklin & Bourne, 1993]. Furthermore, 
mastoparan, an amphiphilic peptide from wasp venom which causes activation of the 
Gi family of G proteins, was found to cross-link to a cysteine residue near the N- 
terminus of GqO [Higashijima & Ross, 1991]. A third site for receptor interaction has 
been identified proximal to the C-terminus and is represented by amino acids 311-328 
in G tla, since activation of Gt by rhodopsin was blocked by a peptide corresponding 
to these residues [Hamm, 1991],
Some of the regions responsible for effector interaction have also been 
identified. A synthetic peptide corresponding to residues 293-314 of G tla was shown 
in vitro to activate cGMP-PDE [Rarick et al., 1992]. The construction of chimaeric 
Gsa subunits has provided a means of examining G protein-effector interaction. 
Systematic mutation of a 121 residue domain within the C-terminal half of chimaeric 
Gia/Gga permitted identification of four effector-activating regions of Gga, 
corresponding to amino acids 235-240, 261-262, 277-285 and 349-356. Mutations 
within these four regions of the chimaera prevented activation of adenylyl cyclase 
[Berlot & Bourne, 1992]. More recently, Skiba et d.{\996\ have shown that the N- 
teiminal 1-45 region of phosphodiesterase y (PDEy) containing the central polycationic 
region binds to G ta’s a3 helix and a3/a5  loop in both active and inactive states, while 
the C-terminal region of PDEy binds to the conserved switch region of activated 
confoimations by using Gta/Gjla chimaeras.
____■•S.
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Signalling components are known to undergo several co-translational and post- 
translational covalent modifications, including ADP ribosylation, phosphorylation and 
lipid modifications such as myristoylation, palmitoylation, polyisoprenylation and 
addition of glycosylphosphatidylinositol (GPI) [Turner, 1992]. Lipid modification of 
proteins plays a major role in regulating their subcellular location and function 
[Deschenes et d., 1990; Turner, 1992]. Many proteins involved in cellular signalling, 
i.e.receptors and G protein a  subunits, have been shown to be post-translationally 
acylated by one or more lipid molecules, and these modifications have been shown to 
promote membrane targeting and attachment [Resh, 1994; Casey, 1994; Wedegaertner 
etal., 1995].
1.3,5.1. ADP-ribosylation
Some of the a  subunits of G proteins are substrates for bacterial toxin-mediated 
modification. ADP ribosylation is a well known posttranslational modification whereby 
pertussis toxin, produced by Bordetella pertussis, catalyses mono-ADP ribosylation of 
Gia family subunits resulting in attenuation of inhibition of adenylyl cyclase activity. 
Arginine and cysteine specific mono ADP ribosyltransferases as well as enzymes that 
catalyse the removal of ADP ribose from ADP ribosylated amino acid residues have 
been identified in several cell types, suggesting that ADP ribosylation might be a 
reversible modification [Moss and Vaughan, 1988; Tanuma etal., 1988; Inageda and 
Tanuma, 1991]. Although the identification of an endogenously ADP ribosylated G 
protein a  subunit has not yet been clearly reported in vivo, there has been much 
evidence to support ADP ribosylation of G protein a  subunits by both arginine and 
cysteine specific mono ADP ribosyltransferases [Tanuma & Endo, 1989; Donnelly et 
d., 1992].
%
Another example is that cholera toxin, produced by Vibrio cholera, causes the 
persistant activation of the adenylyl cyclase system by this enzymatic transfer of ADP 
ribose from NAD+ to an arginine residue in G^a close to the site which houses the 
GTPase activity of the protein. The Got subunit is locked in its GTP-bound form and 
causes constitutive activation of adenylyl cyclase [Gilman, 1987].
1.3.5.2. Prénylation
It has been shown that many proteins involved in cellular signalling are 
modified by the addition of isoprene units, either farnesyl or geranylgeranyl groups, to 
their C-termini [Deschenes etal., 1990; Casey, 1994]. The presence of a motif 
consisting of a cysteine-aliphatic-aliphatic-any amino acid (CAAX) at the C-terminus is 
required for the process. However, this is not the only determinant for isoprenylation 
since the a  subunits of Gjl, Gi2 , Gi3 and Gq have such a motif at their C-termini but 
are not substrates for isoprenylation [Cox a/., 1993; Casey, 1994].
The addition of either farnesyl or geranygeranyl groups to CAAX containing 
polypeptides is not a random process, but is instead governed by the exact composition 
of the CAAX motif. Gy subunits, yi and y2 , have the C-terminal sequences CVIS and 
CAIL, respectively. yi is modified by the addition of a farnesyl residue whilst y2 , like 
all other y subunits, is modified by a geranylgeranyl group, suggesting that the extreme 
C-terminal residue is responsible for the direction of isoprenylation [Casey et al. ,
1.3.5.3. M yristoylation
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I1994]. Isoprenylation of y subunits plays an important role in membrane binding of the 
Py complex [Simonds, 1994].
il
It has been shown that the addition of myristic acid, a 14-carbon saturated fatty 
acid, to a protein may play a role in determining its membrane association properties 
[Deschenes e ta l, 1990]. The consensus sequence for this modification in Ga subunits 
is an N-terminal glycine residue at position 2 with a hydroxylamine residue four amino 
acids downstream. The addition of myristate to glycine-2 via an amide bond has been 
demonstrated in G ila, Gi2a , Gi3a, Gta, GqO and G%a but not in Gga. Although 
Gga is not myristoylated, the glycine residue at position 2  is nevertheless important in 
the signalling properties of the molecule. Mutation of the glycine to alanine, or deletion 
of the N-terminal region of G^a caused a reduction in the ability of Gga to activate 
adenylyl cyclase and to interact with the py complex [van der Neut etal., 1993]. This 
may be due to an inhibition of palmitoylation as gly 2  is required for palmitoylation of 
G ila and G%a [Galbiati etal., 1994; Hallak et d ., 1994].
1.3.5.4. Palmitoylation
Recently, a number of a  subunits have been shown to undergo the post­
translational process of palmitoylation. These include those that are myristoylated ie, 
GqO, G ila, G{2a , Gi3a and G%a, and also G^a and Gqa which do not undergo 
myristoylation. Palmitate is generally esterified to cysteine residues via thio-ester bonds 
[Casey, 1994; Casey, 199:^. The amide bond attaching the myristate is very stable and 
once attached, it is essentially permanently bound, although there has been a report of 
a demyristoylation of mature MARCKS protein [Manenti e ta l, 1994]. The thio-ester 
bond linking the palmitate is, however, much more labile and can be enzymatically 
cleaved.
The palmitoylation of some forms of p21ras is part of the overall process of 
isoprenylation. Following the addition of farnesyl or geranylgeranyl groups, 
proteolysis and carboxymethylation, a palmitoyltransferase adds palmitate to specific
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cysteine residues near the site of isoprenylation [Hancock etal, 1989]. This enzyme is 
poorly characterised and has yet to be purified. However, the enzyme requires the prior 
isoprenylation of p21ras. Given this specificity, this enzyme is unlikely to be 
responsible for addition of palmitate to G protein a  subunits and Src family members.
As mentioned above it has been shown that palmitoylation occurs in GgO 
[Parenti etal, 1993; Linder etal, 1993], in Gi2a , GqO and G qa/G na [Parenti e ta l,
1993], in Gi2a  and G jsa [Viet era/., 1994], and in gustducin [Hoon et al., 1995].
The residues responsible for undergoing this process have been identified as cysteine-3 
in Goct and GgO [Parenti et al., 1993; Degtyarev et al., 1993a], and cysteine 9 and 
cysteine 10 which are both palmitoylated in Gqa [Wedegaertner eta l, 1993].
The role of palmitoylation of G protein a  subunits is not yet clear, although it 
has been suggested that it may play a role in membrane association since palmitate 
negative mutants of Goa have been shown to have a decreased avidity of interaction 
with the plasma membrane [Grassie et a l, 1994]. The ability of this protein to still 
interact with the plasma membrane reflects the presence of other determinants for 
membrane attachment, e.g.the presence of myristate at the N-terminus. The ability of 
palmitate negative mutants of Gga to interact with the plasma membrane is less clear.
Degtyarev g/aZ. [1993b] found no effect on membrane attachment of C3S G^a when 
expressed in COS-7 cells whilst Wedegaertner et a/. [1993] found that palmitate was 
absolutely required for membrane association of G^a when expressed in HEK-293 
cells.
McCallum et a l [1995] have shown that the palmitoylation status of the 
cysteine residues at positions 9 and 10 in murine G n a  played a central role in defining 
membrane assosciation of this G protein and indicated that much of the particulate
/fraction of the expressed palmitoylation-resistant mutants was to represent non- 
functional rather than correctly folded protein by mutations of C9S, CIOS or a 
combination of both alterations. Treatment with an inhibitor of myristoyl-CoA:protein
I I I
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N-myristoyltransferase, 2-hydroxymyristate, prevented myristoylation of G ila, but 
not its palmitoylation or membrane association, and prevention of myristoylation by the 
introduction of the S6 D mutation into this G protein also prevented palmitoylation and 
comprised membrane interaction, suggesting that palmitoylation, but not 
myristoylation, plays a key role in membrane association of G jla [Galbiati et a l , 
1996].
Palmitoylation of G proteins is a dynamic process. The half life of palmitate on 
Gga is approximately 50-90 min [Degtyarev e ta l,  1993b; Wedegaertner & Bourne, 
1994] while the half life of the protein is approximately ll-22h [Levis & Bourne, 
1992; Degtyarev e ta l, 1993b]. Upon agonist activation of a receptor, the half life of 
the a  subunit decreases to around 6 h while the half life of the palmitate on the Gga 
subunit decreases to around 2 min. It is clear that the regulation of the protein and its 
attached palmitate on it are under very different control processes. It may be that 
reversible palmitoylation serves as a dampener of receptor mediated second messenger 
generation. In removing the palmitate, the G protein a  subunit may no longer be able to 
interact with the target effector system and thus second messenger generation would be 
curtailed [Wedegaertner e ta l , 1995].
1.3.5.S. Phosphorylation
Phosphorylation of G proteins is the least well charaterized of the covalent 
modifications. The first evidence that G proteins may be regulated by phosphorylation 
came with the observation that treatment of platelet membranes with partially purified 
PKC resulted in phosphorylation of a 41kDa protein, later demonstrated to be Gia, 
with a stoichiometry of 1 mole Pi per mole of substrate [Katada et al., 1985]. More 
studies with recombinant G proteins have shown that G%a subunit was phosphorylated 
by partially purified PKC on a serine residue near the N-terminus, whereas
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recombinant G ila, Gi2a  and Gi3a were not phosphorylated under the same conditions
[Lounsbury etd ., 1991]. In a reconstituted system containing purified insulin protein
kinase and PKC, phosphorylation of a  subunits occurred on both serine and tyrosine
residues [Krupinski etal., 1989; Pyne etal., 1992].
Recently, Kozasa etal. [1996] have shown that Gi2a  serves as a substrate for
phosphorylation by various isoforms of PKC in vitro suggesting that PKC regulates
a  12"mediated signalling pathway by preventing their association with Py- The y 12 was
shown to be phosphorylated by PKC and the phosphorylated pyi2 associated with
Goa more tightly than the unphosphorylated form [Morishita et a l, 1996]. In v-src
oncogene transformed Rat 1 fibroblasts, G qa/G na were phosphorylated on tyrosine
residues and markedly increased inositol phosphate generation by phosphoinositidase
[Liu etal., 1996].
However, the physiological consequences of this process have yet to be 
demonstrated although phosphorylation of G proteins may function significantly in 
cross-talk between signalling systems.
1.4. Effectors interacting with G proteins
A relatively small number of effector systems convert extracellular signals 
transduced across the plasma membrane by GPCRs and G proteins into intracellular 
responses. These include various ion channels, cGMP phosphodiesterase, adenylyl 
cyclase, phospholipase A2 , phosphoinositidase C and phospholipase D.
1.4.1. Adenylyl cyclase family
It is generally known that adenylyl cyclase catalyses the conversion of 
intracellular ATP to cAMP. This receptor mediated signal is transduced by G^a
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subunits for a stimulatory effect on the enzyme or by Gia subunits (G ila, Gi2a  and
Gi3a) for an inhibitory effect, as mentioned earlier. Cloning studies have identified
multiple types of adenylyl cyclases which are all stimulated by Gga. All adenylyl
cyclases are associated with the plasma membrane and hydropathy analyses suggest
that they span the membrane 12 times. The N- and C-termini are both intracellular and
the various isotypes all possess two large intracellular domains, one (Cl) between
transmembrane helices 6  and 7 and another (C2) located at the C-terminus [Taussig &
Gilman, 1995] .These regions are thought to form catalytic sites, termed C, which are
subdivided into 2 domains a and b in this protein. This molecular architecture
resembles that of ATP driven pumps such as the P glycoprotein [Cooper etal., 1995]
and a K+pump in Paramecium [Schultz etal., 1992].
Portions of the Cl and C2 (C la and C2a) domains are well conserved
displaying -92% homology, and are very similar to the catalytic domains of a series
of membrane bound guanylyl cyclases [Chinkers and Garbers, 1991]. Catalytic activity
of adenylyl cyclase requires the N- and C-terminus [Tang et al, 1991] and also both
Cla and C2a, suggesting that these two domains may interact to produce an active
protein [Tang etal, 1992]. The exact site on the adenylyl cyclase polypeptide required
for catalytic activity and G protein interaction is not yet clear. The amino acid sequence
homology is limited beyond the C la and C2a domains, but the overall structure is
probably well conserved, suggesting that the two sets of 6  transmembrane helices may
play a certain undiscovered role in the function of the enzyme. Potential for cross-talk
between signalling pathways exists at the level of adenylyl cyclase. Nine different
adenylyl cyclase isoforms have been identified, each of them being the product of
distinct genes. The isoforms of mammalian adenylyl cyclase display differential
■ 7-.':
regulation by py dimers, calcium ions and protein kinase C [Choi et a l,  1993;
Jacobiwitz et al., 1993; Yoshimura and Cooper, 1993]. The diterpene forskolin 
stabilizes the interaction with G^a and adenylyl cyclase C domain causing the
II
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constitutive activation of adenylyl cyclase which gives rise to chronically high levels of 
cAMP inside the cell which causes a variety of intracellular effects.
1.4.2. Phosphoinositidase C family
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The phosphoinositidase C (PIC) superfamily comprises at least 16 isoenzymes 
which have been classified into 3 subfamilies, p, y and Ô. All the isozymes function in 
the same manner, hydrolysing phosphatidylinositol-4,5-bisphosphate (PIP2) to yield 
the second messenger molecules sn-1,2-diacylglycerol (DAG) and inositoi-1,4,5- 
trisphosphate (IP3). This bifurcation of the signal leads to the activation of two distinct 
pathways. The lipid molecule DAG causes the activation of PKC which is a family of 
serine/threonine protein kinases and affect many cellular responses including the 
activation of the Raf kinase, which is then able to activate another series of protein 
kinases ending in the phosphorylation and activation of MAP kinase. IP3 , being a polar 
molecule, is released from the membrane to bind to specific receptors located on the 
endoplasmic reticulum. This causes the release of Ca^+ from stores in the ER, again 
leading to effects on cellular systems.
The phosphoinositidase C isozymes differ in their regulation and only those 
belonging to the p class are under direct G protein control [Rhee & Choi, 1992] 
although PLC Ô1 may be stimulated by py [Park etaL, 1993]. Those of the y class are 
activated through their Src Homology 2 (SH2) domains by binding phosphotyrosine 
residues of growth factor receptors. The p isozymes are activated both by the a  
subunits of Gq family members and by the py dimer, which can be generated from any
■class of a  subunit. Both G 14a  and Gigo activate the p i isoform, whereas only Gigcx 
activates the P2 isoform to a significant degree [Wu etaL, 1992; Lee, C. etaL, 1992].
This dual regulation gave rise to pertussis toxin-sensitive activation, caused by the 
release of py from activated a  subunits of Gi family members. The sites of action on
I
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Table 1.2. Regulation of phosphoinositidase Cp isoforms by G protein
The p isoforms of phosphoinositidase C are regulated by G protein a  and Py 
subunits. To date, p i-P s  are known to be activated by a  and py subunits but to 
different degrees. The P4  isoform is not well-characterised. The magnitude of 
stimulation is described in order ++++ > +++ > + + >  + > +/- [Smrcka & Sternweis, 
1993; Lee a/., 1993].
I
I
Ij
„ v , tI
PlCg isoform Activation by G q/na Activation by Ggv
pi + + + +
P2 + / “ + +
P3 ■f" + + + + + +
P4 ? ?
!■
I
Ir4
I
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1PICp for G protein a  subunits and py dimers are apparently distinct, however, and the 
efficacies of their activation differ between the different members of the PICp family 
(PICpi^) as displayed in Table 1.2 [Smrcka & Sternweis, 1993; Lee etaL, 1993].
Recently, Liu etaL [1996] have shown that a newly discovered PIC54 was 
dominantly present in nucleus by immunocytochemical staining and nuclear PIC54 was 
dramatically increased at the transition from Gi- to S-phase, but not in PICpi, PlCy 1 
and PIC01, suggesting that this might play a role in cell growth as one of the early 
genes expressed in the cell cycle.
1.4.3. PhosphoUpase D
S
Phospholipase D (PLD) catalyses the hydrolysis of phosphatidylcholine 
(PtdCho), producing phosphatidic acid(PtdOH) and choline as shown in Figure 1.6 
[Exton, 1990]. PtdOH is a central metabolite in both phospholipid and triglyceride 
metabolism and an effector in several physiological processes including secretion,
DNA synthesis, and cell proliferation [Boarder, 1994; Rose etaL, 1995]. PtdOH is 
metabolized by PtdOH phosphohydrolase to diacylglycerol (DAG), which can activate 
protein kinase C (PKC) as a second messenger. PLD activity was identified in plants, 
bacteria, fungi and mammalian tissues and cells including brain, lung, liver, adipose 
tissue, endothelial cells, HL-60 cells and spermatozoa; lung and brain are the richest 
sources [Massenberg etaL, 1994].
At least two classes of membrane-associated PtdCho-specific PLD enzymes 
have been described in mammalian tissues. One is stimulated by phosphatidylinositol- 
4,5-bisphosphate (PIP%), while the other is stimulated by oleate [Brown et d ., 1993; 
Messenberg etaL, 1994]. The PIP2-dependent PLD activity in monocytic cells and 
brain can be activated by a number of monomeric GTP-binding proteins such as the 
ADP-ribosylation factor (ARE). This ARF-regulated PLD is cytosolic and hydrolyses
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Figure 1.6. The hydrolysis of phosphatidylcholine (PtdCho)
by phosphoiipases
The activation of phospholipase A i and A2 (PLAj and PLA2) results in 
the production of one fatty acyl chain and acylphosphatidylcholine, known as 
lysolecithin, from phosphatidylcholine. The activation of phospholipase C (PLC) 
results in the production of phosphocholine (not shown) anddiacylglycerol 
(DAG). The activation of phospholipase D (PLD) results in the production of 
choline (not shown) and phosphatidic acid (PA). PLA produced arachidonic acid, 
DAG and PA are possible second messengers in cellular signalling. 
Diacylglycerol and phosphatidic acid are interconvertible by the actions of 
diacylglycerol kinase and phosphatidic acid phosphohydrolase. Ri and R% are 
hydrocarbon chains of long chain fatty acids.
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I■phosphatidylethanolamine (PtdEtn) and phosphatidylinositol (Ptdlns) as well as
■VPtdCho. This finding has led to the speculation that PLD functions in protein 
trafficking and vesicular movement by altering the local structural charateristics of 
membranes [Liscovitch & Cantly, 1995].
However, the mechanism of PLD regulation by G protein coupled receptors is 
still a matter of debate. A number of reports have described receptors that are coupled 
to PLD via a G protein including the P2 purinergic receptor [Martin & Michaelis,
1989], oc2-adrenergicreceptor [MacNulty et d., 1992], and m l, m2 and m3 muscarinic 
acetylcholine receptors [Offermanns et at., 1994]. However, there has been no 
adequate distinction between receptors that have a direct G protein-1 inkage and those 
that are dependent on an intermediate step involving the activation of PIC, since this 
PLD response is dependent upon Ca^+ entry [Boarder, 1994]. Besides the receptor 
themselves, Ca^+, PKC, tyrosine kinases, and GTP-binding proteins have been shown 
to be involved in the regulation of cellular PLD activity [Billah, 1993; Exton, 1994].
'Singer etaL [1995] have shown that multiple cytosolic components including 
ARE, RhoA and an unidentified factor which activated PLD in a nucleotide- 
independent manner in a partially purified PLD from membrane of porcine brain were 
involved in PLD stimulation. Stimulation of PLD by purified PKCa or recombinant
PKCa occurred in the absence of any nucleotide and required activators such as Ca^+ 
or phorbol ester and this stimulation was synergistic with either ARE or RhoA, but 
independent of PKC activity since dephosphorylation of the recombinant PKCa with 
phosphatase 1 or 2A resulted in a loss of its kinase activity but had little effect on its
ability to stimulate PLD either alone or in conjunction with ARE [Singer etal., 1996].
More recently, it has been reported that rho protein plays an essential role in 
PLD pathway by demonstrating that cytotoxin B of Clostridium difficile which 
glycosylates this protein inhibits PLD activity. This toxin B treatment also inhibited
PLD activation by the direct G protein activators, AIE4- and GTPyS [Schmidt et aL ,
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1996]. Waksman etal. [1996] have identified a phosphtydylcholine-hydrolising PLD 
gene from chromosome XI of the yeast, Saccharomyces cerevisiae.
1.4,4. Phospholipase A%
The phospholipase Â2 (PLA2) is one of four enzymes that hydrolyze specific 
bonds in phospholipids as shown in Figure 1.6, e.g., phosphatidylcholine and 
phosphatidylethanolamine and is an abundant component of some snake venoms, 
which have the ability to cause hemolysis or rupture of red blood cells. It is also known 
that PLA2 has two forms; extracellular and intracellular. The intracellular PLA2 is 
found in plasma and other intracellular membranes and also the cytosol [Exton, 1994]. 
The cytosolic form which is regulated by protein kinases and Ca^+ is a substrate for 
mitogen-activated protein kinase (MAPK) and PKC, phosphorylation of the enzyme 
leading to its activation [Hazen etal., 1993; Lin etal., 1993].
There is some evidence that G proeins may control PLA2 activity in 
permeabilized neutrophils, HL60 promyelocytes, platelets, RBL basophilic cells, 
Swiss 3T3 fibroblasts, thyroid cells and MC3T3-E1 osteoblasts [Exton, 1994]. In 
addition, there have been reports of guanine nucleotide and AIF'4  effects on PLA2 
activity in isolated membranes from platelets and thyroid cells [Silk etal., 1989]. In rod 
outer segment, light and GTPyS activate CPLA2 activity and both cholera and pertussis 
toxins inhibit it [Jelsema, 1987]. The addition of transducin Py subunits markedly 
activated PLA2, however, transducin a  subunits which by themselves were slightly 
stimulatory inhibited the stimulatory effect of Py subunit [Jeselma & Axelrod, 1987]. 
Antibodies to py subunits inhibited PLA2 response to histamine, but not thrombin 
[Murayama er a/., 1990]. Conversely, antibodies to Gjot and GqCx inhibited both 
responses [Murayama et d., 1990].
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1.4.5. Ion channels
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Recently, Xu et d. [1993] transfected NIH 3T3 fibroblasts with wild-type 
G i2Cx and also a mutant form of G 12a  in which glutamine 228 was changed to leucine.
The mutation decreased the GTPase activity and enhanced transformation activity. 
There was no change in PI metabolism, cytosolic Ca^+ or PLD activity, but production 
of arachidonic acid was enhanced in the presence of serum. However, the nature of the 
G proteins that regulate PLA2 activity remain uncertain and direct coupling between a 
pure G protein subunit and a pure enzyme has not been demonstrated.
a
i-3
It has been shown that Ggcx and Gia can regulate more than a single effector 
system. In addition to stimulating adenylyl cyclase, Ggo can stimulate Ca^+ channels 
of the L-type and a subclass of smooth muscle Ca^+-activated voltage-dependent K+ 
channels (Kca channels). These are functions that are expressed only in specific tissues 
and cell types so that responses to receptors that activate GgO may vary from tissue to 
tissue [Bimbaumer etal., 1994]. The inhibition of voltage-dependent Ca^+ channels 
through the muscarinic and somatostatin receptors was shown to be mediated by the 
pertussis toxin-sensitive G proteins, Gola and Go2a, in secretory cells [Kleuss eta l.,
1991]. Recently, it has been demonstrated that Gpy subunits can modulate N-type Ca^+ 
channels in synaptic neurons [Ikeda, 1996]. The Gy subunit is ineffective by itself, 
however, overexpression of exogenous Gp subunits is sufficient to cause this channel 
modulation [Herlitze et al., 1996].
At least two classes of K+ channels, the muscarinic-type inwardly rectifying K+ 
channel which is found primarily in cardiac artrial cells and in neuroendocrine cells, 
and the ATP-sensitive K+ channel found in cardiac ventricle cells and pancreatic islet 
cells, can be activated by G^a subunits (Gila,Gj2a  and GiScc). These channels are 
also referred to as G protein-gated K+ channels [Birnbaumer eta l, 1994].
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Na"*" channels are another example of ion channels regulated by heterotrimeric G 
proteins. One such type regulated by aldosterone has been shown in patch clamp 
studies to be gated by G proteins, in a similar manner to other ion channels, and the 
G p a  subunit is known to be topographically localized with the channel [Ausiello etal. ,
1992]. Aldosterone stimulates the expression of Gi3a subunit protein which is 
palmitoylated and co-localized with the Na+ channel, and sodium transport is 
significantly inhibited by inhibition of Gj3a palmitoylation in A-6  cells [Rokaw etal. , 
1996].
1.4.6. Regulation of MAP kinase activity
Mitogen activated protein kinases (MAP kinases) are activated by many 
extracellular stimuli that influence cell proliferation and differentiation, including 
growth factors, cytokines and hormones. Signalling via growth factors such as 
epidermal growth factor (EGF) involves phosphorylation of tyrosine residues and a 
series of protein-protein interactions, mediated via Src homology 2 and 3 (SH2/SH3) 
domains, leading to serial activation of p2P ^ (ras), Raf-1 kinase and MAP kinases 
[Blenis, 1993; Crews & Erikson, 1993]. Agonist binding to the EGF receptor leads to 
receptor dimerization and autophosphorylation, resulting in a phosphotyrosine- 
dependent association with She. The subsequent interaction between Tyr(P)- 
phosphorylated She and the Grb2 adaptor protein causes a translocation of the Grb2- 
Sos complex to the membrane, where Sos mediates guanine nucleotide exchange on 
Ras [Li 1993].
Two members of the MAP kinase family are the p44 MAP kinase (extracellular 
signal-regulated kinase 1, ERKl) and p42 MAP kinase (ERK2). When these two 
isoforms are activated by phosphorylation catalyzed by Raf-1 kinase or other MAP 
kinase kinases (MEKs) they in turn catalyse the phosphorylation of a large group of
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substrates located at the cell membrane, cytoplasm and nucleus [Davis, 1993]. 
Inactivation of MAP kinase is by dephosphorylation of the same threonine and tyrosine 
residues catalysed by dual-specificity protein phsophatases [Nebreda, A.R., 1994].
Several Gi-coupled receptors, including the az  adrenergic receptor, 
lysophosphatidic acid (LPA) receptor, m2 muscarinic acetylcholine (m2ACh) receptor, 
and platelet-activating factor (PAF) receptor, have been shown to stimulate MAP kinase 
activity in various cell types as shown in Figure 1.7 [Howe & Marshall, 1993; van 
Corven etal., 1993; Cook etal., 1993; Hordijk etal., 1994; Alblas etd ., 1993; Winitz 
e ta l ,  1993; Honda e ta l ,  1994]. The signalling pathways by which Gi-coupled 
receptors activate MAP kinase, however, are not yet clear, but there is evidence for 
both Ras-dependent and Ras-independent activation of MAP kinases [Koch et a l.,
1994]. The primary G protein subunit(s) responsible for Gi-mediated Ras and/or MAP 
kinase activation has not been identified, but reports have implicated Gpy as an 
activator of overexpressed p44 MAP kinase (ERKl) in COS-7 cells [Crespo et ah,
1994].
van Biesen etal. [1995] have shown that Gpy subunits derived from PTX- 
sensitive G proteins were mediated by Ras-dependent MAPK activation. Release of 
Gpy promotes the tyrosine phosphorylation of She and its subsequent association with 
Grb2-Sos. Both RTK- and Gpy-mediated MAPK activation were completly blocked by 
the expression of dominant negative mutants of mSosl and Ras, demonstrating that 
RTKs and Gpy activate MAPK via a common signalling pathway involving She, Grb2, 
Sos and Ras [van Biesen etal., 1995].
MAPK activation via Gj-coupled receptors was sensitive to inhibition by the C- 
terminal fragment of pARKl (p ARK let), a competitive inhibitor of Gpy-mediated 
signals [Koch et al., 1994]. However, not all GPCRs mediate MAPK activation 
exclusively via receptor-catalysed release of Gpy subunits. For example, MAPK 
activation via receptors coupled to members of the PTX-insensitive Gq family, such as
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Figure 1.7. Scheme of the activation of the Ras-MAP kinase 
signal transduction pathway through growth factor 
and Gj-coupled receptors.
Gj-coupled receptor activation (e.g., LPA) of Ras is mediated by the Gpy 
subunit complex resulting from receptor-mediated dissociation of the 
heterotrimeric Gj protein. Gpy alone or through the recruitment of one or more 
cytoplasmic or membrane associated factors, possibly by pleckstrin homology 
(PH) domain-directed binding, leads to Ras activation. Growth factor receptor 
activation (e.g. EGF) activates Ras through the recruitment, directed by 
SH2/SH3 domains, of the cytoplasmic proteins Grb2 and Sosl. The 
convergence of these two different surface receptor signalling pathways on Ras 
activation in turn leads to the sequential activation of the Raf-1 and MAP kinase 
cascade, producing activation of nuclear genes and cellular responses including 
growth and differentiation.
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a
ml muscarinic acetylcholine receptor and the a i  adrenergic receptor, was insensitive to 
the Gpy séquestrant pARKlct peptide [Hawes etal., 1995], instead, MAPK activation 
occured predominantly via a PKC-dependent pathway. The GTP-bound a  subunit of 
the Gq^Gn protein activated phosphoinositide hydrolysis and PKC and subsequently 
the activated PKC stimulated MAPK activity via a poorly understood mechanism 
involving the activation of Raf kinase [Kolch etal, 1993; Troppmair e ta l, 1994].
Recently, van Biesen etal. [1996] have shown that Ras-independent MAPK 
activation was mediated by the a  subunit of the PTX-sensitive Go protein at the ml 
muscarinic acetylcholine receptor and platelet-activating factor receptor, demonstrating 
that Go-mediated MAPK activation was sensitive to treatment with pertussis toxin but 
insensitive to inhibition by a Gpy sequestrating peptide (pARKlct).
However, a direct role for Gpy in Ras activation or in the regulation of 
endogenous MAP kinase activity has not been established.
i"It has been known that the basic unit of information processing via G protein- 
coupled mechanisms consists of a receptor, a heterotrimeric G protein, and an effector 
enzyme. Despite intense investigation of the individual components of such signal 
transduction cascades and the basic features of cellular response to the presence of 
receptor ligands, little is currently known about regulation of each component.
Chapter 3 aims to examine signalling properties of G protein-coupled receptor 
isoforms which are co-expressed in the cell, and whether they display differences in 
agonist potency, G protein coupling, and activation of effector systems.
Chapter 4 aims to investigate the mechanism of how receptor agonists can 
control the cellular content of G proteins which interact with that receptor.
Chapter 5 aims to investigate signalling charateristics of a constitutively active 
mutant (CAM) receptor. The regulation of signalling cascade elements and the action of 
inverse agonist at this receptor will be discussed.
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Chapter 2. Materials and Methods
Chapter 2. Materials and Methods
2.1. Materials
2.1.1. Chemicals
Amersham International Pic., Buckinghamshire
Amplify, Hyperfilm
Applied Biosystems, Warrington, Cheshire
Amplitaq Dyedeoxy terminator cycle sequencing kit (part no.dOl 150), 
phenol:water:chloroform reagent (68:18:14) (part no. 400765)
Appligene, Birtley, Co. Durham 
Aquaphenol
Boehringer Mannheim UK, Lewes, East Sussex 
BSA, aprotinin, DNase free RNase
Difco, Detroit, Michigan, USA
Y east extract, Bacto agar, Bacto tryptone
Calbiochem-Novabiochem (UK) Ltd., Beeston, Nottinghamshire 
Pansorbin cells, DTT
Gibco Life Technologies, Paisley, Lanarkshire
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Scottish Antibody Production Unit, Lanarkshire
Horseradish peroxidase conjugated donkey anti-rabbit IgG
DMEM, inositol free DMEM, glutamine, sodium bicarbonate, newborn calf serum, 
penicillin/streptomycin solution, Lipofectin, Lipofectamine, ultrapure urea, agarose, Ikb 
DNA ladder
National Diagnostics, Aylesbury, Buckinghamshire
Sequagel-6
Porton Products, Porton Down, Wiltshire 
Pertussis toxin
Promega Ltd., Southampton, Hampshire
DNA minipreps, DNA maxipreps, PGR preps, DNA clean-up system, calf 
intestinal alkaline phosphatase (CIAP), T7 promoter primer, Taq DNA 
polymerase, 4 dNTPs, T4 DNA ligase, all restriction endonucleases
Qiagen Ltd., Surrey 
DNA extraction kit
Sigma Chemical Co. Ltd., Poole, Dorset
Trypsin, NP-40, gelatin, o-dianisidine hydrochloride, 7-deoxycholic acid, 
bromophenol blue, TEMED, forskolin, Coomassie Blue R-250, sodium 
azide, geneticin sulphate, soybean trypsin inhibitor, PMSF, Triton X-lOO, 
thimerosal, ampicillin, low melting point agarose, mineral oil. Ponceau S,
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TRH, PMA, endothelin-1, phentolamine, phenylephrine, noradrenaline, 
prazosin
Stratagene
pfu DNA polymerase
All other reagents and chemicals were of analytical grade and obtained from Fisons 
Scientific Equipment, Loughborough, Leicestershire.
2.1.2. Radiocheinicals
Amersham International pic., Buckinghamshire
[a-32p]ATP, cyclic pH]AMP, myo-[2-3H]inositol (17.M 7.6 Ci/mmol), 
pH]prazosin (24 Ci/mmol), [9,10-3H(N)]palmitic acid (40-60 Ci/mmol)
Du Pont NEN (UK) Ltd., Stevenage, Hertfordshire 
PH]TRH (45-70 Ci/mmol) 
ICN Flow, Irvine, Lanarkshire 
Trans label (1180 Ci/mmol)
2.1.3. Antisera
All antisera used in this study are detailed in Table 2.1. The methods of 
production of the antisera have been described previously [Goldsmith etal. ,1988].
2.1.4. Plasmids
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Table 2.1. Specificity of antisera
The antisera used in this study are shown along with the peptide 
sequences to which they were raised, the corresponding areas of the G protein a  
subunits which correspond to these amino acids, the a  subunits which the 
antisera identify and the references dealing with their production. All of the Ga 
antisera were made in house. ERK-1 anti peptide antisera were provided by 
Dr.N.G. Anderson, Hannah Research Institute, Ayr.
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All plasmids used in this study are house kept except plasmid pBluescript SK" 
with a full length version of the rat thyrotropin-releasing hormone receptor short 
isoform was provided by Dr. Pilar de la Pena, University of Oviedo, Spain.
2.2. Cell culture
2,2.1. Cell Growth
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Cells were grown in continuous monolayer culture in 75 cm^ sterile tissue 
culture flasks (Nunc, Roskilde, Denmark) in sodium pyruvate-free Dulbecco's 
Modified Eagle's medium supplemented with 5 -10 % (v/v) semm ( as indicated for 
each cell line), 2 mM L-glutamine, 100 I.U./ml penicillin, 100 pg/ml streptomycin. 
Buffering of the medium was achieved by the addition of 0.375 % (W/V) sodium 
bicarbonate and growing the cells in an atmosphere of air : CO2 in the ratio of 95 % : 5 
%. Cells were incubated in 10 ml of the above medium in a VSL incubator (Scotlab, 
Strathclyde) at 37°C and allowed to reach confluency. The medium was changed 
regularly,generally every 4 days,
2.2.2. Maintenance of cells
Parental Rat 1 fibroblasts and clones derived from these cells expressing the
long and the short TRH receptor cDNA isoforms were grown in the above medium 
containing 5 % newborn calf serum. The receptor expressing clones were further
maintained in the presence of 750 pg/ml geneticin sulphate. Rat 1 fibroblasts 
transfected to stably express the rat aiA/D> the hamster a\B, and the bovine « ic  
adrenoceptor cDNA species were obtained from Dr.D.E.Clark (Syntex, Palo Alto, CA) 
under license to Syntex from Dr. L.F. Allen (Duke University, NC) and were grown I
2.2.3. Passaging of confluent cell cultures
containing DMEM and aliquots of 1 ml were each added to 8  new flasks containing 9 
ml of medium and placed in an incubator.
2.2.4. Storage and recovery of cells
6 2
in the same medium. Rat 1 fibroblasts transfected to stably express the hamster wild 
type and constitutively active mutant aiB  adrenergic receptor cDNA species were 
obtained from Dr, Susanna Cotecchia (University De Lausanne, Switzerland) and were
■■■maintained in the presence of 300|xg/ml geneticin sulphate. COS-7 cells and HEK 293 
cells were grown in DMEM containing 10 % (v/v) fetal bovine serum.
Upon reaching confluency, each flask of cells was usually split 1: 8  into new 
flasks. Medium was removed and the monolayer trypsinized by addition of a solution
containing 0.1% (w/v) trypsin, lOmM glucose, 0.67mM EDTA, pH7.4. When cells 
had detached from the flask, trypsinization was terminated by the addition of 10 ml 
DMEM containing 5 - 10 % newborn calf serum. The cell suspension was then 
decanted into a sterile 50 ml polypropylene centrifuge tube (Nunc,Roskilde, Denmark) 
and centrifuged in a bench top centrifuge (MSE) at 1000 rpm for 5 mins. The
:supernatant was discarded and the pellet of cells resuspended in 8  ml of serum
To provide a stock of cells for further use, cells were cryogenically stored in 
liquid nitrogen. After trypsinization and centrifugation as above, cells were 
resuspended in 1 ml per confluent flask of freezing medium. This was DMEM 
supplemented with 2 0  % (v/v) of the appropriate serum and 10 % (v/v) dimethyl 
sulphoxide. 1 ml of the cell suspension was added to sterile freezing vials (Nunc, 
Denmark). To prevent formation of ice crystals in the cells, the freezing vials were
.1
2.2.6. Labelling of cells with pH]palmitic acid
2.2.7. Pulse-chase of cells with Trans label
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1
placed in a polystyrene box packed with cotton wool and frozen slowly overnight at 
-80°C. The cells were then transferred to liquid nitrogen.
To bring the frozen cells up, vials were removed from liquid nitrogen and 
thawed at 37°C . The contents were placed in a 50 ml centrifuge tube and diluted with 
13 ml of DMEM containing 10 % serum and centrifuged at 1000 rpm for 5 rains as 
above. The supernatant was then discarded and the pellet resuspended in 10 ml DMEM 
containing 5-10 % serum and the whole added to a 75 cm^ flask. Cells were 
maintained as described above.
2.2.5. Treatment of cells with drugs and toxins
Cells which were to be pretreated with agonist, antagonist and pertussis toxin 
were grown to approximately 70 % confluency. Medium was then removed by 
aspiration and 9 ml of fresh DMEM was then added to each flask. Agonist, antagonist 
and toxin were prepared fresh as a lOx stock in DMEM and filter sterilized as described 
above. 1 ml was added to each flask to a desired final concentration. Cells were then 
grown for various times prior to harvesting as described in section 2.2.8.
150 pCi/ml of [9, lO-^Hjpalmitate was added to cells stably expressing the aiB  
adrenergic receptor in DMEM containing 5 % (v/v) dialyzed newborn calf serum, 5mM 
sodium pyruvate and incubated for 4 hrs. Cells were then harvested and total lysates 
immunoprecipitated as described in section 2.5.2.
Cells were trypsinized and seeded in 6 -well culture plates. At about 70 % 
confluency, 2/3 of the growth medium was replaced with DMEM lacking methionine 
and cysteine, supplemented with glutamine, antibiotics,and 50 pCi/ml Tran^^S-label 
(final concentration in well). After the labeling period (16hrs), the radioactive medium 
was removed, and the now close to confluent cell layer was washed once with 2 ml of 
normal DMEM culture medium. They were subsequently incubated in 1.5 ml/well 
normal culture medium in the presence or absence of 100|iM phenylephrine. At 
appropriate times, the medium was removed and cells were dissolved in 2 0 0  p,l/well of 
1 % (w/v) SDS and scraped. The cell suspension was transferred to a screw-cap test 
tube and heated to 100°C for 20 min to denature proteins and nucleic acids, and then 
the samples were either stored at - 20®C or processed directly for immunoprécipitation 
as described in section 2.5.2.
2.2.8. Harvesting of cells
After cells reached confluency or the particular treatment time had elapsed they 
were harvested by scraping the monolayer into the medium and the cells collected in a 
50 ml centrifuge tube on ice. The tubes were centrifuged at 2000 rpm for 5 min at 4°C 
in a Beckman TJ-6  benchtop centrifuge. The supernatant was discarded and the cell 
pellet was resuspended in 50 ml of ice-cold PBS (137 mM NaCl, 4 mM NagHPO^, 
0.27 mM KCl, 0.15 mM KH2PO4 , pH 7.4) and centrifuged as before. Again the 
supernatant was discarded and the pellet was resuspended in Ix PBS and re­
centrifuged. The supernatant was again discarded and the pellet was stored at -80°C 
until required.
2.2.9. Transient transfection of cells
6 4
2.2.10. Stable transfection of cells
6 5
For the transient expression of receptor cDNA, COS-7 cells or FIEK 293 cells 
were used. These cells were grown to approximately 50 % confluency in 100 mm 
tissue culture dishes as described above. DNA (5 -10 pg) was added to a 13 ml sterile 
polypropylene centrifuge tube containing 20-30 pi of Lipofectin and sterile Milli Q 
H2O, to a final volume of 300 pi. DNA/liposome complexes were allowed to form for 
15 min during which time the cells were washed twice with serum free DMEM. 10 ml 
of serum free DMEM was then added to the DNA/liposome complexes and the whole 
added to one 100 mm dish of cells. Cells were then incubated for 8-12 hrs to allow the 
DNA to enter the cell. Medium was then replaced with DMEM containing 10 % 
newborn bovine serum and cells were incubated for approximately 72 h before being 
harvested as described in section 2.2.8,
Rat 1 fibroblasts were grown to approximately 60 % confluency in 100 mm 
tissue culture dishes. cDNA (5-10 pg) encoding either the long or short isoform of the
rat TRH receptor together with 0.5-1 pg of the plasmid pSV2-neo (Invitrogen) was 
added to a sterile 13 ml polypropylene tube containing 40 pi of Lipofectin and serum
':i,
free medium to a final volume of 200 pi. DNA/liposome complexes were allowed to 
form for 15 min during which time the cells were washed twice with serum free 
DMEM. 10 ml of serum free DMEM was then added to the DNA/liposome complexes 
and the whole added to one 100  mm dish of cells.
After 16 h medium was replaced with normal DMEM containing 5 % newborn 
bovine serum, and 48 h later cells were trypsinized and split 1:3 into new 100mm 
tissue culture dishes and were maintained in the above medium supplemented with 750 
pg/ml geneticin sulphate to initiate selection. Resulting geneticin-resistant clones were 
picked and seeded into 24-well plates with normal medium containing geneticin .1
sulphate (750 pg/ml) and 1 week later cells were transferred into 25 cm^ flasks and 
again transferred into 75 cm^ flasks when they were confluent and expanded for 
further use.
2.3. Preparation of plasma membrane fractions
Membranes were prepared according to the method of Koski and Klee (1981). 
Frozen cell pastes were thawed on ice and resuspended in 2 ml of ice-cold TE buffer 
(10 mM Tris HCl, pH7.5, 0.1 mM EDTA ) and transferred to a pre-chilled glass 
homogenizer tube. The cells were then homogenized, on ice, with 25 strokes of a 
hand-held teflon-on-glass homogenizer. The resulting homogenates were transferred to 
polypropylene centrifuge tubes and the homogenizer tube washed with a further 1 ml 
of ice-cold TE buffer and the contents added to the centrifuge tube.
Centrifuge tubes were placed in a type 50Ti rotor (Beckman) and centrifuged at 
SQOgcc^? for 10 min at 4®C in a Beckman L5-50B ultracentrifuge. The pellet, which 
contained nuclei and unbroken cells, was discarded and the supernatant transferred to 
fresh pre-chilled centrifuge tubes and centrifuged at 48,000g^ for 10  min at 4®C.
The supernatant was discarded and pellet resuspended in 5 ml of TE buffer and 
recentrifuged at 48,000^^^ for 10 mins at 4®C. Again the supernatant was discarded 
and pellet resuspended in TE buffer to give an approximate protein concentration of 1-3 
mg/ml. The samples were then frozen at -SO^C in lOOpl fractions until required.
2.4. Determination of protein concentration
Protein concentrations were determined by the method of Lowry e/ n/.[1951], 
using BSA as standard. The samples were read at 750 nm on a Shimadzu UV-1201 
UV visible spectrophotometer.
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2.5. Preparation of samples for SDS-PAGE
2.5.1. TCA/deoxychoIate precipitation of proteins
2.5.2. Immunoprecipation of G-proteins
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iThe required amount of crude plasma membranes as indicated for each 
experiment, was placed in a 1.5 ml microcentrifuge tube on ice and 6.3 pi of 2 % (w/v) 
7-deoxycholic acid, sodium salt added. 700 pi of dH2 0  and 250 pi of 24 % (w/v) 
trichloroacetic acid were then added sequentially and the tubes were vortexed briefly 
and incubated on ice for 15 mins before being centrifuged on an MSE microcentrifuge 
at 13,000 rpm for 5 min. The supernatant was discarded and the pellet dissolved by the
addition of 20 pi of 1 M Tris base. Samples were then prepared for SDS-PAGE by the
addition of 20 pi of SDS-PAGE sample buffer containing 5 mM urea, 0.4 mM DTT, 
0.4 mM Tris HCl, pHS.O, with a few crystals of bromophenol blue.
To 200 pi of SDS-denatured cell suspension from section 2.2.7 was added 
800 pi of solubilization buffer (1 % (w/v) Triton X-100, lOmM EDTA, lOOmM 
NaH2P0 4 , 10 mM NaF, 100 mM Na3V0 4 , 50 mM HEPES, pH 7.2) and 100 pi of 
Pansorbin (Calbiochem). Samples were incubated at 4°C with continuous rotation for 
1-2 h for nonspecific preclearing. Following centrifugation of the samples at 13,000xg 
for 1 min at 4°C, the supernatant was collected and subjected to immunoprécipitation 
by addition of 100 pi protein A-agarose along with 10 pi of the specific G-protein 
antisemm and rotated at 4°C for 3 h.
Immune complexes were then recovered by centrifugation at 13,000xg for 
Imin and washed by resuspension-centrifugation three times each with 1 ml of wash
buffer ( 1% (w/v) Triton X-100, 100 mM NaCl, 100 mM NaF, 50 mM NaH2P0 4 , 50 
mM HEPES, pH 7.2, 0.5 % (w/v/) SDS). The final protein A-agarose pellet was 
resuspended in 50 pi of SDS-PAGE sample buffer containing only 5mM DTT and 
incubated at 100°C for 5 min. Samples were cooled down at room temperature for 5 
min, spun briefly, and the supernatant was loaded onto the gel.
2.6. SDS-Polyacrylamide gel electrophoresis
2.6.1. 10% SDS-PAGE ; Lower resolving gel
SDS-PAGE was carried out on vertical slab gels of typical dimensions 11 cm x 
14 cm X 1.5 mm containing 10 % (w/v) acrylamide using the discontinuous buffer 
system of Laemmli [1970]. Resolving gels were prepared by mixing stock acrylamide 
solution [30% (w/v) acrylamide, 0.8% (w/v) N,N'~methylene bisacrylamide], buffer 1 
[1.5 M Tris HCl, pH 8 .8 , 0.4 % (w/v) SDS], 50 % (v/v) glycerol and dHzO to give 
final concentrations of 10 % (w/v) acrylamide, 0.24 % (w/v) N,N'-methylene 
bisacylamide, 0.375 M Tris HCl, pH 8 .8 , 0.1 % (w/v) SDS, and 3 % (v/v) glycerol. 
Gel polymerization was achieved by the addition of TEMED and freshly prepared 
ammonium persulphate to final concentration of 0.1 % (v/v) and 0.05 % (w/v) 
respectively. Upper stacking gels were as described in section 2.6.3 and 
electrophoresis was carried out as described in section 2.6.4.
2.6.2. 6M urea SDS-PAGE ; Lower resolving gel
In order to separate GqCt and G u a , SDS-PAGE was carried out on vertical 
slab gels of dimension 16 cm x 20 cm x 1.5 mm with the addition of 6  M urea to the
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acrylamide mix described in section 2.6.1 [Kim & Milligan, 1994]. Gels were 
allowed to polymerise for 4-5 h prior to electrophoresis.
2.6.3. Upper stacking gels
The upper stacking gel was prepared by mixing stock acrylamide solution ( 30 
% (w/v), 0.8 % (w/v) N,N'-methyllene bisacrylamide), buffer 2 (0.5 M Tris HCl, pH
6 .8 , 0.4 % (w/v) SDS and dH^O to give final concentrations of 3 % (w/v) acrylamide, 
0.08 % (w/v) N,N'-methylene bisacrylamide, 0.125 M Tris HCl, pH 6 .8 , and 0.1 % 
(w/v) SDS. Gel polymerization was performed as described in section 2.6.1.
2.6.4. Electrophoresis running conditions
The running buffer contained 25 mM Tris HCl, pH 8.5, 0.192 M glycine and 
0.1 % (w/v) SDS. Electrophoresis was toward the anode at 60 V, 30 mA per slab until 
the bromophenol blue dye front was 0.5 cm from the bottom (standard 10 % gels) or 
100 V, 50 mA per slab until the prestained lactate dehydrogenase molecular weight 
marker was around 5 cm from the bottom (urea containing gels).
2.7. Staining of SDS-PAGE gels
2.7.1. Staining of gels with Coomassie Blue
Following electrophoresis, gels were soaked, with gentle shaking on a rotary 
shaker, for 1 hrs in 45 % (v/v) methanol, 10 % (v/v) acetic acid containing 0.25 % 
(w/v) Coomassie Blue R-250. Destaining was achieved by washing gels in several 
changes of 45 % (v/v) methanol, 10 % (v/v) acetic acid.
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2.7.2. Staining of pHJcontaining gels
Following Coomassie Blue staining and destaining of the gels containing 
pHJpalmitate labelled samples, gels were subjected to Amplify (Amersham) with 
gentle shaking for 1 hour to intensify the signal before being dried and subjected to 
autoradiography as described in section 2.11.
2.8. Western blotting
2.8.1. Transfer of proteins to nitrocellulose
Electrophoresed proteins were electroblotted onto nitrocellulose membranes 
essentially as described by Towbin et al.{l919]. Transfer was performed toward the 
anode at 2A for 2hrs in 25 mM Tris HCl, pH 8.3, 192 mM glycine and 20 % (v/v) 
methanol. Following transfer, blotted proteins were visualised by staining the 
nitrocellulose membrane in 0.1 % (w/v) Ponceau S, 3 % (w/v) trichloroacetic acid for 
approximately 2 min. After the positions of molecular mass standards were marked, 
the membrane was destained fully by washing in Ix PBS.
2.8.2. Incubation of nitrocellulose membranes with antisera
Non-specific binding sites on the membrane were then blocked by incubation in 
5 % (w/v) gelatin in Ix PBS for 2 h at 37°C. The membrane was then incubated 
sequentially over night at 37°C in an appropriate dilution of primary antibody followed 
by a 1:250 dilution of donkey anti-rabbit IgG horseradish peroxidase conjugate. 
Membranes were washed sequentially for 3 x 10 min at room temperature between
70
each incubation with PBS containing 0.2 % (v/v) NP-40 followed by Ix PBS. All 
antibody dilutions were carried out in 1 % (w/v) gelatin in PBS containing 0.2 % (v/v) 
NP-40.
2.8.3. Development of immunoblots
1 ml of freshly prepared 1 % (w/v) o-dianisidine hydrochloride was added to 
40 ml of PBS, pH7.4, and the whole added to the newly washed nitrocellulose 
membranes. Visualization of cross-reacting polypeptides was initiated by addition of 5 
pi of stock H2O2 (30 % v/v). Immediate termination of the peroxidase reaction was 
achieved by immersing the membranes in 1 % (w/v) sodium azide. The developed 
immunoblot was rinsed in H2O and allowed to dry.
2.9. Densitometric analysis of immunoblots
Immunoblots were densitometrically scanned on a Bio-Rad GS-360 imaging 
densitometer and analyzed on an Apple Macintosh Quadra 800 microcomputer.
2.10. Autoradiography
Destained gels from experiments containing ^%-labelled protein or Amplify 
(Amersham) treated gels were dried onto Whatman No.3 chromatography paper under 
a vacuum line attached to a Bio-Rad 583 gel drier at 8 CPC for 2 h. Autoradiogrphy was 
performed at -80®C for an appropriate time on Fuji X-ray film (^%-labelled protein) or 
Hyperfilm (pH]-labelled proteins) in a Kodak X-o-matic cassette with intensifying 
screens. Films were developed in a Kodak X-o-mat developing machine.
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2.11. Phosphorimaging
Gels containing 35s-labelled proteins were dried as described in the preceding 
section and subjected to phosphorimaging for the indicated time before being analysed 
on a Fujix BAS 1000 phosphorimager linked to an Apple Macintosh Quadra 650 
microcomputer.
2.12. Radioligand binding assays
2.12.1. Binding experiments with pH]TRH
These were performed routinely with approximately 10 nM pHjTRH at 30°C 
for 1 h in 20 mM Tris/HCl (pH 7.4)/ 50 mM sucrose/ 20 mM MgCl2/ 100 pM 
guanosine 5'-[/3y- imido]triphosphate (Gpp[NH]p) (buffer B) in the absence and 
presence of 100 pM TRH to define maximal and non-specific binding, respectively. 
Specific binding, defined as above, represented "^0 % of the total binding of 
pH]TRH. In experiments designed to assess the maximal binding capacity of 
membranes of transfected cells for this ligand, the specific radioactivity of a single 
concentration ('^10 nM) of pH]TRH was varied by addition of TRH in a final volume 
of 50 pi, and measured specific binding was subsequently corrected on this basis.
All binding experiments were terminated by rapid filtration through Whatman 
GF/C filters which had been presoaked in assay buffer, followed by three washes of 
the filter with 5 ml ice-cold buffer B using a Brandell Cell Harvester. Filters were 
soaked overnight in 10 ml of Ultima Flo scintillation fluid cocktail prior to counting in 
a Rackbeta scintillation counter. In some instances, the binding data were manipulated 
according to the equations derived by Scatchard [1949] or DeBlasi e?n/.[1989].
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2.12.2. Binding experiments with pHJprazosin
Binding assays were performed by the methods of Morrow & Crese [1986] 
and initiated by the addition of 10-20 pg of protein to an assay buffer (50 mM Tris- 
HCl, 0.5 mM EDTA, pH 7.4) containing pH]prazosin (0.005 - 1 nM in saturation 
assays and 1 nM for competition assays) in the absence or presence of increasing 
concentrations of the test drugs in a final volume of 250 pi. Nonspecific binding was 
determined in the presence of 10 pM phentolamine. Reactions were incubated for 30 
min at 25°C, and bound ligand was separated from free by vacuum filtration through 
Whatman GF/C filters as indicated in section 2.12.1.
2.13. Adenylyl cyclase assay
This was essentially the method of Salomon and co-workers [1979], except the 
amount of [a-32p]-ATP was reduced to IpCi per sample. This assay measures the 
production of p^P]-cAMP from the substrate [a-^^P]-ATP. The cAMP thus produced 
is separated from the unreacted [a-^^P]-ATP by a two-step column method.
2.13.1. Sample preparation and reaction
Assays were performed in a reaction volume of 100 pi using 50 pi of an assay 
mix comprising 4 mM creatine phosphate, 100 mM NaCl, 100 U/ml creatine 
phosphokinase, 200 mM Tris-HCl (pH 7.5), 10 mM MgCl^, 0.4 mM ATP (pH 7.5), 
2 mM cAMP, 2 pM GTP (pH 7.5), [a-32p]„ATP ( Ix W  cpm), 10-20 pg of 
membrane protein and an appropriate ligand. Reaction tubes were kept on ice at all 
times and the reaction started by removal to a 30®C water bath. After 15 min the 
reactions were terminated by placing onto an ice-slurry and adding 10 0  pi stopper
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solution which comprised 2 % (w/v) SDS, 45 mM ATP, 13 mM cAMP. 50 pi of [8 - 
3H]-3'5'cAMP (approximately 10000 cpm) was added to measure recovery from the 
coulumn. Reactions were then boiled for 10 min, 750 pi of dH2 0  was added, and the 
p2p] _ and pH]-cAMP content determined.
2.13.2. Preparation of Dowex and alumina columns
2.13.3. Separation of cAMP on Dowex columns
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The methods used to quantitate the amount of cAMP produced by each sample 
was identical to that of Salomon [1979] and involves the separation of cyclic AMP 
from other nucleotides by Dowex and then Alumina chromatography. Dowex H+ 50x4 
(200-400) was washed sequentially in twice its volume with 1 M HCl, 1 M NaOH and 
finally 1 M HCl. The Dowex was mixed with dH2 0  to a slurry (1:1,v/v) and then 2 ml 
added to glass wool stoppered columns. The water was allowed to drain out and the 
columns washed with 2 ml 1 M HCl and stored at room temperature. Prior to use, the 
columns were washed with 4 ml 1 M NaOH and with 4 ml of 1 M HCl followed by 20 
ml of dH2 0 .
Alumina columns were prepared by the addition of 1 g dry neutral alumina to 
glass wool stoppered columns and the columns washed with 12 ml 1 M imidazole 
buffer (pH 7.3) followed by 15 ml of 0.1 M imidazole (pH 7.3) and then stored at 
room temperature. On the day of use, each column was washed with 8  ml of 0.1 M
imidazole (pH 7.3).
Prior to sample chromatography, the nucleotide elution profiles for each 
column were determined. This was performed by applying pH]-cAMP to the columns 
and determining the elution volume. Stock pH]-'cAMP was diluted in dH2 0  to give
approximately 10000 cpm in 50 pi. 50 p,l cAMP solution was added to 950 pi of dH2 0  
and applied to a Dowex column. The cAMP was eluted from the column by successive 
washes of the column with 0.5 ml H2O. Fractions were collected and mixed with 5ml 
of Ultima Flo scintillation cocktail and radioactivity determined by scintillation counting 
using a dual label programme. The elution volumes required to elute the cAMP from 
the Dowex columns were then determined graphically. Recovery from the Dowex 
columns was always greater than 70 %. The elution volume required to elute the cAMP 
from the alumina columns was determined as for the Dowex columns except the eluting 
buffer was 0.1 M imidazole (pH 7.3). Recoveries were similar to that obtained for the 
Dowex columns.
2.13.4. Determination of cAMP produced by membrane fractions
Samples (total volume of 950 pi) were added to prepared Dowex columns and 
the ATP eluted with 0.5 ml water. Dowex columns were then washed with 6  ml dH2 0  
and the combined eluate was applied directly onto the alumina columns. The cAMP 
fraction was eluted into vials containing 14 ml scintillation fluid with 6  ml imidazole 
(pH 7.3). The recovery of cAMP from the columns was routinely greater than 75 %. 
When recovery fell below 60 % the columns were discarded and fresh columns 
prepared.
The cAMP fractions obtained were counted on a dual label scintillation counting 
programme which automatically corrected for spillover from each channel. The amount 
of cAMP produced by each sample was calculated by taking into account the recovery 
from each column, based on the recovery of the pHJcAMP internal standard. Data 
were then calculated as pmoles of cAMP produced per min per mg membrane protein, 
and the assay was sensitive to approximately 5 pmoles/min/mg.
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2.14.1. Preparation of Dowex formate
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2.14. Total inositol phosphate assay
The conversion of Dowex chloride (1x8-200, Sigma) to Dowex formate was 
achieved by the addition of formic acid in two steps. 100 g of Dowex chloride beads 
were swirled gently with 1 L of dHaO, allowed to settle, and the water containing fines 
decanted. This process was repeated for a total of 3 washes. The beads were then 
transferred to a sintered funnel and washed with 2 L of 2 M NaOH to exchange X-CÎ 
with X-OH. Subsequently, they were washed with 5 - 6  L of dH2 0  to remove NaCl 
and excess NaOH, and then washed with 1 L of 1 M formic acid. Finally 20-30 L of 
dH2 0  were applied to wash away excess formic acid until the pH was constant at 5-5.5 
as measured with narrow range pH paper (pH4-6). The prepared Dowex was stored at 
room temperature in an approximately 1; 1 ratio of Dowex : dH2 0 .
'CharacterizationDf the Dowex-formate was achieved by applying a standard 
amount of pHjIPg in 1 ml of 5 mM NaTB/0.5 mM EDTA to 1 ml of the resin. The
I
eluate was collected in 1 ml fractions which were then mixed with 4 ml scintillation 
fluid. pH]IP3 was then quantified by liquid scintillation counting and % recovery of 
the standard calculated.
2.14.2. Preparation of samples
Cells were seeded in 24-well plates and labelled to isotopic equilibrium by 
incubation with 1 pCi/ml myo-[2-^H]inositol in 0.5 ml inositol-free DMEM containing 
2 % (v/v) dialyzed newborn calf serum for 24 hrs. On the day of experiments, the 
labeling medium was removed, and the cells were washed twice with 0.5 ml of Hank's 
modified balanced solution (1.25 mM CaCl2 , 5.4 mM KCl, 0.5 mM MgCl2 , 0.85 mM
MgS0 4 , 137 mM NaCl, 4.16 mM NaHCOs, 0.33 mM NaH2P0 4 , pH7.4), containing 
2 % (w/v) bovine serum albumin and 10 mM glucose (HBG). Cells were then washed 
twice for 10 min with HBG supplemented with 10 mM Li Cl (HBG/LiCl) and 
subsequently stimulated with agonist in HBG/LiCl for 20 min at 37°C. Reactions were 
terminated by the addition of 0.5 ml of ice-cold methanol, and then cells were scraped 
and transferred to insert vials. Chloroform was added to a ratio of 1:2 (CHCI3 : 
MeOH) and samples extracted for 1 h prior to the addition of chloroform and water to a 
final ratio of 1 : 1 : 0.9 (CHCI3 : MeOH : dH2 0 ). To separate the phases of water and 
lipid completely, the vials were centrifuged at 3000 rpm for 5 min in a tabletop 
centrifuge, and 800 pi of the upper phase was taken and transferred into new vials. 
Lower phase (300 pi) was allowed to evaporate and then samples were subjected to 
liquid scintillation counting.
Dowex-formate (0.5 ml) was added to each 800 pi upper phase fraction 
containing inositol phosphates together with 3 ml of dH2 0 . The Dowex-formate beads 
were allowed to settle out and the supernatant was removed by aspiration. Unbound 
label was then removed by succesive washing of the beads with 3 ml volumes of 
dH2 0 , solution I (5 mM NaTB/60 mM HCOONH4 ), and with dH2 0  again. Finally, 
after aspiration, 1 ml of solution II ( 1 M HCOONH4/0 . 1 M HCOOH) was added, 
beads were allowed to settle, and 800 pi of the supernatant was mixed with 4 ml of 
scintillation fluid and counted as above.
2.15. Phospholipase D assay
2.15.1. Preparation of solvents and TLC plates
To prepare the TLC running solvent, 2,2,4-Trimethylpentane (isooctane) : 
ethylacetate : glacial acetic acid : dH2 0  (solvent I) of a final ratio 5:11:2:10 were mixed
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and shaken in a 500 ml separating funnel. After settling down, the lower phase was 
drained and discarded, and the organic upper phase was placed in a glass TLC tank. 
TLC plates (Whatman LK5 DF) were pre-run in solvent I for 2 hrs to equilibrate each 
lane, dried for 10 min in a fume hood, and baked at 120°C for 20 min prior to loading 
samples.
78
2,15.2, Preparation of samples
Cells were seeded in 24-well plates in DMEM containing 5 % newborn calf 
serum. When the cell confluency reached alx)ut 70 %, the medium was replaced with 
500 pi of the above medium containing 4 pCi/ml of [9,10 (n)-^H]palmitic acid (51 
mCi/ml) .2 4 -3 6  hrs later, the medium was replaced with 500 pi of HBG as described 
in section 2.14.2 to wash away un-incorporated pH] palmitic acid and incubated at 
37°C for 20 min. Cells were then incubated with 500 pi of HBG containing 0.3 % 
(v/v) butan-l-ol (HBG/butanol) at 37°C for lOmin. After aspirating the HBG/butanol, 
cells were treated with 200 pi HBG/butanol containing test drugs for 20 min. 
Reactions were terminated by removal of the drug containing solution and immediately 
adding 500 pi of ice-cold Analar grade methanol. Cells were scraped into screw- 
capped glass vials, and remaining cells were removed with a further 2 0 0  pi methanol.
Samples were extracted with 700 pi of analar grade chloroform at room 
temperature for 15 min and 585 pi dH2 0  then added to give a final ratio of chloroform 
: methanol : water of 1 ; 1 : 0 .8  prior to centrifugation at 1 2 0 0  rpm in a table top 
centrifuge for 5 min. 450 pi of the lower chloroform phase was taken into new glass 
vials and dried down by vacuum centrifugation in a Jouan RC centifugal evaporator for 
1 hr. Dried samples were resupended in 2  x 25 pi of solvent II [chloroform : methanol, 
(19 : 1, v/v)] and loaded onto TLC plates by using a positive displacement pipette. 
Samples were applied to the adsorbant strip at the bottom of each lane between 1 cm
 ■...................................................................................................................
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from the bottom and 0.5 cm from the top of the adsorbant strip. 7 pi of standard 
phosphatidylbutanol was applied to alternate lanes. The plates were run to 1 - 2 cm 
from the top in solvent I as indicated in section 2.15.1, and then removed to dry in 
the fume hood for 10 min. The position of phosphatidylbutanol was located by staining
i|with iodine for 2-3 min. This area on each lane was then scraped and transferred to 
insert vials contained 4 ml scintillation fluid and counted.
Î
2.16. Regulation of activity/mobility of ERK-1
tl
The activation of extracellularly regulated kinase-1 (ERK-1) was determined by 
an electrophoretic-mobility shift assay [Marshall ef 1992], Cells were grown in 
DMEM containing 5 % newborn calf serum in 100mm tissue culture dishes. When 
cells were nearly confluent, they were maintained in serum-free DMEM for 48 h. The 
cells were then stimulated by an appropriate ligand in serum-free DMEM at 37^C for 5 
min. Plates were transferred to 4°C and medium was removed. Cells were washed 
with 10 ml ice-cold IxPBS and subsequently lysed in 450pl of lysis buffer containing 
25 mM Tris/HCl, pH7.5, 40 mM p  -nitrophenol, 25 mM NaCl, 10 % (v/v) ethylene 
glycol, 10 pM dithiothreitol, 0.2 % (w/v) NP-40, 1 pg/ml aprotinin, 1 mM sodium 
vanadate, 3.5 pg/ml pepstatin A and 200 pM phenylmethanesulphonyl fluoride 
(PMSF) at pH 7.5.
The cells were then scraped and transferred into microfuge tubes, and 
solubilized by passing approximately 10 times through a 1 ml syringe with a 26G 
needle. Following centrifugation of the lysed samples in a microfuge at 13,000 rpm for 
5 min at 4^C, the supernatant was transferred into a new microfuge tube and 100 pi of 
Laemmli loading buffer was added as described in section 2.5.1 prior to boiling for
;21
5 min.
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Samples were applied to 10 % SDS-PAGE containing 6  M urea as described in 
section 2,6.2 and samples were immunoblotted, as described in section 2.9, 
using an anti-peptide antiserum raised against amino acids 325 - 345 of ERK-1, also 
refened to as p44 MAP kinase.
%
2.17. Growth of Escherichia coli strains
Exoli strains were routinely grown in Luria-Bertani medium (LB-medium) 
which consisted of 10 g/L bacto-tryptone, 5 g/L of bacto-yeast extract, 10 g of NaCl, 
pH 7.0. E.coli cells harbouring plasmids with antibiotic resistance genes were selected 
on LB agar plates supplemented with the appropriate antibiotics. Liquid cultures of
transformed strains were also supplemented with the relevant antibiotics and were 
routinely propagated at37°C with continuous shaking.
All media and solutions, unless otherwise stated, were sterilized by autoclaving 
for 15 min at 121°C. Ampicillin (50 mg/ml dH2 0 ), kanamycin (10 mg/ml dH2 0 ) and 
tetracyclin ( 5 mg/ml ethanol) were prepared as stock solutions and sterilized by 
filtration through 0 .2 2  pm syringe filters.
Stock E.coli cells were streaked onto LB agar plates (15 g/L Bacto-agar in LB 
medium) in the absence of any antibiotic. The agar plates were incubated overnight at 
37°C. A single colony was picked for expansion and grown up overnight at 37°C in 5 
ml of L-broth. The liquid culture was then used to prepare competent cells. MC 
1061/P3 cells (Invitrogen) transformed with plasmid pcDNA I, and JM 109 cells 
transformed with plasmid pCMV and DH5ct cells transfoimed with plasmid pcDNA3 
or recombinant plasmids derived from them were grown in LB medium or on LB agar 
plates supplemented with 50 pg/ml of ampicillin. A full length version of the rat 
thyrotropin-releasing hormone (TRH) receptor long isoform cDNA (2.2 kb) was 
sucloned into the EcoR I site of pcDNA I. A full length version of the rat TRH receptor
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short isoform was obtained in pBluescript SK“ from Dr.Pilar de la Pena, University of 
Oviedo, Spain. This was subcloned into pCMV5 between the Xba I and BamH I sites 
of the multiple cloning region.
For long term storage, bacteria were conserved in 15 % (v/v) glycerol and 85 
% (v/v) LB medium at -8 CPC. Basically, sterile 80 % (v/v) glycerol was added to the 
overnight culture to a final concentration of glycerol of 15 % (v/v). 1 ml aliquots were 
snap-frozen in a slurry of dry ice and ethanol and stored at -80^0 until required.
2.18. Preparation of chemically competent E .coli
Competent cells for heat-shock transformation were prepared according to 
Flanahan [1985]. A liquid culture (5 ml) of E.coli cells which had been grown 
overnight at37°C, was inoculated into 500 ml of LB medium and cultured at 37°C in a 
shaking incubator until an OD^oo of approximately 0.25 absorbance units (equivalent 
to approx. 1 X 10  ^cells/ml ) was reached. The cell suspension was then cooled on ice 
for approximately 30 min and cells recovered by centrifugation at 10,000 rpm for 10 
min at 4°C in a Beckman J-2-21 centrifuge containing a JA 14 rotor. E.coli cell pellets 
were resuspended in a total volume of 40 ml of ice-cold sterile buffer I [100 mM 
RbCl2 , 50 mM MnC^, 30 mM CH3COOK, 10 mM CaCl2-2 H2 0 , 15 % (w/v) 
glycerol, pH 5.8]. The suspension was left on ice for 15 min and recentrifuged as 
before. Cell pellets were resuspended in a total volume of 3.5 ml of ice-cold buffer II 
[10 mM RbCl2, 10 mM MOPS, 75 mM CaCl2 2 H2O, 15 % (w/v) glycerol, pH 6 .8 ] 
and pooled. The suspension was left on ice for 15 min and then 250 pi aliquots were 
snap frozen in a slurry of dry-ice and ethanol, and stored at - 80 °C.
2.19. Transformation of chemically competent E .co li with plasmid 
DNA
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‘r-Competent cells were thawed on ice and 250 pi added to plasmid DNA (50-100 
ng of supercoiled plasmid DNA or 5 pi of a ligation reaction) followed by incubation 
on ice for 15 min. The cells were then heated at 42°C for 90 seconds and returned to 
ice for 2 min prior to the addition of 800 pi of LB medium. Cells were allowed to 
recover by incubation at 37°C for 1 h in a shaking incubator.
Aliquots of 100 pi and 200 pi were spread onto LB agar plates containing 50 
pg/ml of ampicillin. Plates were incubated overnight at 37^C and transformed colonies
selected and grown up overnight in 10 ml LB medium containing 50 mg/ml 
ampicillin.
2.20. Preparation of plasmid DNA
2.20.1. Preparation of double stranded plasmid DNA by alkaline lysis
ai
This method of plasmid DNA isolation was used to prepare plasmid DNA for 
diagnostic restriction digestion only [Birnboim and Doly, 1979]. A total of 3 ml liquid 
overnight culture was sedimented by centrifugation in a micricentrifuge at 13,000 rpm 
for 3 rain. Cell pellets were resuspended in 200 pi of solution I (50 mM glucose, 25 
mM Tris/HCl, pH 8.0, 10 mM EDTA). Cells were then lysed by the addition of 200 pi 
of freshly prepared solution II [0.2 M NaOH, 1 % (w/v) SDS]. After several 
inversions, samples were neutralized with 200 pi of solution III (60 ml of 5 M 
potassium acetate, 11.5 ml of glacial acetic acid and 28.5 ml of dH^O, giving final 
concentrations of 3 M potassium and 5 M acetate). After mixing by gentle inversion, 
plasmid DNA was recovered in the supernatant following centrifugation in a microfuge 
at 13,000 rpm for 5 min. Plasmid DNA was then isolated by precipitation with ethanol
8 2
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as described in section 2.22. DNA precipitates were resuspended in 50 pi of 20 
pg/ml DNase-free RNase in sterile dH20.
2.20.2. Small scale preparation of double stranded plasmid DNA
This was carried out as described by the manufacturer (Promega). A total of 3 
ml of overnight culture was centrifuged as described in section 2.20.1 and the 
resulting pellet resuspended in 200 pi buffer 1 (50 mM Tris/HCl, pH 7.5, 10 mM 
EDTA, 100 pg/ml RNase A). Buffer 2 (200 pi) [0.2 M NaOH, 1 % (w/v) SDS] was : :
added and the cells lysed by inversion. Buffer 3 (200 pi) (1.32 M potassium acetate) 
was added to neutralize the solution, again by inversion, and centrifuged at 13,000 rpm 
in a microcentrifuge for 5 min. Purification resin (1 ml) was added to the supernatant 
and plasmid DNA was isolated by purification on a minicolumn according to the 
manufacturers instructions.
2.20.3. Preparation of double stranded plasmid DNA for automated 
DNA sequencing
This was achieved by a modification of the method in the preceding section. An 
entire 10 ml overnight culture was centrifuged in a Beckman TJ6 benchtop centrifuge 
for 15 min at 3000 rpm. The cell pellet was resuspended in 300 pi of buffer 1 
(section 2.20.2), lysed using 3(X) pi of buffer 2 and then neutralized with 300 pi of 
buffer 3 as decribed in section 2.20.2. Following centrifugation of the lysate, 
purification resin (1 ml) was added and the whole applied to a minicolumn. Resin was 
washed with 3 ml of wash buffer (0.09 M NaCl, 10 mM Tris/HCl, pH 7.5, 2.2 mM 
EDTA, 55 % (v/v) analar ethanol) and purified DNA eluted using 100 pi H2O. The 
resulting DNA solution was stored at -20°C until required.
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2.21. Ethanol precipitation of DNA
DNA was precipitated from solution with 0.1 vol of 3 M sodium acetate, pH 
7.0 and 2.5 vol of absolute ethanol at - 20°C for 20 min. DNA was recoved by 
centrifugation at 13,000 rpm for 10 min. The pellet was subsequently washed with 70 
% (v/v) ethanol at - 20°C, dried at 65°C on a heating block, and then resuspended in 
deionized H2O.
DNA from the preparation of plasmid DNA described in section 2.20.1 was 
precipitated at room temperature without the addition of 3 M sodium acetate.
DNA obtained from PCR amplication which was to be used in automated 
sequencing was precipitated on ice in the presence of 0.1 volumes of 3 M sodium 
aceteate, pH 5.2.
2.22. Quantitation of DNA and RNA
The concentraion of DNA in a given sample was determined by measuring the 
absorbance at 260 nm (A260) of a 1:200 dilution of the sample in sterile Milli Q H2O, 
assuming 1 absorbance unit was equivalent to 50 pg/ml of double stranded DNA, 40 
pg/ml for single-stranded DNA and RNA, and 20 pg/ml of single stranded 
oligonucleotide. The purity of the DNA was assessed by measuring the A28O in parallel 
and calculating the A26O • A280 ratio. A ratio of approximately 1.8 for DNA and 2.0 for 
RNA was considered to be sufficiently pure for use otherwise a phenol : chloroform 
extraction was carried out as described in section 2.23.
2.23. Phenol/chloroform extraction of DNA
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DNA was initially extracted with phenol:chloroform (50:50, v/v) and then with 
chloroform:isoamyl alcohol (24:1, v/v). Extracted DNA was then precipitated with 
ethanol as described in section 2.21.
2.24. Digestion of plasmid DNA with restriction endonucleases
Plasmid DNA, generally 1 pg, was digested in a volume of 10 pi using buffer 
condition recommended by the manufacturers and with 4-10 units of appropriate 
restriction enzymes. The composition of the buffers used are indicated in Table 2.2.a 
and the enzymes used in these buffers are indicated in Table 2.2.b
2.25. Separation of digested plasmid DNA by electrophoresis
Digested DNA was routinely analysed by agarose gel electrophoresis as 
described by Sambrook e/a/. [1989]. Samples were prepared by the addition of 6x 
loading buffer [30 % (v/v) glycerol, 0.25 % (w/v) bromophenol blue] to a Ix final 
concentration. Samples between 0.5 and 5 kb were electrophoresed through 0.8 % 
(w/v) agarose gels containing Ix TAE buffer (40mM Tris acetate, 1 mM EDTA, pH 
8.0) and 2.5 mg/ml ethdium bromide. For DNA fragments smaller then 0.5 kb, 
electrophoresis was performed using 1.5-2 % (w/v) agarose.
Electrophoresis was carried out, towards the anode, at 75 - 100 mA at room 
temperature in a horizontal electrophosis tank containing Ix TAE buffer. Ethidium 
bromide stained DNA fragments were visualized under UV light and photographed. 
Size was assessed by comparison with a 1 kb ladder.
2.26. Purification of DNA from agarose gels
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Table 2.2. Restriction enzyme buffer compositions and use by 
various restriction enzymes
Digestion of DNA by restriction enzymes was carried out using the 
buffer conditions recommended by the manufacturer. The conmposition of the 
buffers used are listed in panel A. Enzymes used together with their respective 
buffers and reaction conditions are shown in panel B.
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Table 2.2.
A.Buffers
B.Enzymes 
Buffer Enzymes
A
C
E
Apa I 
Cla I, Hae III
BamH I, Hind III
Buffer Enzymes
B Stu I
D Bgl I, Bgl II, Nco I
Not I, Sal I, Xba I, Xho I 
H EcoR I, Pstl
Bufter pH Tris/HCl MgCl2 NaCl C4 Hfi0 4 Mg DTT
(at 37«C) (mM) (mM) (mM) (mM) (mM) ÏV
A 7.5 6 6 6 - 1 j!
B 7.5 6 6 50 - 1 1
C 7.9 10 10 50 - 1 :i
D 7.9 6 6 150 - 1 #
E 7.5 6 6 100 - 1
H 7.5 90 10 50 - - ■
J 7.5 6 7 50 - 1 %
M= 7.8^ 25+ - 100* 10 1
+ Tris Acetate * Potassium Acetate ^ at 25°C 
= Buffer M was used only in double digestions
 ...zji:-:
In order to purify a desired DNA fragment, DNA was electrophoresed through 
low-melting point agarose at appropriate concentrations at 50 mA at 4^C. The fragment 
of interest was excised from the gel and was then melted in a heating block (Techne) at 
70°C for 5 min. Immediately, 1 ml of Promega PCR purification resin was added and 
the contents mixed by vortexing for 30 sec. The resin was applied to a Promega mini 
column and was then washed with 80 % (v/v) isopropanol. Purified DNA was eluted 
with preheated sterile Milli Q H2O as described in section 2.20.2.
2.27. Phosphatase treatment of DNA fragments
To prevent recircularization of vector DNA during ligation, digested vector 
DNA was treated with CIAP to remove the 5 'phosphate group, CIAP treatment was 
performed using 0.5 units of enzyme in a buffer (50 mM Tris/HCl, pH 9.0, ImM 
MgCl2 , 100 mM ZnCl2 , 1 mM spermidine) at 37°C for 2 h. The reaction was stoped 
by the addition of SDS and EDTA to final concentrations of 0.5 % (w/v) and 5 mM, 
respectively, followed by heat treatment at 75°C for 10 min. Vector DNA was purified 
from the reaction mixture by extraction with phenol : chi oroform (50:50, v/v) followed 
by extraction with chloroform:isoamyl alcohol (24:1, v/v) and precipitation with 
ethanol as described in section 2.21.
2.28. Ligation of DNA fragments
Ligation of vector and insert DNA was routinely carried out overnight at 10- 
16°C in a reaction volume of 10 pi containing Ix ligation buffer (30 mM Tris/HCl, pH
7.8, 10 mM MgCl2 , 10 mM DTT, 1 mM ATP), 1.5 units of T4 DNA ligase plus 
vector and insert DNA fragments. Reactions were performed using ratios of
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vector:insert of 1:1, 1:5, and 1:10. Ligated DNA was transformed as described in 
section 2.19.
2.29. Reverse transeriptase-PCR
2.29.1, RNA extractions
Total RNA was extracted by the acid phenol/guani dinium thiocyanate method 
of Chomczynski and Sacchi [1987]. Growth medium was withdrawn from a 75cm^ 
flask and 750 pi RNAzol (Biogenesis) was added. Cells were scraped into a sterile 
microfuge tube and solubilized by passing the lysate a few times through a sterile 
pipette and then freezing at -80°C for 30 min. RNA was extracted from the lysate by 
adding 100 pi of chloroform, mixing vigorously and placing on ice for 5 min. After 
centrifugation at 13,000 rpm for 15 min at 4°C, an equal volume of isopropanol was 
added and total RNA was allowed to precipitate on ice for 30 min. Following recovery 
by centrifugation as above, RNA pellets were washed with 75 % (v/v) ethanol (- 
20OC), dried and resuspended in 30 pi of 1 mM EDTA, pH 7.0.
2.29.2. Reverse transcription
Prior to reverse transcription, residual genomic DNA was removed by 
digestion with RNase-free DNase. RNA (30 pg) was ethanol precipitated and 
dissolved in 40 mM Tris/HCl, pH 7.9, 10 mM NaCl, 6 mM MgCl2 . RNAguard(17 
units) and RNase-free DNase (5 units) were added and digestion was carried out at 
37°C for 15 min. Reactions were terminated by purification of the RNA through a 
clean-up column (Promega). RNA was then precipitated with NaCl/ethanol as above 
and redissolved in 20 pi of Milli Q H2O.
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Table 2.3. Oligonucleotide primers and PCR conditions
Oligonucleotide primers for the RT-PCR amplification of TRH receptor 
isoforms, o.\ adrenergic receptor subtypes and CAM ojb  adrenergic receptor 
cDNA used in this study were synthesized by Dr. V. Math on an Applied 
Biosystems DNA synthesiser at the Biochemistry department. University of 
Glasgow.
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Table 2.3
A.OÏigonucIeotide primers
TRH receptor isoforms Sense
a i  a/d adrenocptor 
aiB  adrenoceptor 
«lA/D&otlB AR 
a i c  adrenoceptor
CAM aiB  AR
Anti sense
Sense
Sense
Antisense
Sense
Antisense
Sense
Antisense
5'-CAACCTCATGTCTCAGAAGTTTCG-3'
5'-AATGAAGACCTTCGATCAGTTGG-3'
5’-TTGGAAGGAGCCAGTGC-3'
5'-ACAAGGAATGCGGAGTC -3'
5'-GAAGGCGCGCTTGAACT-3'
5'-TTCTCCGTGAGACTGCT-3'
5'-CCAGGTCCTTGTGCTGT-3'
5'-GA CGA CA A GGA ATGCGGAGTC-3 ' 
5'-GTCCACGGCCGATAGGTGTAA-3'
B.PCR conditions
* The annealing temperature was calculated to be 5-10*^0 lower than the melting
temperature of the oligonucleotides.
■
3a
3
a
Receptor Dénaturation Annealing-**" Extension Cycles J
TRHr isoforms 950C/5min 6 (PC/lmin 72oC/2min
95°C/lmin 60°C/lmin 72«C/3min 30
95°C/imin 60oC/lmin 720C/5min
aiA R  subtypes 95»C/5min 49°C/30sec 72oC/lmin '■E
95oC/30sec 49°C/30sec 72«C/lmin 30 ia
95°C/30sec 49°C/30sec 72oC/5min 1
a iB  CAM 95oC/5min 60«>C/2min 72oC/2min 1
94°C/lmin 6 Qoc/2 min 72°C/3min 33
94‘^ C/lmin 60°C/2min 72°C/5min 1
Reverse transcription was carried out with 0.5-10 pg of DNase-treated RNA 
using a First-strand cDNA synthesis kit (Pharmacia). Basically RNA was denatured by 
heating at 65°C for 10 min. Bulk cDNA synthesis reaction mix (5-10 pi) with 0.2 pg 
of oligo d(T)i8 primer, 1.8 mM each dNTP and buffer (45 mM Tris, pH 8.3, 6 8  mM 
KCl, 15 mM DTT, 9 mM MgCl2 , 0.08 mg/ml BSA) was added and reverse 
transcription was allowed to proceed at 37°C for 1 h. Reactions were stopped by 
heating at 90^C for 5 min. Reverse transcribed RNA was then stored at -20°C or used 
directly for PCR.
2.29.3. PCR
Amplifications were routinely performed in a reaction volume of 50 pi 
containing 50-200 ng of DNA template, dNTPs (0.2 mM each dATP, dCTP, dGTP, 
dTTP), 25 pmoles each of sense and antisense oligonucleotide primers, as indicated in 
Table 2.3a, 1.5 mM MgCl2 , Ix thermophilic buffer (50 mM KCl, 10 mM Tris/HCl, 
pH 9.0, 0.1 % Triton X-100) and 2.5 units of Taq DNA polymerase (Promega). 
Samples were overiayed with light mineral oil to prevent evaporation, and the reaction 
was earned out on a Hybaid Omnigene thermal cycler as indicated in Table 2.3b for 
each PCR condition.
For site-directed mutagenesis or for the creation of new restriction enzyme 
cleavage sites, PCR was carried out with Pfu DNA polymerase (Stratagene). Reactions 
were performed in 20 mM Tris/HCl, pH 8.2, 10 mM KCl, 6  mM (NH4)2S0 4 , 2 mM 
MgCl2 , 0.1 % Triton X-100, 10 pg/ml BSA using 25 pmol each primer and dNTPs as 
above. Pfu DNA polymerase (5 units) was added after the reaction mixture had been 
heated to 95°C for 10 min. The temperature cycling condition (30 cycles) were 94^C 
for 42 sec (dénaturation), annealing (temperature as noted in Table 2.3b) for 1 min,
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and 17PC for 3-10 min (extension), depending on the DNA fragment size to be 
amplified.
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2.30. DNA sequencing
In order to yield accurate sequence data for ss and ds DNA templates, 
symmetrical PCR fragments, and site-directed mutants, cycle DNA squencing was 
performed.
2.30.1. Sample preparation for cycle sequencing
Sequencing of double stranded DNA was performed using automated cycle 
squencing with the Taq DyeDeoxy DNA sequencing kit (Applied Biosystems). 
Reactions were performed in a volume of 20 pi using 1 pg of plasmid DNA in 5 pi of 
dH2 0  together with 4 pi of 5x TACS buffer, 1 pi dNTP mix, 1 pi each DyeDeoxy A, 
T, G, C Terminator, 2 pi ampliTaq DNA polymerase and 3.2 pmol of primer for 
double stranded DNA sequencing (0.8 pmol for ssDNA). dH2 0  was added to give a 
final reaction volume of 2 0  pi.
Reactions were overiayed with mineral oil and cycle sequencing (30 cycles) 
was performed on a Hybaid Omni Gene thermal cycler preheated to 96®C with cycling 
conditions of 96°C, 30 sec (dénaturation), 50°C, 50 sec (annealing), and 60®C, 4 min 
(extension). Excess terminator dyes were then removed by two extractions with 
phenol:watenchlorofoim (68:18:14) and DNA was recovered by precipitation with 
ethanol as descibed in section 2,21. DNA pellets were dried at 85°C for 1 min in a 
thermal cycler and then either stored at -2 0 ^  or resuspended in 4 pi of formamide
reagent (a mixture of 5 pi deionized formamide and 1 pi 50 mM EDTA, pH8.0) and
*electrophoresed immediately.
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2.30.2. Preparation of PAGE gels for DNA sequencing
Samples were analysed by polyacrylamide electrophoresis using gels 
comprising 6  % acrylamide Sequagel-6  solution (National Diagnostics) and ran in Ix 
TBE buffer (0.9 M Tris, 0.9 M boric acid, 0.02 M EDTA, pH 8.0). Polymerization 
was initiated by addition of 600 pi of 10% APS per 75 ml of gel solution. Gels were 
cast using an ABI 373 DNA sequencing apparatus (Applied Biosystems) and were pre­
run at 1200 V/ 30 mA for 30 min. Prior to loading, samples were heated to 95®C for 2 
min to ensure complete dénaturation. Electrophoresis was performed overnight as pre­
run conditions. Automated sequencing data were then analysed using Gene Jockey 
software program.
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Chapter 3. Comparison of the signalling properties of the 
long and short isoforms of the rat thyrotropin- 
releasing hormone (TRH) receptor
3.1. Introduction
The hypothalamic neuropeptide thyrotropin-releasing hormone (TRH) plays 
pivotal roles in the pituitary-thyroid axis. This tripeptide (pyroglutamyl-histidyl- 
prolineamide) is known to rapidly stimulate the synthesis and release of pituitary 
thyroid stimulating hormone (TSH) as well as prolactin (PRL) [Murdoch etal., 1985; 
Laverriereeffit/., 1983; Kourides etaL, 1984; Shupnik e td .,  1986]. Although TRH 
was first discovered in the hypothalamus and characterised by its ability to stimulate 
TSH production from pituitary cells, it has since been identified in several 
extrahypothalamic brain structures and in the gastrointestinal tract [Hokfelt et al., 
1989]. Putative TRH receptors have been characterised in detail in terms of affinity for 
TRH and related peptides [Hinkle era/., 1974; Vale etaL, 1977; Sharif & Burt, 1983; 
Szirtes et at., 1986; Phillips & Hinkle, 1989; Ladram et al., 1992], and TRH 
interaction with those plasma membrane receptors has been shown to influence several 
potential second messenger systems.
The isolation of cDNA clones encoding mouse [Straub, etal., 1 9 ^ ] and rat [de 
la Pena, etal, 1992, Sellar etal, 1993] versions of the TRH receptor confinned these 
to be single-polypeptide putative seven-transmembrane-element receptors, as 
anticipated for G-protein coupled receptors. Although a series of reports have indicated 
that these receptors couple in a pertussis-toxin-insensitive fashion to the stimulation of 
inositol phosphate and diacylglycerol production [Hsieh and Martin, 1992, Kim e t a l ,
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1994], and indeed have been shown directly to do so by interaction with Gqa and 
G lia, many groups have shown coupling to other G proteins, Gga and Gia.
A number of reports in which TRH responses have been analysed in GH3 and 
other related cell lines of pituitary origin have indicated both a direct interactionof the 
TRH receptor with Gg to cause activation of adenylyl cyclase [Paulssen et al., 1992] 
and aTRH-mediated activation of G|2  and thence an increase in Ca^+ flux through L- 
type Ca^+ channels [Gollasch eta l,  1993], although it is uncertain whether the TRH 
receptor directly interacts with Gi2 or whether this occurs subsequent to stimulation of 
protein kinase C.
The longest open reading frame in the largest TRH receptor cDNA clone 
encodes a protein of 412 amino acids known as long isoform. A second isoform of the
rat TRH receptor was subsequently cloned from a GH3-cell library [de la Pena e t a l ,
1992]. This short isoform of the receptor, which appeared to be derived from the same 
gene as the long isoform by differential splicing mechanisms, was also shown to be
:•
expressed in the pituitary. Sequence analysis indicates identical sequence with the 
notable exception of a 52-base pair deletion located between nucleotides 1392 and 1443 
at the 3' end of the coding region and thus results in a clear variation in the carboxyl 
terminus of the receptor protein. Thus, the open reading frame in this short splice 
variant encodes a 387 amino acids protein as displayed in Figure 3.1.
Hence, the existence of two splice variants of the rat TRH receptor raises the 
possibility that the range of effects reported in response to TRH treatment of pituitary- 
derived GH-cell lines may reflect the activation of two pharmacologically similar, but 
genetically distinct, receptor species. To examine this question, cDNA species
encoding each of the long and the short isoforms of the rat TRH receptor have been
expressed in Rat 1 fibroblast cells which do not endogenously express the receptor and 
the signalling properties of the two isoforms then examined.
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3.2. Results
3.2.1. Correlation between TRH-receptor expression levels and TRH- 
stimulated inositol phosphate generation for Rat 1 fibroblasts 
expressing long and short receptor isoforms.
• i
Rat- 1 fibroblasts were stably transfected with either 10 pg of plasmid pcDNA I , 
containing the long isoform of the rat TRH receptor [Kim etal., 1994], or 10 pg of 
plasmid pCMV5, into which the short isoform of the rat TRH receptor [de la Pena et 
al, 1992] had been subcloned. In both cases 1 pg of plasmid pSV2neo was co- 
transfected along with the receptor-containing plasmids to allow for selection of clones 
expressing resistance to geneticin sulphate. Resistant colonies were selected and 
expanded and expression of the TRH-receptor isoforms initially screened for by the |
ability of 10 pM TRH to promote generation of pH]inositol phosphates after labelling 
of cells with 1 pCi/ml of myo-pH]inositol as indicated in section 2.14.
A number of clones producing elevated levels of pH]inositol phosphates in f
response to TRH were further defined (Figure 3.2) by analysis of the specific 
binding to membranes of a single concentration of pH]TRH ( 10 nM) in the presence of 
the poorly hydrolysed analogue of GTP, Gpp[NH]p (100 pM) as described in section
2 .12 .1 . Such clones exhibited a range of levels of TRH-receptor binding as shown in 
Figure 3.2 and the correlation between receptor levels and fold stimulation of inositol 
phosphate levels above basal was high in cells transfected with plasmids incorporating 
cDNA for either the long or short splice variants of the TRH receptor (r = 0.94).
3.2.2, Specific detection of mRNAs encoding either the long or short 
isoforms of the rat TRH receptor
I
Clone 32, transfected to express the long isoform of the receptor, and clone 1, 
transfected with the short-isoform cDNA, were selected for detailed study. To confirm 
solely the expression of the expected TRH-receptor isoforms in these cells, RNA was 
isolated and subjected to reverse transcription followed by PCR (RT-PCR) by using a 
primer pair which straddles the splice variation site in the TRH-receptor gene as 
described in section 2.29 and Table 2.3. A single PCR product of 376 bp was 
obtained from RNA isolated from clone 32, and a single PCR product of 324 bases 
from RNA isolated from clone 1 as shown in Figure 3.3. These were the expected 
products from the long and short isoforms, respectively. Confirmation of this was 
obtained from PCR reactions performed with the two cDNA species ligated into the 
plasmids used for their expression. No product was obtained either when template was 
excluded from the PCR reaction or when RNA isolated from parental Rat 1 fibroblasts 
was subjected to RT-PCR with these primers.
3.2.3. [^HjTRH-blnding characteristics of long and short splice 
variants of the rat TRH receptor
%
Maximal levels and the affinity of TRH binding to the long and short isoforms 
of the receptor expressed in membranes of clones 32 and 1 were examined by analysis 
of competition curves between pH]TRH (approximately lOnM) and various 
concentrations of TRH in the presence of 100 pM Gpp[NH]p as decribed in section  
2 .1 2 .1  Analysis of such data indicated that the long isoform of the receptor was 
expressed at 75Q±30 fmol/mg of membrane protein in clone 32, and the short isoform 
of the receptor was expressed at 860±170 fmol/mg of membrane protein in clone 1 as 
shown in Figures 3.4a and 3.4b
The estimated Kd for the binding of TRH to these receptors in these assay 
conditions was 85±3 nM for the long isoform and 71±34 nM for the short isoform
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:(mean±S.E.M.;w=3 in each case). These values were not significantly different {p 
=0.76). These values must, however, be interpreted with caution, as binding 
parameters based on analysis of binding of pH]~labelled agonist ligands can only be 
expected to provide approximate values. Similar binding experiments were also 
performed in the absence of Gpp[NH]p as shown in Figures 3.4c and 3.4d, In such 
experiments, the Hill coefficient (slope) of the displacement curve of specific pHJTRH 
binding by TRH was substantially less than 1. Analyses of such data by a two-site fit 
model indicated that 57±8% (mean±S.D., n =3) of the long isoform of the receptor 
was in the high-affinity state in these experiments.
This was not significantly different ip =0.31) from the short isoform, in which 
some 48+11% (mean+S.D., n =3) of the receptors were estimated to be in the same 
high-affinity state. The estimated K4  for the binding of TRH to the high affinity state of 
the long isoform was 8.2±4.0 nM (mean±S.D., n = 3), and for the short isoform it 
was 12.1±3.8 nM (mean±S.D., n =3). These values were not significantly different 
from one another ip =0.29). The characteristics of the low-affinity state of the receptor 
for TRH for each isoform were not amenable to analysis by this means, as the 
estimated eiTors were at least as great as the values obtained.
3.2.4. Comparison of the ability of TRH to stimulate inositol phosphate 
generation in Rat 1 fibroblast clones expressing either the long or 
the short isoforms of the rat TRH receptor
Examination of the ability of TRH to stimulate inositol phosphate generation in 
myo -pHJinositol-labelled clone 32 and clone 1 cells in the presence of 10 mM LiCl, as 
described in section 2.14, demonstrated that the EC50 for TRH was highly similar 
for the two receptors (7.5±1.7 nM for long isoform, 6.0±0.9 nM for short isoform) as 
shown in Figure 3.5. This was unaffected by pretreatment of the cells with 25 ng/ml
of pertussis toxin for 16 hrs, conditions able to cause ADP-ribosylation of essentially 
the entire population of pertussis toxin-sensitive G proteins in these cells (data not 
shown).
3.2.5. Inositol phosphate generation by either the long or the short TRH 
receptor isoforms : time-course studies
Examination of time courses of inositol phosphate generation by the two TRH- 
receptor splice variants was assessed over a period of 25 min as described in section
2 .14 .2 . In both clone 32 (long isoform) and clone 1 (short isoform) the rate of 
inositol phosphate generation was linear over this time period. As clone 1 produced a 
larger fold stimulation of inositol phosphate generation than clone 32, a second clone 
(clone 7) expressing the short form of the receptor was also tested in parallel as 
displayed in Figure 3.6. This clone also demonstrated linear kinetics of inositol 
phosphate production in response to TRH.
3.2.6. Inability of TRH to alter the adenylyl cyclase activity in 
membranes of cells expressing either the long or short isoforms 
of the rat TRH receptor
The potential for either the long or short isoforms of the TRH receptor to 
regulate adenylyl cyclase activity was assessed in membranes of clones 1 and 32 as 
described in section 2.13. TRH (lOpM) was unable, however, either to stimulate 
basal or to inhibit forskolin (lOpM)-amplified adenylyl cyclase activity as displayed in 
Table 3.1.
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3.2.7. Similar expression levels of both phosphoinositidase C and 
adenylyl cyclase regulatory G proteins
In order to examine if this lack of regulation of adenylyl cyclase might reflect 
the G-protein profile of Rat 1 fibroblasts expressing either the long or the short 
isoforms of the rat TRH receptor, levels of expression of the a  subunits of the G- 
proteins associated with stimulation of phosphoinositidase C (Gq G n), and stimulation 
(Gs) and inhibition (Gi2 , GjS) of adenylyl cyclase were assessed by immunoblotting as 
described in section 2.8. Each of these polypeptides was demonstrated to be 
expressed in membranes of these cells as shown in Figure 3.7.
3.2.8. Inability to regulate ERK-1 activity substantially in Rat 1 
fibroblasts expressing either the long or short isoforms of the rat 
TRH receptor
TRH stimulation of the ERK-1 (MAP kinase) cascade has recently been 
reported in pituitary GH3 cells [Ohmichi etal., 1994]. This observation was confiimed 
as shown in Figure 3.8a by demonstrating that addition of 10 pM TRH for 5 min to 
GH3 cells resulted in the characteristic decrease in mobility of the ERK-1 (44 kDa 
MAP kinase) in SDS/PAGE, as described in section 2.16, which is routinely 
correlated with phosphorylation and activation of this protein [Leevers and Marshall, 
1992; de Vries-Smits etal., 1992; Hordijk etal,  1994]. In clones of Rat 1 fibroblast 
cells expressing either the long or the short isoform of the TRH receptor which had 
been maintained in the absence of serum for 48 hrs, treatment of 10 pM TRH for 5 min 
had only a small modulatory effect on the fraction of the cellular population of this 
polypeptide in the activated form as shown in Figure 3.8b.
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Treatment of the cells with the phorbol ester, phorbol 12-myristate 13-acetate 
(PMA), equally resulted in only minimal modulation. In parallel experiments both 
epidermal growth factor (10 nM) and lysophosphatidic acid (10 pM), which have both 
previously been noted to cause stimulation of ERK activity in Rat 1 cells and clones 
derived from them [Hordijk e ta l ,  1994; Alblas etal., 1994; Anderson & Milligan, 
1994; Winitz etal., 1993] produced this characteristic mobility shift in essentially the 
total cellular population of ERK-1 (Figure 3.8b). Pertussis-toxin (25 ng/ml, 16 hrs) 
treatment of the cells prevented lysophosphatidic acid regulation of ERK-1 mobility, 
but not that produced by epidermal growth factor (Figure 3.8c).
3.3. Discussion
It has generally been observed that TRH acts as a phosphoinositidase-C-linked 
hormone, the receptor for which interacts with pertussis toxin-insensitive G proteins of 
the Gq class [Hsieh & Martin, 1992; Kim etal., 1994; Aragay e ta l ,  1992]. In a 
number of reports, however, particularly in GH3 cells and related rat anterior-pituitary 
cell lines, which are perhaps the most widely used model cell systems for analysis of 
TRH receptor function, interactions of TRH receptors with other G proteins [Paulssen 
eta l,  1992; Gollasch etal,  1993], most prominently Gg and Gi2 which are viewed 
traditionally as being responsible for stimulatory and inhibitory regulation of adenylyl 
cyclase have been demonstrated.
The identification of expression of splice variants of the TRH receptor in GH3 
cells [de la Pena etal,  1992] offered a potential explanation of these findings and begs 
the question of whether these splice variants display different functional properties. A 
number of molecularly distinct receptors are now appreciated to result from differential 
splicing of pre-mRNA derived from a single gene and, particularly in the cases of the 
splice variants of the EP3 prostanoid receptor [Namba etal., 1993] and the pituitary
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adenylate cyclase-activating-polypeptide (PACAP) receptor [Spengler et a l,  1993], 
vei7  different second-messenger generation functions have been recorded for the 
individual forms.
Splice variation in the rat TRH receptors results from the presence or absence of 
a 52-bp segment in the C-terminal tail to yield either a 412 amino acid polypeptide (long 
isoform) or a 387 amino acid version (short isoform) [de la Pena etal., 1992]. This is a 
reflection that the absence of a 52-bp fragment not only removes genetic information, 
but also results in a frame shift such that the amino acid sequence downstream of the 
deletion is altered and a different stop codon is encountered, which is not in frame in 
the long isoform.
In this study, I have examined whether the signalling characteristics of the two 
isoforms differ following stable expression of each isoform in Rat 1 fibroblasts, to 
assess whether reported regulation of effector systems other than phosphoinositidase C 
might reflect activation of one isoform rather than another. The initial preconceptions 
were that this might be a property of the short isoform, as assessed by RT-PCR, this is 
the minor form of the receptor in both normal pituitary and GH3 cells [de la Pena et al., 
1992].
After isolation of clones expressing specific pH]TRH-binding sites, it was 
determined that the clones expressed only the expected splice variant form of the 
receptor by reverse transcription of RNA isolated from these clones and subsequent 
PCR using a primer pair designed to generate fragments which would demonstrate the 
presence or absence of the 52-bp section which differs between the two isoforms 
(Figure 3.3).
Both receptor isoforms displayed similar binding affinity for pH]TRH 
(Figure 3.4). Most of the binding experiments were performed in the presence of 100 
pM Gpp[NH]p. The rationale for this approach was that no radiolabelled antagonists 
are available for the TRH receptor, and when binding experiments with pH]TRH were
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performed in the absence of Gpp[NH]p the data indicated a mixture of apparent low- 
and high-affinity sites with h values substantially below 1 (Figures 3.4c and 3.4d) 
However, Gpp[NH]p converts all G protein linked receptors into a G protein 
free state, which displays lower but uniform affinity for agonists and thus allows easier 
estimation of the binding parameters of B^ax and Kd for a ligand. Under these 
conditions the h values for the self-competition experiments were close to 1. These 
were assessed by using the formalisms of DeBlasi et al. [1989] as these relate 
specifically to self-competition experiments in which the h value from the data is close 
to 1.0 as described in the legends of Figures 3.4a and 3.4b  for confirmation of the 
suitability of this approach in this case. However, even under such conditions the
estimated values for the binding parameters should be treated with a degree of caution, 
as agonist-binding characteristics are difficult to analyse unambiguously. Under these 
conditions both the long and short isoforms of the rat TRH receptor bound TRH with 
an estimated Kd of some 80 nM (Figure 3.4).
A series of pH]TRH-binding experiments in the absence of Gpp[NH]p were 
performed and analysed using two-site displacement models. The estimated Kd for
ITRH at the high-affinity state for each isofonn was close to 10 nM. These values are similar to the measured EC50 of 5-10 nM for TRH stimulation of inositol phosphate 
production observed for clones expressing both the long and short TRH-receptor splice 
variants (Figure 3.5), and, hence, indicate that it is the high-agonist-affinity state of 
the receptor which is able to interact with the cellular G protein population to produce 
effector regulation.
This similarity of EC50 values for TRH-mediated stimulation of inositol
phosphate production is in agreement with analysis of TRH regulation of Cl~ flux in 
■Xenopus oocytes after injection of cRNA species corresponding to the two isoforms 
[de la Pena etal., 1992]. Given the location of the splice variation site in the C-terminal 
tail and the demonstration that Tyr-106 in the third transmembrane helix of the receptor
_____
plays a key role in the binding of TRH [Perlman et al,  1994], it should not be 
considered surprising that the two splice variants display very similar binding and 
activation affinities for TRH.
In contrast with the reported activation of adenylyl cyclase by TRH in GH cells, 
which has been demonstrated to occur via a direct activation of Ggct [Paulssen et d . , 
1992], I was not able to record any ability of either TRH receptor splice variant to alter 
adenylyl cyclase activity either positively or negatively in membranes of the TRH 
receptor expressing clones of Rat 1 cells (Table 3.1). This is not a reflection of a lack 
of expression of the relevant G-proteins, which have been demonstrated to be 
expressed by these cells (Figure 3.7).
It may of course be a reflection of the adenylyl cyclase isoform distribution in 
the individual cell lines, an area which remains essentially uncharted, but, as all forms 
of hormonally regulated adenylyl cyclase are activated by Gg [Tang & Gilman, 1992], 
it seems unlikely. It is, therefore, concluded that neither isoform of the rat TRH 
receptor displays appreciable ability to interact with either Gg or indeed with Gi2 , at 
least when expressed in this genetic background. As such the results can provide no 
evidence in this study for either of the splice variants of the TRH receptor providing a 
locus for bifurcation of signalling information, as has recently been described for a 
variety of receptors, including the TSH receptor [Allgeier etal,  1994, and for review 
Milligan, 1993]. Recent data have also noted the ability of TRH to stimulate MAP 
kinase (ERK) activity in GH3 cells [Ohmichi etal,  1994], but it was unable to produce 
a significant effect in clones of Rat 1 cells expressing either the long or short isoforms 
of the rat TRH receptor (Figure 3.8).
In such cells it has previously been reported that both receptors with intrinsic 
tyrosine kinase activity such as the epidermal growth factor receptor and G protein- 
coupled receptors, which are able to cause activation of Gi2ct and hence inhibition of 
adenylyl cyclase activity, cause activation of this cascade, e.g. the endogenously
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expressed receptor for lysophosphatidic acid or the transfected aaClO adrenoceptor
[Alblas e ta l ,  1993; Anderson & Milligan, 1994; Winitz et al., 1993]. It has also
previously been noted that the endogenously expressed receptor for the peptide
endothelin, and indeed stimulation of the cells with phorbol esters, has little ability to
cause activation of ERK in these cells [Hordijk etal., 1994]. Hence, as TRH also
functions to cause activation of a phosphoinositidase C, and thus stimulation of protein
kinase C, it is not surprising that in this genetic background neither of the TRH
receptor isoforms regulated a signalling cascade necessary to produce this effect.
The data produced herein demonstrate that no obvious functional differences are
observed for the long and the short isoforms of the rat TRH receptor, at least when
expressed in Rat 1 fibroblasts, and further demonstrate a high selectivity of coupling of
both of these isofonns to stimulation of phosphoinositidase C over regulation
of adenylyl cyclase.
Figure 3.1. Seven transmembrane spanning model of the TRH
receptor
Panel A shows the proposed topology of the TRH receptor cloned from 
rat pituitary cells with respect to the plasma membrane [de la Pena et al., 1992a; 
Zhao e/a/., 1992]. The receptor is proposed to form seven transmembrane 
helices (TM1-TM7) based on hydropathy analysis of the receptor sequence. 
Asn3 and AsnlO are proposed to be glycosylated based upon the consensus 
glycosylation sequence, N-X-S/T, with X being any amino acid residue. Cys 98 
and Cys 179 are proposed to form a disulfide bond [Cook etal., 1996; Han & 
Tashjian, 1995].
Panel B shows the divergent carboxyl-terminal amino acid sequences 
of the long (412 a.a.) and short (387 a.a.) isoforms of the rat TRH receptor [de 
la Pena eZ a/., 1992b]. Amino acid sequences of the deleted sequence and 
its boundaries in the short isoform are shown with the numbers indicating the 
amino acid position in the open reading frame. Putative sites for 
phosphorylation by protein kinase C (©) and casein kinase II (*) are indicated 
in the carboxyl terminal domain.
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Figure 3.1.
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Figure 3.2, Correlation between TRH-receptor expression levels
and TRH-stlmulated inositol phosphate generation for Rat
1 fibroblasts expressing long and short receptor isoforms
The specific binding of a single concentration of pH]TRH (lOnM) 
defined by the absence and presence of lOpM TRH in the presence of lOOpM 
Gpp[NH]p was measured as was the ability of lOpM TRH to stimulate 
production of inositol phosphates as described in section 2.14 in a number of 
clones of Rat 1 fibroblasts transfected to express either the short (closed circle) 
or long (open square) isoforms of the rat TRH receptor. The receptor-binding 
data have not been corrected for receptor occupancy. Clones which were 
transfected with receptor-containing plasmids and which became resistant to 
geneticin sulphate, but failed to display specific binding of pH]TRH, also failed 
to accumulate inositol phosphates. Data are taken from the following clones: 
long isoform, clones 25, 32, 34 and 42; short isoform, clones 1, 4, 5, and 7. 
The maximal levels of inositol phosphate stimulation were obtained from 
clone i (4110 dpm) and clone 32 (2040 dpm). The results represent the means 
of 3 determinations. Similar results were obtained in 2 further experiments.
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Figure 3.3. Specific detection of mRNAs encoding either the 
long or short isoforms of the rat TRH receptor
RNA isolated from either clone 32 (transfected with long-isoforai 
cDNA) (lane 2) or clone 1 (short isofonn) (lane 3) was reverse-transcribed and 
PCR was performed with the primers as described in section 2.9 |  and 
Table 2.3. Positive controls were provided by the long (lane 5) and short (lane 
6 ) cDNA species, and a negative control (lane 4) was obtained by omission of 
template. A 1 kb ladder provided size markers (lane 1).
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376bp (long) 
324bp (short)
1 2 3 4 5 6
.__ '   _ - J
Figure 3.4. [^HJTRH-binding characteristics of long and short
splice variants of the rat TRH receptor
The ability of various concentrations of TRH to compete with pHJTRH 
for binding to the TRH-receptor isoforms expressed in membranes (50p,g) of 
clones 1 (short isoform) and 32 (long isoform) was assessed in the presence 
(a,b) (closed symbols) or absence (c,d) (open symbols) of lOOpM Gpp[NH]p 
as described in section 2.12.1,
(a) Clone 1: In the example displayed, pHJTRH was 9.9 nM and the 
estimated IC50 for TRH was 150 nM; h was 1.11. Application of the 
formalisms of DeBlasi e?«/.[1989] therefore allows estimation of a for TRH 
of 140 nM.
(b) Clone 32: In the example displayed, pHJTRH was 10.7 nM and 
estimated IC50 for TRH was 93 nM; h was 1.09. These data provide an 
estimate of Kd for TRH of 82 nM.
(c) Clone 1: In the example displayed, pHJTRH was 11.0 nM and the 
estimated IC50 for TRH was 27 nM; h was 0.78. A h value of less than 1 
implies the likely existence of more than one detected affinity state for TRH and 
precludes use of the formalisms of DeBlasi et «/.[1989J. Application of two- 
component fit model allowed estimation of the Kd of the high-affinity site for 
TRH of 8 .6  nM.
(d) Clone 32: In the example displayed, pHJTRH was 11.0 nM and the 
estimated IC50 for TRH was 38 nM; h was 0.6. Application of a two- 
component fit model allowed estimation of the Kd of the high-affinity site for
TRH of 10.5 nM.
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Figure 3.5. Comparison of the ability of TRH to stimulate 
production of inositol phosphate generation in clones 
expressing either the long or the short isoforms of the rat 
TRH receptor
The ability of various concentrations of TRH to stimulate production of 
inositol phosphates was assessed in cells of clones 1 (short isoform) (open 
circles) and 32 (long isoform) (closed squares) as described in section 2.14. 
Results are presented as percentage of maximal effect (defined as the stimulation 
obtained with lOpM TRH).
The basal levels of inositol phosphate in this experiment were 1110 dpm for 
clone 1 and 595 dpm for clone 32. The maximal levels in clones 1 and 32 
were 8730 dpm and 1980 dpm, respectively. The data displayed are the mean 
of triplicate assays from represent!tive experiments (n=3).
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Figure 3.6. Inositol phosphate production by either the long or
the short TRH-receptor isoforms : time-course studies
The ability of TRH ( 10p,M) to stimulate inositol phosphate production 
was assessed as described in section 2.14 at various time points over a period 
of 25 min in clones 1 (closed circles) and 7 (closed triangles) (both short 
isoform) and clones 32 (open squares) (long isoform). The higher fold 
stimulation of inositol phosphate generation in clone 1 in response to TRH in 
these studies was largely a reflection of lower levels of inositol phosphates being 
present in incubations performed in the absence of TRH.
The basal levels of inositol phosphate in clones 1, 7, and 32 were 460 dpm, 
830 dpm, and 750 dpm respectively. The results represent the mean of 
triplicate determinations. The experiment shown is typical of three 
independent experiments which gave similar results.
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Figure 3.7. Rat 1 fibroblasts expressing either the long or the 
short isoforms of the rat TRH receptor express similar 
levels of both phosphoinositidase C and adenylyl cyclase 
regulatory G proteins.
Membranes (15 pg, panel A; 30 p,g, panel B; or 20 pg, panel C) from 
Rat 1 fibroblast clone 32 (long isoform) (lanes 1 and 2) and clone 1 (short 
isoform) (lanes 3 and 4) were resolved by SDS/PAGE (10% acrylamide), 
transferred to nitrocellulose and subsequently immunoblotted with specific 
antisera as described in section 2,8 and Table 2.1 to detect the presence of 
the a  subunits of the phosphoinositidase C-linked G proteins Gq^Gji (A), and 
the adenylyl cyclase-stimulatory, Gg (B), and inhibitory, Gi2 (C), G proteins.
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Figure 3.8. Neither the long or the short isoforms of the rat TRH 
receptor is able to regulate ËRK-1 substantially in Rat 1 
fibroblasts
Figure 3.8a shows that TRH alters the gel mobility of ERK-1 in GH3 
cells. GH3 cells were deprived of serum for 48 h and then challenged with (2) 
or without (1) TRH (lOpM) for 5 min. Cell lysates were resolved by 
SDS/PAGE (10% acrylamide containing 6M urea) and immunoblotted as 
described in section 2.16 for the presence and mobility of ERK-1. After 
challenged with TRH a substantial fraction of this polypeptide migrated through 
the gel with decreased mobility, a characteristic associated with phosphorylation 
and activation of this polypeptide.
Figure 3.8b shows that epidermal growth factor (EGF) and 
lysophosphatidic acid, but not TRH or phorbol myristate acetate, regulate ERK- 
1 in Rat 1 fibroblasts expressing short or long forms of the TRH receptor. Cells 
of clone 32 (TRH-receptor long isoform, lanes 1-6) and clone 1 (TRH-receptor 
short isoform, lanes 7-12) were deprived of serum for 48h and then 
subsequently challenged with vehicle (lanes 1, 7), lOfxM lysophosphatidic acid 
(lanes 2,8), 10 nM EGF (lanes 3,9), 10 nM EGF plus 10 p,M TRH (lanes 
4,10), 10p,MTRH (lanes 5,11) or 1 pM phorbol myristate acetate (lanes 6,12) 
for 5 min. Cell lysates were resolved by SDS-PAGE (10% acrylamide 
containing 6M urea) and immunoblotted as above for the presence and mobility 
of ERK-1.
Pertussis toxin (25ng/ml, 16h) treatment of the cells expressing the long 
isoform of the Rat TRH receptor prevented lysophosphatidic acid regulation of 
ERK-1 mobility, but not that produced by epidermal growth factor as shown in 
Figure 3.8c with lanes of vehicle (lane 1), lOpM lysophosphatidic acid (lane 
2), 10 nM EGF (lane 3), lOpM TRH (lane 4), and 1 pM phorbol myristate 
acetate (lane 5).
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Table 3.1. Both the long and short isoforms of the rat TRH 
receptor are unable to regulate adenylyl cyclase activity in 
membranes of receptor-expressing Rat 1 fibroblast clones
Adenylyl cyclase activity was measured as described in section 2.13 in 
membranes of clones 1 and 32. Results are presented as means ± S.D. (n = 4). 
A similar lack of ability to regulate adenylyl cyclase activity was observed in 
membranes from two further clones [(clone 34, long isoform; clone 7, short 
isoform (results not shown)].
Adenylyl cyclase activity 
(pmol/min/mg membrane protein)
Receptor Isoform
Condition Long (clone 32)
Short 
(clone 1)
Basal 76 ±0.1 100 ± 3.0
TRH (lOpM) 74 ± 0.8 99 ± 1.0
Forskolin (lOpM) 160 ± 3.0 220 ± 11.0
Forskolin (lOpM) 
+ TRH (lOpM) 160 ± 5.0 230 ± 6.0
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4.1. In troduction
Chapter 4. Accelerated degradation of Guct/Gqa by agonist 
occupancy of a i adrenergic receptor subtypes
i
Wi
The natural catecholamines norepinephrine (NE) and epinephrine activate
adrenergic receptors in three families, a i ,  a 2, and p. Multiple subtypes have been
c lo n ed  w ith in  each  fam ily: th ree  a i  ad ren e rg ic  recep to rs  (A/D, B, an d  C), th re e  ct2
ad ren erg ic  recep to rs (A, B, an d  c ;  th e  h u m an  fo rm s a re  a lso  ca lled  CIO, C2, an d  C4
adrenergic receptors, respectively, based on their chromosomal location), and three p
adrenergic receptors (1, 2, and 3) [Lomasney et aL, 1995]. The reasons for
conservation of multiple subtypes remain uncertain, since all subtypes in each family
couple preferentially to the same effector when overexpressed, a  i adrenergic receptors 
.to activation of phosphoinositidase C, «2 adrenergic receptors to inhibition of adenylyl 
cyclase, and p adrenergic receptors to activation of adenylyl cyclase.
There are many closely related a i  adrenergic receptor subtypes that have been 
indicated by comparisons of the pharmacological profiles of ligands in different tissues 
[Ford et aL,1994]. Three distinct a i  adrenergic receptor cDNA species have currently 
been isolated [Cotecchia a/., 1988, Schwinn etal,  1990, Lomasney etal., 1991], 
otiA/D, « IB , «1C  as shown in Table 4.1, but there has been considerable debate as to 
how closely these reflect the pharmacologically defined subtypes [for review, Ford et 
d.,  1994], even if all of these cDNA species show the same signal transduction 
mechanisms following their heterologous expression in cell lines.
This has arisen partially because of the relative pharmacological similarity of the 
subtypes and partially because the first isolated cDNA species were derived from a
I
'‘i
I
number of different species [Ford a/., 1994, Milligan e/a/., 1994]. Current opinion
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:Favours the view that the cloned a\A  adrenergic receptor correponds to the
pharmacologically defined a  id adrenergic receptor, that the cloned and
pharmacologically defined aiB adrenergic receptor are identical, and that the cloned
a  1C adrenergic receptor may be the equivalent of the pharmacologically defined aiA
adrenergic receptor [Ford etal,, 1994].*
Despite these ongoing concerns, it is generally accepted that they share similar
structural features with other G protein coupled receptors as shown in Figure 4 .1  and 
mediate neurotransmission, vasoconstriction, cardiac inotropy, chronotropy, and 
glycogenolysis. The primary signalling function of a i  adrenergic receptor subtypes is 
to stimulate the hydrolysis of inositol-containing phospholipids via interaction with 
pertussis toxin-insensitive G proteins of the G(^Gn family [Wu et aL, 1992] with 
subsequent activation of phosphoinositidase Cg activity [Wu etal., 1992].
Phosphorylation and desensitization to the effects of agonist, epinephrine, in 
a  1 adrenergic receptors are mediated by p adrenergic receptor kinase (PARK) 1 and 2 
as well as arrestin proteins [Diviani etal., 1996]. On the other hand, truncation of the 
serine- and threonine rich carboxyl portion of the aiB adrenergic receptor abolished 
agonist induced phosphorylation and greatly impaired homologous desensitization of 
the receptor [Lattion et aL, 1994].
Although it has been well established that sustained exposure of many G 
protein-coupled receptors to agonist can result in a reduction in cellular levels of the 
receptor (a process known as down-regulation), it has only been in the recent past that 
agonist-mediated reduction in cellular levels of G proteins has also been observed
[Milligan G., 1993]. Even in such cases, information on the mechanism(s) responsible 
for these effects is fragmentary. To attempt to address this point directly in this study, 
clonal cell lines derived from rat 1 fibroblasts following stable transfection with the 
cloned rat aiA/D, the hamster aiB, and the bovine a ic  adrenergic receptor cDNA 
species were used.
-
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It is noted that in cells expressing each of the three receptor species, sustained
exposure to phenylephrine results in a large, selective downregulation of G n a  and
■Gqa as well as in downregulation of the receptors. These are the G proteins that have 
been demonstrated to couple a j  adrenergic receptors to phosphoinositidase C activity 
and the hydrolysis of inositol-containing phospholipids [Wu et al., 1992]. In each 
case, it is demonstrated that the basal rate of turnover of these G proteins is described 
adequately by a monoexponential with a t 0.5 between 33 and 40 h, while upon 
exposure to agonist, this rate of degradation is markedly increased, such that a 
substantial fraction of the cellular content of these G proteins now has a t  0.5 of 
between 7 and 10 h.
This study shows that G proteins activated by a receptor are degraded 
considerably more rapidly than those in the inactive state and provide a mechanistic 
explanation for how receptor agonists can control the cellular content of G proteins 
which interact with that receptor.
 ^ The nomenclature for the a i  adrenergic receptor subtypes was that originally 
assigned to the cDNA species which were used in this study, except that the cDNA 
originally named the aiA  adrenergic receptor is refened to as the « ia/D adrenergic 
receptor, as this is now widely accepted to be equivalent to the pharmacologically 
defined a  id  adrenergic receptor.
* It has been suggested that the a i c  should be renamed the « ia , and aiA/D should be 
renamed a  id  according to the recent International Union of Pharmacology (lUPHAR) 
meeting report [Hieble et al., 1995].
:î
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4.2. Results
4.2.1. Specific detection of mRNAs encoding a i  adrenergic receptor 
subtypes
Rat 1 fibroblast cells transfected to stably express each of the three cloned a l  
adrenergic receptor subtypes were obtained from Dr.D.E.Clarke (Syntex, Palo Alto, 
CA) under the license to Syntex from Dr.L.F.Allen (Duke University, NC) and used 
for this study. The presence of aiA/D, «IB and a i c  adrenergic receptor mRNA in 
appropriately transfected cells only was confirmed by reverse transcriptase-PCR
analysis of RNA isolated from untransfected parental rat 1 fibroblast and each of the 
clonal cell lines examined in this study as described in section 2.29 using 
oligonucleotide primers specific for each of the three molecularly defined a l  
adrenoreceptor subtypes as described in Table 2.3. and is shown in Figure 4.2.
I
s
4.2.2. The ability of phenylephrine to displace pH]prazosin binding in 
membranes of a i  adrenergic receptor expressing cells
Membranes derived from all three clonal cell lines were examined for their 
levels of expression of the a  1 adrenergic receptor subtypes by measuring the specific 
binding of the a l  adrenergic receptor antagonist pH]prazosin as described in section 
2 .1 2 .2 . aiA/D, «IB and a i c  adrenergic receptor subtypes were found to be 
expressed at levels of 2.1 ±0.1, 2.8 ± 0.5, and 7.0 ± 0.9 pmol/mg membrane protein, 
with Kd values for the binding of pH]prazosin of 110 ± 20, 76 ± 13, and 150 ± 26 
pM, respectively (data provided by Dr.Christine Brown). Displacement of specific 
pH]prazosin binding by varying concentrations of the a i  adrenergic receptor agonist
I
1^4.2.3. Stimulation of inositol phosphate production by all the a j  
adrenergic receptor subtypes
fibroblasts
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phenylephrine was achieved with p lC ^  values (and Hill < coefficients) of 5.1 ±0.1 
(nn= 0.76 ± 0.09), 4.7 ± 0.2 (nn = 1.06 ± 0.07), 5.2 ± 0.1 (nn = 0.90 ± 0.06), 
respectively, for the « ja /d , «IB, and a i c  adrenergic receptor subtypes as displayed in 
Figure 4.3.
Addition of the poorly hydrolysed analogue of GTP, Gpp[NH]p (100 pM), to 
such assays produced no significant alterations in the positions of such displacement 
curves [5.1 ±0.1 (nn = 0.99 ± 0.03), 4.6 ±0.1 (uh= 0.89 ± 0.05), 4.9 ± 0.2 (ng = 
1.12 ± 0.16) for the aiA/D, «IB, and a i c  adrenergic receptor subtypes] as shown in 
Figure 4.3.
Accumulation of inositol phosphates in Li Cl (lOmM)-treated a l  adrenergic 
receptor subtype expressing cells, which had been labeled for 24 h with myo-[2- 
3H]inositol as described in section 2.14, was found to be markedly stimulated by 
phenylephrine as shown in Figure 4.4 However, it was in a manner that was 
insensitive to pretreatment of the cells with pertussis toxin (25ng/ml) for 16 h (data not 
shown), confirming a functional coupling of these receptors to the cellular G protein 
machinery. Half-maximal stimulation of inositol phosphate generation in response to 
phenylephrine was produced with between 0,3 and 1 pM agonist in a range of 
experiments with each of the three a l  adrenergic receptor subtype expressing cell lines 
as shown in Figure 4.4. 3
4.2.4. Phenylephrine-mediated downregulation of G q a/G n a levels in 
membranes of a i  adrenergic receptor subtype-expressing Rat 1
%
Sustained exposure of cells expressing each of the three a i  adrenergic receptor 
subtypes to varying concentrations of phenylephrine resulted in a reduction of 
membrane-associated levels of a combination of the phosphoinositidase C-linked G 
proteins Gqoi and G n a  by, maximally, approximately 50-70% as determined by 
immunoblotting of membranes of agonist-treated and untreated cells with antiserum CQ 
as indicated in Table 2.1, which identifies the C-terminal decapeptide, which is 
entirely conserved between these two closely related G proteins. No significant 
alterations in immunologically detected levels of other G protein a  subunits expressed 
by these cells (G^a, Gi2a) were noted to be associated with phenylephrine treatment 
(data not shown). Downregulation of G qa/G na was found to be dose dependent with 
EC50 for phenylephrine close to 6(X) nM for all three a i  adrenergic receptor subtype- 
expressing cells as shown in Figure 4.5.
4.2.5. Time course of agonist-mediated downregulation of G qa/G na
In cells expressing the aiA/D and aiB adrenergic receptor subtypes, half- 
maximal effects in response to a maximally effective concentration of phenylephrine 
(lOOpM) were produced after some 8h, whereas in cells expressing the a i c  subtype, 
this figure was determined to be 4h as shown in Figure 4.6, a difference that might 
reflect the higher levels of expression of the receptor in these cells. In all cells treated 
with agonist over a sustained period ( 16h), a similar membrane-bound plateau level of 
G qa/G iia was established at some 30-50% of that present in untreated cells.
4.2.6. Phenylephrine treatment of a i  adrenergic receptor subtype
expressing cells results in downregulation of both Gqa and Gi la .
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each of the three a  1 adrenergic receptor subtypes was non-selective between these G 
protein a  subunits.
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GqO and G n a  comigrate in 10% (w/v) acrylamide SDS-PAGE. Therefore, to 
determine both the relative levels of expression of these two phosphoinositidase C- 
linked G proteins in the rat 1-derived clonal cell lines and whether phenylephrine- 
mediated downregulation of G qa/G na in any of these cells was selective for either of 
these highly homologous G protein a  subunits, membranes from untreated and 
phenylephrine (lOOpM) treated cells were resolved by SDS-PAGE using 12.5% (w/v) 
acrylamide gels containing 6M urea as indicated in section 2.6. and section 2.8, 
conditions shown to be effective in resolving these G proteins by Mullaney et 
^7/.[1993], Shah & Milligan [1994], and Svoboda & Milligan [1994].
Figure 4.7 demonstrates that steady-state levels of G na were substantially 
(over 2-fold) greater than Gqa in these cells and that phenylephrine-driven down­
regulation of membrane-associated Gqa and G n «  from the clonal cell lines expressing
fi
4.2.7. Time course of a i  adrenergic receptor subtype-stimulated 
enhancement of G qa/G ija protein degradation
In order to address the mechanism(s) of phenylephrine-mediated reduction in 
membrane-bound levels of G qa/G na, cells of the a l  adrenergic receptor subtype- 
expressing clones were incubated with Trans ^%-label for 16h, and subsequently the 
decay of with time in immunoprecipitated Gqa/Gn« was monitored in cells that 
were either untreated or treated with phenylephrine (100pM) as described in section  
2.2.7 and section 2.5.2.
Analysis of the rate of decay of ^%-labeled G qa/G na indicated that in the 
untreated aiA/D (Figure 4.8a), aiB (Figure 4.8b), and a i c  (Figure 4.8c) 
adrenergic receptor subtype-expressing cells, this process was described adequately by
:
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monoexponentiais with estimated half-time {t 0 .5) ranging from 33 to 40h. However, 
the decay of -labeled G qa/G na in each of the cell lines in the presence of 
phenylephrine was more rapid, and the data were more effectively modeled by a two- 
component fit than by a single exponential as shown in F igure 4.8a, b, and e. 
Addition of phenylephrine was associated with a substantial component of the decay in 
which t 0.5 for G qa/G n« was markedly accelerated to 10.2, 10.9, and 7.7h in rat 1 
fibroblasts expressing aiA/D, «IB, and a i c  adrenergic receptor subtypes, 
respectively.
There was, however, a second component of the decay rate for G qa/G na that 
was not enhanced compared to the single phase decay observed in the untreated cells. 
Because of the lower steady-state level of expression of Gqa relative to G n a , it was 
not attempted to examine whether the agonist-induced acceleration of Gqa/Gn« 
degradation could be observed independently for both of these G-proteins. In contrast 
to the effect of phenylephrine on the rate of removal of ^%-labeIed Gqa/Gn«, this 
agonist had no effect in any of the a i  adrenergic receptor subtype-expressing cells on 
the rate of decay of ^^S-labeled Gi2a, which had been immunoprecipitated with 
antiserum SG as indicated in Table 2.1 (data not shown). This G protein has been 
shown to be involved in receptor-mediated inhibition of adenylyl cyclase [McKenzie & 
Milligan, 1990; Simonds e ta l ,1989].
4 .3 .D iscussion
Although the basic observation that maintained agonist activation of a G 
protein-linked receptor can result in a marked and selective reduction in cellular levels 
of the G protein(s) activated by that receptor is now well established [Milligan, 1993], 
far less is known about the mechanisms responsible for such phenomena. Studies from 
Hadcock a/. [1990, 1991] have noted complex regulation of G proteins following
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available, all three a i  adrenergic receptor cDNA species used in this study have
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receptor stimulation, including alterations in both protein and mRNA stability of a 
variety of G proteins, which is then integrated to result in upregulation of some G 
proteins and downregulation of others. By contrast, Mitchell etal.{\993] noted that 
muscarinic ml acetylcholine receptor-mediated downregulation of the a  subunits of the 
phosphoinositidase C-linked G proteins G ^G n was accompanied by a selective 
accelerated rate of degradation of these G proteins. In this sudy, it has been sought to 
further analyse such effects by examining the process of downregulation of the a  
subunits of Gqand/or G ji in rat 1 cells transfected to express individual molecularly 
defined a j  adrenergic receptor subtypes.
In such cells, expressing one of the rat o ia /d , the hamster aiB, and the bovine 
a i c  adrenergic receptors and labeled with myo-pH]inositol, exposure to the a% 
adrenergic receptor agonist phenylephrine resulted in stimulation of inositol phosphate 
production in a fashion that was resistant to pretreatment of the cells with pertussis 
toxin. Such a feature was hardly unexpected, but is the pattern anticipated for receptors 
that couple to phosphoinositidase C-linked G proteins of the Gq family. Maintained 
exposure of these cells to phenylephrine resulted in downregulation of each of the 
receptor subtypes as shown in Table 4,2 and selective downregulation of some 
combination of the a  subunits of Gq/Gn.
Agonist-induced downregulation of G protein-linked receptors is a common 
regulatory feature. However, in the subfamily of a 2 adrenergic receptors, while both 
the a 2Cio and a 2C2 receptor are readily down-regulated by agonist treatment, the 
a 2Cq receptor has been reported to be largely resistant to downregulation [Eason &
Liggett, 1992]. Mutation of the site for palmitoylation in the C-terminal tail of the 
a 2Cio adrenergic receptor has been reported to render it resistant to agonist-mediated 
downregulation without altering its ability to couple to the Gj-like G proteins [Eason et 
al, 1991; Kennedy & Limbird, 1993]. Although direct information is not currently
3
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cysteine residues in their predicted C-terminal tail in a context that makes them likely 
sites of palmitoylation. It would be interesting to examine if mutation of these residues 
results in an agonist-mediated downregulation resistant form of these receptors and 
whether this interferes with agonist-mediated downregulation of Gc/Gji-
Agonist-mediated downregulation of the a  subunits of Gq^Gn has now been 
reported for a variety of receptors, including the muscarinic m l acetylcholine receptor 
[Mullaney a/., 1993; Mitchell e ta l ,  1993], the long isoform of the thyrotropin- 
releasing hormone receptor [Kim et a l ,  1994], and the gonadotropin-releasing 
hormone receptor [Shah & Milligan, 1994]. However, only for the first of these has 
any mechanistic analysis been provided. In Chinese hamster ovary cells transfected to 
express the rat muscarinic m l receptor, accelerated degradation of a combination of 
Gq'Gii was recorded without detectable alteration in levels of mRNA of either of these 
polypeptides [Mitchell etal, 1993],
In this study, those observations were expanded to show that in the genetic 
background of rat 1 fibroblasts, the basal half-life of the a  subunits of Gq/Gn can be 
adequately modelled as a single monoexponential consistent with 10 .5  in the region of 
33-40h and that agonist occupancy of any of the a i  adrenergic receptor subtypes leads 
to a fraction of the cellular Gq'Gn population being degraded much more rapidly. Data 
from each of the systems, however, are not consistent with all of the cellular content of 
these G proteins being degraded more rapidly in the presence of agonist. A maximally 
effective concentration of phenylephrine was able to cause downregulation of between 
50 and 70% of the total Gqot/Gna population in these cells in a range of experiments.
As the immunoprécipitation experiments that were performed in the G protein 
turnover studies made use of an antiserum that identifies G qa/G na equally [Mitchell et 
d., 1991], as it is directed at an epitope that is identical in these two G proteins as 
idicated in Table 2.1, and these two G proteins are widely co-expressed [Strathmann 
& Simon, 1990], I then wished to examine the possibility that each of the a i
123
' 'S ,
adrenergic receptor subtypes was able to cause downregulation of only one of these 
two G proteins. To do so, observations that separation of these two polypeptides can 
be achieved in SDS-PAGE systems that incorporate high concentrations of urea were 
used [Mullaney etal, 1993; Svoboda & milligan, 1994; Shah & Milligan, 1994].
Immunoblotting of membranes of the clones used in this study with antiserum 
CQ following their resolution in such gels demonstrated that the steady-state levels of
G n a  expression was over 2-fold higher than that of Gqa. Furthermore, they indicated 
that sustained phenylephrineoccupancyof each of the a j  adrenergic receptor subtypes 
resulted in a downregulation of both G n a  and Gqa. Although it was not analysed in 
these clonal cell lines, it was previously shown in cellular fractionation studies of
.
Chinese hamster ovary cells on sucrose density gradients that the subcellular 
distribution of these two G proteins is identical [Svoboda & Milligan, 1994].
An epitope-tagged constitutively activated mutant of Gga has been 
demonstrated to have a substantial! y reduced half-life compared with the epitope-tagged 
wild type protein when expressed in S49 lymphoma ey e  cells [Levis & Bourne,
1992], and agonist activation of an IP prostanoid receptor can result in downregulation 
of this epitope-tagged variant of Gga when this G protein is stably expressed in 
neuroblastoma NGI08-15 cells [Mullaney & Milligan, 1994]. Thus, although it has not 
been formally demonstrated for any G protein other than G^a, it is reasonable to 
surmise that activation of the G protein might be the key feature that controls its rate of 
degradation.
The palmitoylation status of both the activated mutant of Gga and the wild type 
protein following activation of a Gga-linked receptor is altered compared with the basal 
state of the wild type protein [Mumby et ah, 1994; Degtyarev et a l ,  1993; 
Wedegaertner & Bourne, 1994]. Kinetic evidence indicates that this is likely to reflect 
accelerated depalmitoylation [Wedegaertner & Bourne, 1994]. How relevant this is to 
agonist-mediated downregulation of Gga remains to be explored, but it is certainly true
124
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that in a number of systems, agonist occupation of Gga-linked receptors has been
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noted to result in large selective downregulation of this G protein [McKenzie &
Milligan, 1990; Adie etaL, 1992; Adie & Milligan, 1994].
It will thus now be of considerable interest to examine whether agonist 
activation of the a i  adrenergic receptor subtypes in these cells results in an alteration in
"IÎthe palmitoylation status of the a  subunits of Gq^Gn. As with the previous sudies on 
muscarinic ml receptor regulation of G qa/G ua levels [Mitchell etal., 1993], Northern 
blot analysis of mRNAs corresponding to these G proteins in untreated and 
phenylephrine treated cells did not provide evidence for regulation at the mRNA level 
[WisQ etal., 1995].
The data provided herein demonstrate that agonist occupation of a i  adrenergic 
receptor subtypes can selectively regulate the cellular levels of both Gqoc and G n a .
,
The mechanism of this effect is a selective acceleration of the rate of degradation of 
these G proteins.
:
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Figure 4.1. Seven transmembrane spanning model of the hamster
a iB  adrenergic receptor
The deduced amino acid sequence and putative topography of the 
hamster a ie  adrenergic receptor is depicted. Seven transmembrane domains 
(7TMD) are defined by hydropathy analysis of the receptor sequence. The amino 
acid identities with residues in 7TMD of the rat aiA  and the bovine a i c  
adrenergic receptor are 73% and 65%, respectively. Solid circles indicate amino 
acids identical in the corresponding position in the hamster adrenergic 
receptor which shows 45% identity in 7TMD. Potential sites of N-linked 
glycosylation are indicated by crosses at Asn 10, 24, 29 and 34 [Lomasney et 
d., 1991].
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Figure 4.2. Specific detection of mRNAs encoding three subtypes 
of cloned a i  adrenergic receptor
The presence of the three cloned a i  adrenergic receptor subtypes in 
appropriately transfected cells was confirmed by reverse-transcriptase PCR 
analysis as described in section 2 .2 9 .1 . RNA was isolated from untransfected 
parental and transfected rat 1 fibroblast cells which stably express the « i a /D ,  
a  IB, and a i c  adrenergic receptor mRNA, reverse transcribed and subjected to 
PCR with the oligonucleotide primers specific for each of the three molecularly 
defined a  i adrenergic receptor subtypes as described in Table 2.3.
Parental cells (lanes 1-3) and cells transfected aiA/D (lanes 4-6), aiB 
(lanes 7-9), and a i c  (lanes 10-12) adrenergic receptor cDNA are shown with 
specific primers of a^VD (lanes 1, 4, 7, and 10), aiB (lanes 2, 5, 8, and 11), 
and a i c  (3, 6, 9, and 12). No message was detected in untranfected parental 
cells. On the other hand, each mRNA encoding a i  adrenergic receptor subtypes 
was detected specifically in cells expressing aiA/D (lane 4), aiB (lane 8), and 
a ic  (lane 12) with their appropriate primers.
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Figure 4.3. The ability of phenylephrine to displace [^H] prazosin 
binding in membranes of a i adrenergic receptor expressing 
cells .
The ability of phenylephrine in the absence (filled symbols) or presence 
(open symbols) of Gpp[NH]p (100//M) to displace the specific binding of pH] 
prazosin to membranes of aiA/D-panel (I), am  panel (II) and a ic  panel 
(Ill)-adrenergic receptor expressing Rat 1 fibroblasts was assessed as described 
in section 2.12.2. Typical examples, representative of 4 independent 
experiments, are displayed (see Results for details).
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Figure 4.4. The a i  adrenergic receptor subtypes all cause 
stimulation of inositol phosphate production.
Rat 1 fibroblasts transfected to stably express the aiA/D (pane! a), aiB 
(panel b) and aic-adrenergic receptor subtypes (panel c) were labelled with 
inositol (1 pCi/m!) for 36 h prior to treatment with varying 
concentrations of phenylephrine for 20 min. Total inositol phosphates were 
measured as described in section 2.14. Stimulation of inositol phosphate 
generation was found to be dose-dependent with an EC50 for phenylephrine 
between 0.3 and 1.0 jaM. for all three cell lines in a range of experiments. The 
data displayed are the mean of triplicate assays from representative experiments; 
bars represent S.E.M.
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Figure 4.5. Phenylephrine-mediated downregulation of G q a/G n a  
levels in membranes of a i  adrenergic receptor subtype- 
expressing Rat 1 fibroblasts.
Membranes (15 p-g) derived from « ia/D- panel (a), aiB- panel (b) 
and a  1C- panel (c) adrenergic receptor-expressing rat 1 fibroblasts which were 
either untreated or had been treated with varying concentrations of phenylephrine 
for 16h were resolved by SDS-PAGE [10 % (w/v) acrylamide] as described in 
section 2 .6  and then immunoblotted using the anti-Gqa/Gna antiserum CQ 
as primary reagent as described in section 2.8. Quantitative analysis, as 
described in section 2.9 from these studies on the a ic  adrenergic receptor 
expressing cell line is displayed in panel (d).
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Figure 4.6. Time course of agonist-mediated downreguiation
of Gqa/Gjia.
Membranes (15 j^ g) derived from cxiA/D-panel (a), «iB-panel (b) 
and aiC"panel (c) adrenergic receptor-expressing rat 1 fibroblasts either 
untreated or treated with 100 pM phenylephrine for the times indicated were 
resolved by SDS-PAGE [10 % (w/v) acrylamide] as described in section 2.6 
and subsequently immunoblotted using anti serum CQ as described in section  
2 .8 . Quantitative analysis, as described in section 2.9, from these studies on 
the a  ic-adrenoceptor expressing cell line is displayed in panel (d).
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Figure 4.7. Phenylephrine treatment of a i  adrenergic receptor 
subtype expressing cells results in downregulation of 
both Gqa and Gi la .
Membranes (60 |xg) from o ia /d - (lanes 1 and 2), aiB- (lanes 3 and 4) 
and a ic -  (lanes 5 and 6) adrenergic receptor-expressing rat 1 fibroblasts, 
untreated (lanes 2, 4 and 6), or treated with phenylephrine (100 pM, 16 h) 
(lanes 1,3 and 5) were resolved by SDS-PAGE in a 12.5 % (w/v) acrylamide, 
0.0625 % (w/v) bis-acrylamide gel system containing 6 M urea as described in 
section 2,6.2 and subsequently immunoblotted as described in section 2.8.
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Figure 4.8. Time course of a j adrenergic receptor subtype-
stimulated enhancement of G qa/G na protein degradation
Whole cell [3%]-amino acid pulse-chase analysis of G (^/G na from 
each a i  adrenergic receptor-expressing rat 1 cells isotopically labelled and 
experimentally processed as described in section 2.2.7. In the chase phase 
cells expressing ctiA/D-panel (a), a iB panel (b), and a i c  adrenergic 
receptor-panel (c) were incubated with medium containing non-radiolabelled 
amino acids in the absence (filled symbols) or presence (open symbols) of 100 
piM phenylephrine. Cell activity was stopped at the indicated time and the cell 
extract processed for immunoprécipitation as described in section 2.5.2. 
Following resolution of the proteins, the dried gels were exposed to phosphor 
storage screen autoradiography and the radiolabelled G (p/G na analysed as 
described in section 2.11. Results represent the means from four independent 
experiments.
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Table 4.2. Exposure of rat 1 cells expressing adrenergic 
receptor subtypes results in downregulation of these 
receptors.
Rat 1 cells expressing the three a i  adrenoceptor subtype cDNAs were 
exposed to amaximally effective concentration of phenylephrine (100/<M) or 
vehicle for 6hrs. Membranes were prepared from these cells as described in 
section 2.3 and pH] prazosin binding experiments performed as described in 
section 2.12.2. Results are presented as % of the pH] prazosin binding sites 
present after treatment with phenylephrine compared to treatment with vehicle.
Condition Receptor subtype
[^Hjprazosin binding 
% control
otlA/D «IB «1C
26 ± 9 53 ± 4 38 ± 7
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Chapter 5
Signalling characteristics of a constitutively 
active mutant (CAM) of the aiB-adrenergic
receptor
5.1. Introduction
Different receptors for adrenaline and noradrenaline couple preferentially to 
different subfamilies of G proteins to allow the same hormones to regulate distinct 
effector pathways [Milligan a/., 1994]. The a i  adrenergic receptor subtypes 
represent the prototypic examples of G protein-coupled receptors (GPCRs) which 
interact with pertussis toxin-insensitive G proteins to cause stimulation of 
phosphoinositidase C activity as described in section 4.1 [Byiund, 1992].
In experiments designed to analyse which segments of the intracellular 
loops of receptors define the identity of the G proteins regulated by different 
adrenergic receptors, substitution of a small region of the human fe-adrenergic 
receptor in the extreme distal end of the third intracellular loop with the equivalent 
region from the hamster aiB-adrenergic receptor resulted in the expressed 
construct displaying elevated basal activation of adenylyl cyclase activity compared 
to the wild type receptor in the absence of an agonist ligand [Samama etal., 1993, 
Pei^ra/., 1994].
This construct was designated as the CAM (constitutively active mutant) fe- 
adrenergic receptor. Generation of a reciprocal construct in which a small section of 
the a  iB-adrenergic receptor was replaced with the equivalent region of the fe- 
adrenergic receptor resulted in this construct (CAMaiB-adrenergic receptor) as 
shown in Figure 5.1 [Cotecchia era/., 1990, Kjelsberg etal., 1993, Allen etal. , 
1991] displaying elevated basal activation of phosphoinositidase C.
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Although it has been well established that sustained exposure of many 
GPCRs to agonist can result in a reduction in cellular levels of the receptor (a 
process known as downregulation) [Dohlman eta l, 1991] it is only in the recent 
past that it has also become clear that agonist-occupation of GPCRs can result in a 
reduction in cellular levels of the G protein(s) activated by the receptor [Milligan, 
G., 1993]. The mechanism responsible for agonist-mediated G protein regulation 
seems primarily to be enhanced proteolysis of the activated G protein a  subunit as it 
has been demonstrated in clones of Rat 1 fibroblasts transfected to express 
individual a i  adrenergic receptor subtypes [see chapter 4]. Thus, in the first half of 
this study the ability of the a i  adrenergic receptor agonist phenylephrine to regulate 
cellular levels of G ^  and G n a  in Rat 1 fibroblasts transfected to express stably 
either the wild type or the CAMaiB-adrenergic receptor were compared.
A recent reappraisal of receptor theory has concluded that even wild type 
receptors are not entirely quiescent in the absence of agonist ligands and that the 
position of the equilibrium between an inactive conformation of the receptor [R] 
and a conformation [R*] capable of activating a cognate G protein may vary 
between different receptors and can be modulated by mutation [Samama et al. , 
1993; Lefkowitz etal., 1993; Tiberi & Caron, 1994; Bond etal., 1995; Milligan et 
at., 1995; Mullaney 1996].
The current view is that agonist ligands function because they display 
preferential affinity for [R*], act to selectively stabilize this form of the receptor and
thus move the equilibrium between [R]<----->[R*] to the right [Samama et al. ,
1993; Lefkowitz etal., 1993; Tiberi & Caron, 1994; Bond etal., 1995; Milligan et 
al., 1995]. Ligands which display preferential affinity for [R] will move the 
equilibrium in the other direction, will reduce agonist-independent activity and, on 
this basis, have been termed “inverse agonists” as described in section 1.2.4.3 
[Costa & Herz, 1989; Samana gW/., 1993; Lefkowitz etal., 1993; Tiberi & Caron,
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5.2.1. Cells transfected to express the wild type or CAMaiB-
adrenergic receptor express only the anticipated form of the 
receptor.
1994; Leeb-Lundberg etal., 1994; Adie & Milligan, 1994; Chidiac etal., 1994; 
Samamae/ût/., 1994; Bond etal., 1995; Milligan etal., 1995; Mullaney etal., 
1996].
If CAM variants provide useful models for an [R*] state of a receptor it
'must be predicted that as long as such mutations have the inherent capacity to relax 
to the [R] conformation then they will potentially provide useful models for 
detection of inverse agonists and a means to explore their mechanisms of action. In 
the second half of this study the regulation of the CAMaie-adrenergic receptor by 
the a-adrenergic receptor inverse agonist phentolamine is assessed whether this 
CAM receptor provides a useful screening system for inverse agonists.
5.2. Results.
RNA was isolated from clones of Rat-1 fibroblasts stably transfected with 
cDNA species encoding either the wild type hamster aiB-adrenergic receptor or an 
altered form of this receptor (CAMa le-adrenergic receptor [Cotecchia et al., 1990,
Kjelsberg etal., 1993, Allen etal., 1991]) in which a fragment of the distal end of 
the third intracellular loop was replaced with the equivalent segment of the human
P2-adrenergic receptor. The RNA samples were subjected to reverse transcription 
(RT) followed by polymerase chain reaction (PCR) using a primer pair designed to 
straddle the region altered to generate the CAMaie-adrenergic receptor as described 
in section 2.29 and Table 2.3. Such RT-PCR resulted in the anticipated I'
generation of a fragment of 597bp from both cell lines as shown in Figure 5.2.
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transfected cells reflects the modified receptor.
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The alteration in sequence to produce the CAMaiB-adrenergic receptor
introduces a specific site for the restriction enzyme Stu~l which should cleave the 
PCR product virtually in the centre to generate fragments of 292 and 305 bp. 
Treatment of the PCR product from the clone transfected with the CAMaiB- 
adrenergic receptor cDNA resulted in all of the fragment being digested whereas 
equivalent treatment with the PCR fragment derived from the cells transfected with 
the wild type aiB-adrenergic receptor cDNA had no effect as shown in Figure
5.2 . These results confirmed the identity of the expressed receptors and indicated 
that the entire cellular population of the CAMaiB-adrenergic receptor cDNA
5.2.2. The wild type receptor is expressed at higher levels than the 
CAMaiB adrenergic receptor.
‘Inositol phosphate generation in the absence of added agonist, measured 
using a Li+ blockade accumulation assay, was some 2 fold higher in cells of the 
clone expressing the CAMa ip-adrenergic receptor compared to the wild type 
receptor when the results were modified to account for the level of ineorporation of 
pH]inositol into cellular phospholipids and around 3-4 fold higher when the 
generation of pH]inositol phosphates was not corrected in this manner (data not 
shown but see Figure 5.5) as has previously been recorded [Cotecchia et al. ,
1995]. This was despite ligand binding studies, using the specific binding of the 
a i-adrenoceptor antagonist pH]prazosin as described in Section 2.12, which 
demonstrated that the CAMa ip-adrenergic receptor was expressed at lower levels 
than the wild type receptor as shown in Figure 5.3.
5.2.3. Antagonists bind the wild type and CAMaiB adrenergic
receptor with similar affinity but agonists show substantially 
higher affinity for the CAM receptor.
The estimated affinity for pH]prazosin binding as described in Section  
2 . 1 2 . 2  to the wild type and the CAMaiB-adrenergic receptor were very similar 
(Kd= 8 . 6  ± 1.5 X 10-11 M at wild type and 9.6 ± 1.9 x 10-H M at the CAM 
receptor, mean ± S.E.M. n = 3 in each case). Competition for the binding of 
pH]prazosin by the a i  antagonist phentolamine to the wild type (Ki = 2 .1± 0 .1  x 
10"® M) and the CAM (Ki = 1.1 ±0 . 1  x lO'^M) aiB-adrenergic receptor was %
achieved with similar affinities as shown in Figure 5.4a, but the potencies of the 
agonists phenylephrine and noradrenaline to compete for the binding of 
pH]prazosin were approximately 160 fold higher at the CAMaiB-adrenergic 
receptor (IC50 (corrected for radioligand occupancy) for noradrenaline = 5.3 ± 0 .2  
X 10“^  M, for phenylephrine = 2.4 ± 0.2 x 10-8 M) than at the wild type receptor 
(IC50 (corrected for radioligand occupancy) for noradrenaline = 9.3 ± 0.5 x 10-7 
M, for phenylephrine = 4.6 ± 0.3 x 10-  ^M) (means ± S.E.M., n= 3 in all cases) as 
shown in Figure 5.4b.
5.2.4. Phenylephrine, but not endothelin 1, stimulates inositol
phosphate generation to both greater levels and more potently 
in cells expressing the CAMaiB-adrenergic receptor compared 
to the wild type receptor.
Stimulation of inositol phosphate generation from pH]inositol-labelled cells 
as described in Section 2.14 by the agonists noradrenaline (EC50S = 5.3 ± 0.6 x 
10"  ^M compared to 7.7 ± 0.6 x 10-7 M) and phenylephrine (EC50S = 5.1 ± 0.4 x
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10'^ M compared to 5.9 ±0.1 x 10-7 M) (means ± S.E.M. n = 3) was also greater 
than 100 fold more potent in cells of the clone expressing the CAMaiB-adrenergic 
receptor than in those expressing the wild type receptor as shown in Figure 5.5a 
and 5.5b. Furthermore, the maximal ability of phenylephrine to stimulate inositol 
phosphate production was substantially greater ( 170±20 %, mean±S.E.M., n=3) at 
the CAMa %B-adrenergic receptor as shown in Figure 5.5a
These effects could be clearly attributed to the specific forms of the aiB~ 
adrenergic receptor expressed and not simply to some trivial example of clonal 
variation as inositol phosphate generation in response to endothelin 1, acting at the 
endogenously expressed ETa endothelin receptor, was similar both in maximal 
effect (in the CAMa ig-adrenergic receptor expressing cells endothelin 1 produced 
108.6±5.8% of the inositol phosphate response observed in the cells expressing the 
wild type receptor) and in the potency of the ligand (EC50 = 4.8±2. 1 x IQ-^M at the 
CAMaiB-adrenergic receptor and 3.0±1.2 x IQ-^M at the wild type receptor.
mean±S.E.M., n=3 in each case) as shown in Figure 5.5c.
5.2.5. Phenylephrine stimulates phosphatidylbutanol generation to 
both greater levels and more potently in cells expressing the 
CAMaiB-adrenergic receptor compared to the wild type 
receptor.
I
Stimulation of phosphatidylbutanol generation from pHJpalmitate-labelled 
cells as described in Section 2 .15  by the agonist phenylephrine was 
approximately 30 fold more potent in cells of the clone expressing the CAMaiB- 
adrenergic receptor than in those expressing the wild type receptor as shown in 
Figure 5.6. EC50S were 3.2 x 1Q-7M for wild type and 9.7 x IQ-^M for the CAM 
receptor, respectively (means ± S.E.M., n=3). Furthermore, the maximal ability of
:
f c r
141
■Î
' t
__
phenylephrine to stimulate phosphatidylbutanol production was about 2 fold 
greater at the CAMa iB-adrenergic receptor as shown in Figure 5.6.
5.2.6. Membrane levels of Gqa and Gj %a are reduced by
phenylephrine treatment of both wild type and CAM aig- 
adrenergic receptor expressing cells but the effect is greater in 
the CAM receptor expressing cells.
Sustained exposure of the two clones to a concentration of phenylephrine 
(lOO/^M) which resulted in maximal generation of pH]inositol phosphates in both 
cell lines resulted in a reduction in cellular levels of some combination of the a 
subunits of the phosphoinositidase C-linked, pertussis toxin-insensitive, G proteins 
Gqand G n when immunoblotting experiments were performed using SDS-PAGE 
(10% (w/v) acrylamide) conditions which are unable to resolve these two 
polypeptides and with an antiserum (CQ) which identifies a common epitope shared 
at the extreme C-terminus of these two polypeptides (36±5% for the wild type and 
72±8% reduction for the CAM receptor, repectiveiy).
Resolution of these two G protein a subunits by SDS-PAGE (10% (w/v) 
acrylamide) which incorporated 6M urea into the resolving gel as described in 
Section 2.6 indicated that cellular steady-state levels of G n a  were higher than 
Gcfi but that very similar levels of each of these G proteins were present in 
membranes of untreated wild type receptor and CAMais-adrenoceptor expressing 
cells as shown in Figure 5.7. Phenylephrine treatment resulted in a 
downregulation of both of these polypeptides in cells expressing both wild type and 
the CAMaiB-adrenoceptor as shown in Figure 5.7. Importantly, however, the 
maximal degree of Gqa and G ^ a  downregulation which could be achieved in
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response to phenylephrine treatment was substantially greater in the clone 
expressing the CAMaiB-adrenoœptor.
5.2.7. More pronounced down-regulation of G q a /G n a  is produced 
by the CAM than the wild type aiB-adrenergic receptor by ail 
concentrations of phenylephrine.
Sustained exposure of the wild type and the CAMa iB-adrenoceptor
■fexpressing cells to varying concentrations of phenylephrine indicated that the 
enhanced capacity to cause downregulation of these two G proteins was observed 
at all concentrations of the agonist by immunoblotting as described in Section 2.8 
and as shown in Figure 5.8a. However, in contrast to the differences in affinity 
of phenylephrine at the wild type and CAMa ig-adrenoceptor measured in binding 
assays and for inositol phosphate generation, the potency of phenylephrine to cause 
downregulation of Gq^Gn was only slightly greater in cells expressing the 
CAMaiB-adrenoceptor (1.5+1.1 x 10-^M) than in those expressing the wild type 
a  iB-adrenoceptor (6.5±1.8 x 10‘^ M)(mean±S,E.M, n=3 in each case) as shown in 
Figure 5.8b.
5.2.8. Phenylephrine treatment of both wild type and CAMaiB- 
adrenergic receptor expressing cells accelerates the rate of 
degradation of G qa/G na.
Wild type and CAMqib-adrenergic receptor expressing cells were labelled 
with Transp5s]label and immunoprecipitated as described in Section 2.2.7.  
Little difference in the turnover of G qa/G na could be observed between the wild 
type and CAMaiB-adrenergic receptor expressing cells in the absence of agonist J
exposure to a j  antagonists
5.2.10. Time-dependent upregulation of the CAMaiB-adrenergic 
receptor following exposure to phentolamine
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ligand as shown in Figure 5.10. Half-lives for these G proteins, as assessed in 
p5S]amino acid pulse-chase experiments were adequately described by 
monoexponential function, being between 33-36 hours in individual experiments.
'As anticipated from previous studies [Chapter 4], the rate of degradation 
of Gq^Giia in the cells expressing the wild type aiB-adrenergic receptor was 
accelerated by the presence of 100/<M phenylephrine (estimated t 0.5 = 21.1 ± 2.7 
h) as shown in Figure 5.9a. A similar effect of phenylephrine was observed in 
the cells expressing the CAMaiB-adrenoceptor, except that the rate of degradation 
(t 0.5 = 14.1 ± 1.6 h)(means±S,E.M., n=3 in each case) as shown in Figure 
5.9b was somewhat more pronounced than in the wild type expressing cells.
i!
5.2.9. Upregulation of the CAMaxB-adrenergic receptor following
Sustained (24h) treatment of CAMaiB-adrenergic receptor expressing cells 
with a i  antagonists resulted in upregulation of CAMaiB-adrenergic receptor 
levels, but not in wild-type a  ib-adrenergic receptor expressing cells as shown in 
Figure 5.10a. Phentolamine, HV-723, and WB 4101 were able to increase the 
receptor levels approximately 3 fold. Furthermore, this upregulation of CAMaiB- 
adrenergic receptor levels was also observed in response to YM12617, 
corynanthine, and 5-methyl urapidil with approximately 2 fold over vehicle 
(control) as shown in Figure 5.10b.
-------
As phentolamine produced a large upregulation of the CAMaiB-adrenergic 
receptor levels, this effect was examined over a range of time courses. The bulk of 
upregulation of the CAMaiB-adrenergic receptor was produced in response to the 
presence of phentolamine in around 36h as shown in Figure 5.11.
5.2.11. Phentolamine produces an upregulation of the CAMaiB- 
adrenergic receptor as measured by Scatchard analysis of 
[^H]prazosin binding.
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In order to confirm that the enhanced binding of a single concentration of 
pH]prazosin in membranes of phentolamine-treated cells expressing CAMu ib -
'adrenergic receptor represented a true upregulation Scatchard analyses were 
conducted. As shown in Figure 5 .12  saturation analysis of pHJprazosin binding 
demonstrated the total number of receptor sites to be increased greatly following 
phentolamine treatment (about 3 fold) whereas the affinity for pH] prazosin for the 
CAMaiB-adrenergic receptor was similar following treatment with or without 
phentolamine.
5.2.12. Phentolamine treatment of the CAMaiB-adrenergic receptor 
expressing cells increases agonist-stimulated phospho- 
inositidase C and phospholipase D activity
I investigated whether the large increase in CAMaiB-adrenergic receptor 
levels in response to phentolamine (24h) could cause increase in the basal and 
maximal level of phosphoinositidase C (PIC) as well as phospholipase D (PLD) 
activity, but not in cells expressing wild-type a  iB-adrenergic receptor. As shown in 
Figure 5.13a the maximal level of phosphoinositidase C activity which could be
i
achieved by these cells with a maximally effective concentration of phenylephrine 
was increased 2-3 fold in CAMaiB-adrenergic receptor expressing cells treated 
with phentolamine for 24h.
An approximately 2 fold increase in basal phosphoinisitidase C activity was 
observed in these cells with phentolamine treatment. Despite the increase in 
CAMaiB-adrenergic receptor levels in these cells in response to phentolamine the 
EC50 for phenylephrine was not changed. The same was also true when the 
maximal and basal levels of phospholipase D activity were measured in 
phentolamine pretreated cells expressing the CAMaiB-adrenergic receptor. The 
EC50 for phenylephrine in the treated cells was again similar in the phentolamine 
untreated cells as shown in Figure 5.13b,
5.2.13. a i  antagonists lower phentolamine-upregulated basal 
phospholipase D acivity in cells expressing CAMaiB- 
adrenergic receptor
As phentolamine produced an upregulation of the CAMaiB-adrenergic 
receptor and increased basal phospholipase D activity this system could provide a 
model to detect a i  adrenergic receptor inverse agonists. Phentolamine, HV-723, 
YM-12617, corynanthine, 5-methyl urapidil, and WB-4101 were clearly capable of 
acting as inverse agonists at this CAMaiB-adrenergic receptor as measured by their 
ability to inhibit basal phospholipase D activity. As shown in Figure 5.14 
phentolamine, HV-723, corynanthine, and WB 4101 greatly decreased 
(approximately 80%) the phentolamine-upregulated PLD basal activity. Meanwhile 
YM12617 and 5-methyl urapidil reduced this to a lesser degree (51% and 38% over 
control, respectively).
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5.3. Discussion
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Modifications of GPCRs which result in the receptors displaying agonist- 
independent second messenger regulatory capacity have been observed both by
■designed mutation in the laboratory [Samama fl/., 1993, Pei et aL, 1994,
Cotecchia et aL, 1990, Kjelsberg et aL, 1993, Allen et aL, 1991] and in 
spontaneous mutations [Shenker a/., 1993, Parma a/., 1993, Raymond, J.R.,
1994, Coughlin, S.R., 1994] within the human population. GPCRs of this form 
have been termed constitutively active mutant (CAM) receptors and much recent 
interest has centred on to what degree these provide useful models, at least in 
certain aspects, of the conformational changes which must occur upon agonist 
binding to wild type receptors to allow efficient transmission of a signal via 
activation of heterotrimeric G proteins [Lefkowitz etal., 1993].
Evidence, derived initially from observations that varying degrees of 
overexpression of wild type GPCRs resulted in an increase in basal activity ( i.e. in
the absence of agonist ) of the effector system coupled to that receptor and that there 
was a strong correlation between the level of expression of the GPCR and the 
amount of effector regulation [Milano etaL, 1994, Adie & Milligan, 1994, Chidiac 
etaL, 1994], has indicated that adrenergic GPCRs must have the capacity to exist 
and spontaneously interconvert between a minimum of two (and possibly a 
continuum of) states, an inactive ground-state conformation R and an active 
conformationR* [Milanogtd!., 1994, Samama^ra/., 1994, Milligan a/., 1995, 
GeXh&r etal., 1995].
In efforts to define elements of a i  adrenergic receptors responsible for 
activation of pertussis toxin-insensitive G proteins, Cotecchia and co-workers 
generated a series of receptor chimaeras in which different elements of the third 
intracellular loop of the hamster aiB-adrenergic receptor were replaced by
: rI
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equivalent sequences from the human P2-adrenergic receptor [Cotecchia et aL , 
1990, Kjelsberg etal., 1993, Allen etal., 1991]. One of these chimaeras which 
was derived by replacement of the region 288-294 of the aiB-adrenergic receptor 
with the corresponding sequence of the Pg-adrenoceptor causes a triple mutation 
(Ala293Leu, Lys290His, Arg288Lys) as shown in Figure 5,1 and results in the 
expressed receptor displaying constitutive activation of inositol phosphate 
generation and a capacity to act as a protooncogene as measured by an ability to 
induce focus formation in fibroblasts transfected with this construct [Allen et d ., 
1991].
This is the CAMaiB-adrenergic receptor used in the present study. 
Although the CAMaiB-adrenergic receptor was inherently able to produce this 
effect, addition of agonist potentiated this effect greatly, indicating that this form of 
the receptor did not function in a fully agonist-independent manner [Allen et al., 
1991]. Similarly, although the degree of agonist-independent inositol phosphate 
generation produced by the CAMaiB-adrenergic receptor is markedly greater than 
by the wild type receptor, the CAM receptor still produces a further robust 
stimulation upon addition of agonist [Cotecchia etal., 1995].
In Chapter 4 1 showed that sustained agonist treatment of Rat 1 fibroblasts 
transfected to express high levels of each of the wild type aiA/D, «IB and « ic -  
adrenergic receptors results in a substantial downregulation of the 
phosphoinositidase C-linked Gqa and G n a  and in this chapter I explored whether 
the CAM-mutant of the aiB-adrenergic receptor has the capacity to act more 
effectively in this regard than the wild type receptor. This is clearly the case as 
shown in Figures 5.7 and 5.8 . Addition of 100//M phenylephrine produced a 
markedly greater degree of G protein downregulation in the cells expressing the 
CAMaIB-adrenergic receptor than in those expressing the wild type receptor 
(Figure 5.7). I
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This was despite the fact that the CAMais-adrenergic receptor was 
expressed at somewhat lower steady-state levels than the wild type receptor 
(Figure 5.3). Particular attention was paid to this point by routinely performing 
pH]prazosin binding studies on membranes isolated from the control cells in such 
experiments (i.e. minus agonist or zero time points) to confirm the levels of 
expression in specific experiments. As shown for the wild type aiB-adrenergic 
receptor in Chapter 4, downregulation of Gqot and G n a  by phenylephrine 
occupancy of the CAMaiB-adrenergic receptor appeared to be relatively non- 
selective for these two G proteins, indicating equivalent interactions of these with 
the activated receptor [Milligan, 1993],
Although the CAMaiB-adrenergic receptor did result in higher level 
generation of inositol phosphates in the absence of agonist than the wild type 
receptor, this was also true in response to maximally effective concentrations of 
agonist (Figure 5.5), confirming the data of Cotecchia e? a/. [1995]. Indeed, the
:basal inositol phosphate generation from both receptor variants was only a fraction 
of that produced in response to agonist. Inositol phosphate generation in response I
to maximally effective concentrations of phenylephrine or noradrenaline was 
approximately two-fold higher in the CAMaiB-adrenergic receptor expressing cells 
than in those expressing the wild type receptor. The same was also true when 
phosphatidylbutanol generation by phospholipase D was measured (Figure 5.6). 
By contrast, there was little difference in the maximal ability of endothelin-1 to 
stimulate inositol phosphate generation in the two cell lines. These data indicate that 
it is an inherent property of the CAMaiB-adrenergic receptor, rather than some 
undefined element of clonal cell line variation, which was responsible for the 
greater response to a i  agonists.
There was certainly no higher steady-state levels of Gqa or G n a  in the 
CAMaiB-adrenergic receptor expressing cells (Figure 5.7) and thus it seems
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likely that the CAMa iB-adrenergic receptor is able to activate these G proteins with 
higher stoichiometry than the wild type receptor. As it has been previously recorded 
that the sustained presence of agonist is required to cause downregulation of Gqand 
G ii via the wild type aiB-adrenergic receptor (and indeed for other 
phosphoinositidase C-coupied receptors [Mitchell et fit/., 1993, Shah et al., 1995, 
van de Westerlo etal., 1995]) and because activating mutants of G proteins have 
shorter half-lives than their native counterparts [Levis & Bourne, 1992] for 
example), then an enhanced G protein activation stoichiometry would be fully 
consistent with the observed greater degree of downregulation of these G proteins 
by agonist occupation of the CAMaiB-adrenergic receptor.
Although the EC50 for agonist stimulation of inositol phosphate generation 
was greater than 100 fold lower at the CAMa iB-adrenoceptor compared to the wild 
type receptor, this was not true when agonist-mediated G qa/G na downregulation 
was measured. In this assay the difference in measured EC50  was only 
approximately 4-5 fold. I do not have a ready explanation for these differences but 
it should be remembered that agonist-occupation of the wild type receptor resulted 
in a relatively small % downregulation of the G proteins making quantitation of the 
EC50 value substantially more difficult to quantitate reliably than in the other end 
points measured.
I also examined whether the expression of the CAMa iB-adrenergic receptor 
would result in an agonist-independent downregulation of these G proteins.
Although this is impossible to assess fairly in different clones of cells, I did not 
detect substantially lower steady-state levels of Gqa and G n a  in the CAMaip- 
adrenergic receptor expressing cells. However, given the difficulties of accurately 
measuring small alterations by the use of relative intensity immunoblotting and, as 
noted above, the still relatively small degree of phosphoinositidase C (and thus G 
protein) activation produced by the CAMaiB-adrenergic receptor in the absence of
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agonist compared to that achieved in the presence of agonist, it is perhaps to be 
anticipated that very small (and perhaps technically undetectable) alterations are the 
most which could be expected in the absence of agonist.
Further support for the contention that the CAM form of the a  iB-adrenergic 
receptor provides only limited signalling capacity in the absence of agonist was 
derived from examining the rate of turnover of Gqa/Guct in the cells. Analysis of 
immunoprecipitated Gqct/G11a  following pulse labelling with Trans p-^S] label and 
a chase performed in the absence of phenylephrine indicated the half-life of these 
proteins, which was between 33 and 37h, to be very similar in the two cell lines. 
No differences could be detected between cells harbouring the wild type or the 
CAMaiB-adrenergic receptor. This value is also very similar to data for the half life 
of Gqo/Giia on a completely independent series of clones derived from Rat 1 
fibroblasts in Chapter 4.
Addition of a maximally effective concentration of phenylephrine during the 
chase phase of the experiments resulted in an acceleration in the rate of degradation 
of Gqo/Giia in cells expressing both the wild type and the CAMaiB-adrenergic 
receptor. The acceleration in the rate of degradation of these G proteins due to 
agonist occupancy of the wild type a  iB-adrenergic receptor in this study (measured 
mean half-life in the presence of phenylephrine was approximately 2 1 h) was not as 
great as noted previously and this is entirely consistent with the degree of 
downregulation of the G proteins produced by the receptor being less than that 
observed in chapter 4.
The acceleration in the rate of degradation of G qa/G na was more
pronounced with agonist occupancy of the CAMa iB-adrenergic receptor (measured
half-life in the presence of 100/<M phenylephrine was approximately 14h) and this 
may be primarily responsible for the greater degree of G qa/G na downregulation
produced by agonist treatment of the CAMaiB-adrenergic receptor expressing
i_
cells. However, it must be stated that this difference seems too limited to account, 
in isolation, for the very marked differences in G protein regulation observed.
The data provided herein confirms previous reports that this CAMaiB- 
adrenergic receptor displays a degree of agonist-independent signalling capacity 
which is greater than the wild type receptor. However, the CAM receptor is far 
from being fully agonist-independent and indeed is able to cause greater maximal 
output from the G fp/G na to phosphoinositidase C pathway as well as 
phospholipase D pathway than equivalent levels of the wild type «iB-adrenergic 
receptor upon addition of agonist.
As steady-state basal levels of Gqa and G n a  are not appreciably different 
in the cell lines expressing the two forms of the receptor and the phosphoinositidase 
C response of the endogenously expressed endothelin ET a  receptor is also not 
different in the wild type vs CAMaiB-adrenergic receptor expressing cells then the 
differences in signalling effectiveness of the two receptor variants are not due to 
trivial differences in the individual cell lines. It has been previously established that, 
for a range of wild type receptors expressed in various cellular backgrounds, 
agonist-dependent G protein downregulation is limited to the G proteins activated 
by a receptor [Mitchell etal, 1993, Shah etal., 1995, Mullaney et al., 1995, Adie 
& Milligan, 1994].
Furthermore, it reflects a measure of sustained activation of the G protein 
pool. The extent of the effect must be dependent upon the fraction of the 
appropriate G protein pool which is activated by the receptor because high level 
receptor expression is substantially more effective at producing G protein 
downregulation than low level expression [Mullaney etal., 1995, Adie & Milligan, 
1994], even in situations in which the lower level of receptor is capable of causing 
maximal activation of second messenger generation due to the effector enzyme 
being the limiting component for the output of the signalling cascade [Adie &
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Milligan, 1994, MacEwan etd ., 1995]. The key difference in the present study is 
thus likely to reflect a greater stoichiometry of activation of the G proteins by the 
CAM version of the aiB-adrenergic receptor compared to the wild type receptor.
Meanwhile, there has been considerable recent attention given to the concept 
that inverse agonist ligands may be useful therapeutic agents in a range of clinical 
conditions [Lefkowitzeta/., 1993; Hieble & Bond, 1994; Milano etal., 1994 &
1995; Bond etal., 1995; Milligan eta l, 1995; Bond & Lefkowitz, 1995]. As such, 
simple means to detect compounds with this characteristic would be extremely 
useful. The concept that CAM variants of G protein coupled receptors represent at 
least a partial model of the activated [R*] state of a receptor suggests that they might 
provide the baisis of such a system as they are able to produce greater activation of 
G proteins in a partly agonist-independent manner.
In this study this question has been assessed for the a i  adrenergic inverse 
agonist phentolamine using clones of Rat 1 fibroblast cells transfected to express 
either the hamster wild-type or CAMaiB-adrenergic receptor. The sustained 
presence of phentolamine in the medium surrounding the CAMa ip-adrenergic
: ■receptor expressing cells was able to cause a dramatic upregulation of levels of this 
receptor as assessed in pH]prazosin saturation binding analyses (Figure 5.12).
An increase in levels of the CAMaiB-adrenergic receptor was also observed 
following sustained treatment of cells with HV-723, WB 4101, YM12617, 
corynanthine, and 5-methyl urapidil (approximately two fold over control) (Figure 
5.10).
Interestingly, phentolamine-mediated upregulation of the CAMaiB- 
adrenergic receptor levels was accompanied by a substantial increase in the maximal
phosphoinositidase C activity in response to phenylephrine with a similar potency 
(Figure 5.13). This phenomenon was also observed in phospholipase D activity 
measurement in response to phenylephrine. Unlike other effector enzymes, e.g.
adenylyl cyclase, this may reflect phosphoinositidase C and phospholipase D are 
not the quantitatively limiting protein component of these signalling cascades. This 
provides a useful system to overcome low basal enzyme activity for the selection of 
inverse agonists.
As it was expected that the increase in the CAMajB-adrenergic receptor 
levels in response to phentolamine could cause an increase in the basal level of 
phospholipase D activity, this system was used for screening inverse agonists of 
the receptor. All of the tested a i  antagonists appeared to be clearly capable of acting 
as inverse agonists at this CAMaiB-adrenergic receptor as measured by their ability 
to inhibit phentolamine-stimulated basal phospholipase D activity (Figure 5 .14).
This study provides a basis to suggest that upregulation of CAM G-protein 
coupled receptors may provide a useful and technically simple approach for the 
screening and detection of novel inverse agonist ligands.
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Figure 5.1. Structural model of the constitutively active mutant
(CAM) a iB  adrenergic receptor
Substitution of residues at the carboxyl terminus of the third intracellular 
loop of the a  IB adrenergic receptor appears to render the receptor constitutively 
active, resulting in the stimulation of phosphatidylinositol hydrolysis in the 
absence of agonist-induced receptor activation. The enlarged region illustrates 
the carboxyl terminus of the third intracellular loop and the sixth transmembrane 
domain. Solid circles indicate the amino acids of the wild type aiB adrenergic 
receptor that were mutated; the amino acid residues replaced in the aiB 
adrenergic receptor mutant are shown to the right (Arg288Lys, Lys290His, and 
Ala293Leu).
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Figure 5.1
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Figure 5.2. Cells transfected to express the wild type or CAM 
aiB-adrenergic receptor express only the anticipated form  
of the receptor.
RNA isolated from wild type (lanes 2-3) and CAM (lanes 4-6) a ig - 
adrenergic receptor transfected cells was reverse transcribed and polymerase 
chain reaction then performed with primers (which straddle the region of 
difference between the two forms of the receptor) designed to amplify a 597 bp 
fragment as described in section 2.29. Samples were then treated (lanes 3, 5- 
6 ) or not (lanes 2,4 ) with the restriction enzyme Stu-\. Product derived from the 
CAM form of the receptor is cleaved to yield fragments of 305 and 292bp (lanes 
5-6) whereas that derived from the wild type receptor is resistant to the enzyme 
(lane 3). Lanes 1 and 7 contain molecular size markers.
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Figure 5.3. The wild type receptor is expressed at higher levels
than the C A M a iB -a d ren erg ic  recep to r .
Membranes prepared from cells expressing either the wild type a ie  
adrenergic receptor (squares) or the CAMa ig-adrenergic receptor (circles) were 
analysed for their ability to bind a range of concentrations of pHJprazosin in a 
specific manner as descibed in section 2.3 and  2.12.2. In the experiment 
displayed, the two forms of the receptor bound the pHJligand with very similar 
affinity (Kd = lOOpM) but the levels of expression of the wild type receptor (2.8 
pmol/mg membrane protein ) was greater than that of the CAM receptor (1.7 
pmol/mg membrane protein). Similar results were obtained in two further 
experiments.
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Figure 5.4. Antagonists bind the wild type and C A M ajs- 
adrenergic receptor with similar affinity but agonists 
show substantially higher affinity for the CAM receptor.
The specific binding of pHJprazosin (0.88nM) to membranes of cells 
expressing the wild type (open symbols) or the CAM (closed symbols) aiB 
adrenergic receptor competed for by the antagonist phentolamine (Figure 
5.4a) or (Figure 5.4b) by the agonists phenylephrine (circles) and 
norepinephrine (squares) as described in section 2 . 1 2 .2 .
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Figure 5.5. Phenylephrine, but not endothelin 1, stimulates
inositol phosphate generation to both greater levels and 
more potently in cells expressing the CAMaiB-adrenergic 
receptor compared to the wild type receptor.
Cells expressing the wild type (open symbols) and the CAM (closed 
symbols) aiB-adrenergic receptor were labelled with [^HJinositol and stimulated 
with either varying concentrations of phenylephrine (Figure 5.5a and 5.5b) 
or endothelin 1 (Figure 5.5c). The generation of pHJinositol phosphates was 
then measured as described in section 2.14.
In the experiment shown in Figures 5 .5a  and 5 .5b  the EC50 and Hill 
coefficient for phenylephrine stimulation of inositol phosphate production in the 
CAMa IB adrenergic receptor expressing cells were 1 .6  x 10"%4 and 0.55 and in 
the wild type receptor expressing cells they were 2.4 x lO'^^M and 0.65.
In Figure 5.5b the data for phenylephrine in Figure 5.5a is 
presented as % of maximal effect achieved. Similar results were obtained in two 
further experiments.
In Figure 5.5c, the EC50 and Hill coefficient for endothelin 1 
stimulation of inositol phosphate generation were 3.4 x lO'^M and 0.8 for the 
wild type a  IB adrenergic receptor expressing cells and 2.4 x lO'^M and 1.1 in 
the CAM a  IB adrenergic receptor expressing cells. Similar results were obtained 
in two further experiments using each agonist.
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Figure 5.6. Phenylephrine stimulates phosphatidylbutanol 
generation to both greater levels and more potently in 
cells expressing the CAMaiB-adrenergic receptor compared 
to the wild type receptor.
Cells expressing the wild type (open symbols) and the CAM (closed 
symbols) aiB-adrenergic receptor were labelled with pHJpalmitate and 
stimulated with varying concentrations of phenylephrine. The generation of 
pHjphosphatidylbutanol was then measured as described in section 2.15.
In the experiment shown in Figures 5 .6a  and 5 .6b  the EC50 and Hill 
coefficient for phenylephrine stimulation of phosphatidylbutanol production in 
the CAMa IB adrenergic receptor expressing cells were 9.7 x lO'^M and 0.84 
and in the wild type receptor expressing cells they were 3.2 x 10~'^M and 0.67.
In Figure 5.6b the data for phenylephrine in Figure 5.6a is 
presented as % of maximal effect achieved.
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Figure 5.7. Membrane levels of Gqa and Gi la  are reduced by 
phenylephrine treatment of both wild type and C A M aie- 
adrenergic receptor expressing cells but the effect is 
greater in the CAM receptor expressing cells.
Membranes were isolated from both wild type (lanes 1-2) and CAM 
(lanes 3-4)-aiB-adrenergic receptor expressing cells following treatment with 
either vehicle (lanes 1,3) or phenylephrine (100/<M) (lanes 2,4) for 16h. The 
samples were then resolved by SDS-PAGE under conditions which can resolve 
Gqa from G n a  as described in Section 2.8 and the presence of these 
polypeptides detected with antiserum CQ as indicated in Table 2.1 which 
identifies the C-terminal decapeptide which is completely conserved in these two 
G proteins. Similar results were obtained, on three separate sets of membrane 
preparations.
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Figure 5.8. More pronounced downregulation of Gqa/Gnais 
produced by the CAM than the wild type aiB-adrenergic 
receptor by all concentrations of phenylephrine.
Figure 5.8a shows a G qa/G na immunoblot. Cells expressing either 
the wild type (odd numbered lanes) or the CAM (even numbered lanes) aiB- 
adrenergic receptor were exposed to varying concentrations (lanes 1&2: 
untreated, lanes 3&4: lO’^M, lanes 5&6: lO'^M, lanes 7&8: lanes
8&10: 10"^M, lanes 11&12: 10"^M, lanes 13&14: lO'^M) of phenylephrine for 
16h. Membranes were prepared as described in Section 2.3, resolved by SDS- 
PAGE under conditions which do not resolve Gqa from G n a  and immuno- 
blotted to detect the combined total levels of these two G proteins as described in 
Section 2.8. Such immunoblots were scanned and displayed in Figure 5. 8b. 
The data presented as mean ± S.E.M., n=3, derived from three independent 
experiments on separate membrane preparations. M represents for the standard 
molecular size markers.
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Figure 5.9. Phenylephrine treatment of both wild type and 
CAMaiB-adrenergic receptor expressing cells accelerates 
the rate of degradation of G qa/G na.
Wild type (a) (squares) and CAM (b) (circles) aip-adrenergic receptor 
expressing cells were labelled with Transp^S]label as described in Section 
2 .2 .7 . The radiolabel was removed and the cells maintained in the presence 
(filled symbols) or absence (open symbols) of 100/<M phenylephrine for 
vai'ying periods of time. Samples were taken and Gqa and G n a  
immunoprecipitated with antiserum CQ. The immunoprecipitates were resolved 
by SDS-PAGE under conditions which do not resolve the two G proteins and 
subsequently exposed to a phosphoimager plate for 12h. The radiolabel 
remaining in G ^ /G n a  was then quantitated as described in section 2 .9 . Data 
are represented as best fit to a monoexponential function from one of the three 
independent experiments performed.
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Figure 5.10. Upregulation of the CAMaiB-adrenergic receptor
following exposure to a i  antagonists
Cells expressing either the wild type (Figure 5.10a) or CAM (Figure 
5.10b) aiB-adrenergic receptor were exposed to vehicle (control) or lOpM of 
phentolamine, YM12617, HV-723, corynanthine, 5-methyl urapidil or WB 
4101 for 24h. Membranes were prepared as descibed in section 2,3 and the 
specific binding of pH]prazosin (InM) measured as described in section  
2 .1 2 .2 . Results are presented relative to the levels measured in the vehicle 
treated cells and represent the mean ± S.E.M. of triplicate determinations. The 
experiment shown is typical of two other independent experiments.
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Figure 5.11. Time-dependent upregulation of the CAMaiB- 
adrenergic receptor following exposure to phentolamine
Cells expressing CAMaiB-adrenergic receptor were treated for varying 
times with phentolamine (IpM). Membranes prepared from these cells were then 
assessed for levels of the CAMais-adrenergic receptor as measured by the 
specific binding of pH] prazosin. The results represent the mean ± S.E.M. of 
triplicate determinations. This is typical of three independent experiments which 
gave similar results.
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Figure 5.12. Scatehard analysis of the CAMaiB-adrenergic
receptor treated with or without phentolamine
Cells expressing CAMaiB-adrenergic receptor were incubated for 36h 
with (closed circles) or without (open squares) phentolamine (IpM) and then 
membranes prepared as descibed in section 2.3. Scatchard analyses were then 
performed with pH]prazosin as descibed in section 2.12.2. The results 
represent the mean of triplicate determinations. In this experiment the CAMaiB- 
adrenergic receptor levels were in control (1.7 pmol/mg membrane protein) and 
phentol ami ne- treated (6 .6  pmol/mg membrane protein), and the Kd values of the 
CAMaiB adrenergic receptor for pH] prazosin in control and phentol amine- 
treated preparations were estimated to be 118pM and 176pM, respectively. The 
experiment shown is typical of two other independent experiment.
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Figure 5.13. Phentolamine treatment of the CAMaiB-adrenergic 
receptor expressing cells increases agonist-stimulated 
phosphoinositidase C and phospholipase D activity
Cells expressing CAMaiB-adrenergic receptor were labelled with either 
pH]inositol or pHjpalmitate and incubated for 24h with (closed symbols) or 
without (open symbols) phentolamine ( 1 pM) and then stimulated with varying 
concentrations of phenylephrine. The generation of pH]inositol phosphates 
(Figure 5.13a) or pH] phosphatidyl butanol (Figure 5.13b) was then 
measured as described in section 2.13 and 2.14.
In the experiment shown in Figures 5.13a the EC50 for phenylephrine 
stimulation of inositol phosphate production in the vehicle were 1 .6  x 10‘^M and 
in the phentolamine (l^iM) treated cells they were 1.5 x 10"^M. In the 
experiment shown in Figures 5.13b the EC50 for phenylephrine stimulation 
of phosphatidylbutanol production in the vehicle were 1.9 x 10‘^M and in the 
phentolamine (IfiM) treated cells they were 1.1 x 10"^M. The results represent 
the mean ± S.E.M. of triplicate determinations.The experiment shown is typical 
of two independent experiments which gave similar results.
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Figure 5.14. a i  antagonists lower phentolamine-upregulated 
basal phospholipase D acivity in cells expressing CAM 
aiB-adrenergic receptor.
Upregulated (phentolamine-mediated) basal phospholipase D activity and 
its regulation by various « i  antagonists (phentolamine, HV-723, YM-12617, 
corynanthine, 5-methyl urapidil, and WB-4101) (IpM  each) are shown in cells 
expressing CAMaiB-adrenergic receptor. Cells were pretreated with IpM 
phentolamine for 24h and washed away four times with the assay buffer, and 
then the ability to inhibit pH]phosphatidylbutanol generation was measured as 
described in section 2 .15.
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Chapter 6. Final discussion
Chapter 6. Final discussion
When G protein-coupled receptors (GPCRs) are encountered by external stimuli 
including hormones, neurotransmitters, growth factors, light, and agonists they initiate 
their biological actions to activate or to inhibit the activity of specific effector systems via 
intermediary signal tranducers, guanine nucleotide binding protiens (G proteins).
Over one hundred receptors have been shown to be coupled to members of the G 
protein family to facilitate the activation of effectors and their activities are regulated by 
many well-known mechanisms including downregulation, internalisation, desensitisation, 
etc. The receptor is coupled to a GDP-liganded G protein in the resting state and the 
agonist activation of the receptor causes a conformational change in both proteins leading 
to the exchange of GDP for GTP which promotes dissociation of the G protein from its 
trimeric form into a free active a  and a Py complex. The GTP-bound a  subunit then 
interacts- with the final executor effector system before its intrinsic GTPase activity 
hydrolyses the GTP to GDP, promoting reformation of the holomeric protein which 
reassociates with the receptor [Gilman, 1984; Gilman, 1987].
Many variants of a , p, and y subunits of G proteins have been identified and the 
functional roles for individual G proteins have been revealed. GTP-binding a  subunits and 
the py subunit complex can influence the activity of effector systems including adenylyl 
cyclase, phosphoinositidase C, phospholipase A2, Phospholipase D, various ion channels 
and MAP Kinase activity independently or simultaneously, either synergistically or in 
opposition [Hepler & Gilman, 1992; Clapham & Neer, 1993; Stemweis, 1994; Inglese et 
d ., 1995].
Recently, with the advent of molecular cloning techniques, a number of 
molecularly distinct receptors were shown to result from differential splicing of pre-mRNA 
derived from a single gene. For example, in the cases of the splice variants of the EP3
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prostanoid receptor [Namba et a l , 1993] and the pituitary adenylyl cyclase-activating- 
polypeptide (PACAP) receptor [Spengler et a l, 1993], different second-messenger 
generation functions have been reported for the individual forms.
In chap ter 3 I have focused on analysis of potential functional differences of 
splice variants of the TRH receptor which are co-expressed in GH3 cells [de la Pena et a l, 
1992]. It has been shown that TRH receptors interact with pertussis toxin-insensitive G 
proteins of the Gq class to activate a phosphoinositidase C [Hsieh & Martin, 1992; Kim et 
al., 1994; Aragay etal, 1992]. In a number of reports, interactions of TRH receptors with 
other G proteins [Paulssen e ta l,  1992; Gollasch etal., 1993], most prominently Gg and 
Gi2 which are viewed traditionally as being responsible for stimulatory and inhibitory 
regulation of adenylyl cyclase, have been demonstrated.
I examined whether the signalling characteristics of the two isoforms differ 
following stable expression of each isoform in Rat 1 fibroblasts, to assess whether 
reported regulation of effector systems other than phosphoinositidase C might reflect 
activation of one isoform rather than another. The initial preconceptions were that this 
might be a property of the short isoform. After isolation of clones expressing specific 
pH]TRH-binding sites, it was determined that the clones expressed only the expected 
splice variant form of the receptor by RT-PCR based on the presence or absence of the 52- 
bp section which differs between the two isoforms.
Both receptor isoforms displayed similar binding affinity for pH]TRH, with an 
estimated Kd of approximately 80 nM in the presence of Gpp[NH]p. Attempts to measure 
the affinity of binding in the absence of Gpp[NH]p were restricted but the best estimates 
for the high affinity site were similar to the measured EC50 of 5-10 nM for TRH 
stimulation of inositol phosphate production observed for clones expressing both the long 
and short TRH-receptor splice variants, and suggest that it is the high-agonist-affinity state 
of the receptor which is able to interact with the cellular G protein population to produce 
effector regulation. This similarity of EC50 values for TRH-mediated stimulation of
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inositol phosphate production is in agreement with analysis of TRH regulation of Cl" flux 
in Xenopus oocytes after injection of cRNA species corresponding to the two isoforms [de 
la Pena etaL, 1992]. It should not be considered surprising that the two splice variants 
display very similar binding and activation affinities for TRH because Tyr-106 in the third 
transmembrane helix of the receptor has been shown to play a key role in the binding of 
TRH [Perlman etal., 1994] and the location of the splice variation site is in the C-terminal 
tail.
In contrast with the reported activation of adenylyl cyclase by TRH in GH cells 
[Paulssen et d ., 1992], no ability of the TRH receptor splice variants to alter adenylyl 
cyclase activity, either positively or negatively, in membranes of the TRH receptor 
expressing clones of Rat 1 cells was detected. This was not a reflection of a lack of 
expression of the relevant G proteins which were demonstrated to be expressed by these 
cells. It may of course be a reflection of the adenylyl cyclase isoform distribution in the 
individual cell lines, an area which remains essentially uncharted, but, it seems unlikely as 
all forms of hormonally regulated adenylyl cyclase are activated by Gg (Tang & Gilman,
1992].
Therefore, it was concluded that neither isoform of the rat TRH receptor displays 
appreciable ability to interact with either Gg or indeed with Gi2 , at least when expressed in 
this genetic background. As such the results this study can provide no evidence for either 
of the splice variants of the TRH receptor providing a locus for bifurcation of signalling 
infonnation, as has recently been described for a variety of receptors, including the TSH 
receptor [Allgeiere/a/., 1994, and for review Milligan G., 1993].
The ability of TRH to cause MAP kinase activation was studied in the clones, as 
recent reports have shown TRH to stimulate MAP kinase (ERK) activity in GH3 cells 
[Ohmichi et al., 1994]. I was unable to note a significant effect in clones of Rat 1 cells 
expressing either the long or short isoforms of the rat TRH receptor. The data produced 
herein demonstrate no obvious functional differences for the long and the short isoforms of
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the rat TRH receptor, at least when expressed in Rat 1 fibroblasts, and further demonstrate 
a high selectivity of coupling of both of these isoforms to Gq/Gn stimulation of 
phosphoinositidase C over regulation of adenylyl cyclase.
Signalling functions of a  i adrenergic receptor subtypes and the mechanism of G 
protein regulation were explored in chapter 4. oti adrenergic receptors have been known 
to stimulate the hydrolysis of inositol-containing phospholipids via interaction with 
pertussis toxin-insensitive G proteins of the Gq^Gn family with subsequent activation of 
phospholipase Cg activity [Wu et a l , 1992].
In cells expressing one of the rat aiA/D. the hamster aiB, and the bovine a i c  
adrenergic receptors, exposure to the « i  adrenergic receptor agonist phenylephrine resulted 
in stimulation of inositol phosphate production in a fashion that was resistant to 
pretreatment of the cells with pertussis toxin. Maintained exposure of these cells to 
phenylephrine resulted in down-regulation of each of the receptor subtypes which is a 
common regulatory feature and in selective downregulation of some combination of the a  
subunits of Gq/Gn.
Although the basic observation that maintained agonist activation of a GPCRs can 
cause a marked and selective reduction in cellular levels of the G protein(s) is now well 
established [Milligan, 1993] far less is known about the mechanisms responsible for such 
phenomena. Studies from Hadcock e ta l  [1990, 1991] have noted complex regulation of 
G proteins following receptor stimulation, including alterations in both protein and mRNA
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stability of a variety of G proteins, which is then integrated to result in upregulation of 
some G proteins and downregulation of others. By contrast, it was noted that m l 
muscarinic acetylcholine receptor-mediated downregulation of the G c/G na subunits was 
accompanied by a selective accelerated rate of degradation of these G proteins [Mitchell et 
d ., 1993].
In this sudy, 1 sought to further analyse such effects by examining the process of 
downregulation of the a  subunits of Gq and/or G n in Rat 1 cells transfected to express
aI
individual molecularly defined a i  adrenergic receptor subtypes. Agonist-mediated 
downregulation of the a  subunits of Gq/Gn has now been reported for a variety of 
receptors, including the muscarinic m l acetylcholine receptor [Mullaney et d ., 1993; 
Mitchell etal., 1993], the long isoform of the TRH receptor [Kim e ta l,  1994], and the 
GnRH receptor [Shah & Milligan, 1994]. However, only for the first of these has any 
mechanistic analysis been provided. In Chinese hamster ovary cells transfected to express 
the rat muscarinic m l receptor, accelerated degradation of a combination of G(^Gn was 
recorded without detectable alteration in levels of mRNA of either of these polypeptides
[Mitchell e? a/., 1993].
This study expanded those observations to show that in the genetic background of
Rat 1 fibroblasts, the basal half-life of the a  subunits of Gq^Gji can be adequately modeled 
as a single monoexponential consistent with t 0.5 in the region of 33-40h and that agonist 
occupancy of any of the a i  adrenergic receptor subtypes leads to a proportion of the 
cellular Gq/Gn population being degraded much more rapidly. Data from each of the 
systems, however, were not consistent with all of the cellular content of these G proteins 
being degraded more rapidly in the presence of agonist. A maximally effective 
concentration of phenylephrine was able to cause downregulation of between 50 and 70% 
of the total G t^/Gi la  population in these cells in a range of experiments.
Immunoblotting of membranes of the clones demonstrated that the steady-state 
levels of G n a  expression was over 2-fold higher than that of Gqa. Furthermore, they 
indicated that sustained phenylephrine occupany of each of the a i  adrenergic receptor 
subtypes resulted in a downregulation of both G n a  and G<^. The mechanism of this 
effect was a selective acceleration of the rate of degradation of these G proteins.
Signalling characteristics of a constitutively active mutant (CAM) aiB adrenergic 
receptor; its regulation of signalling cascade elements and the action of inverse agonists at 
this receptor were explored in chapter 5. Modifications of GPCRs which result in the 
receptors displaying agonist-independent second messenger regulatory capacity have been
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observed both by designed mutation in vitro [Samama et al., 1993, Pei et a l,  1994, 
Cotecchiaeta/., 1990, Kjelsberg e ta l, 1993] and in spontaneous mutations [Shenker et 
al., 1993, Parma etal., 1993, Raymond, 1994, Coughlin, 1994]. The CAM receptors 
have shown an increase in basal activity of the effector system coupled to that receptor in 
the absence of agonist.
It has been suggested that the CAM receptors could provide useful models of the 
conformational changes which must occur upon agonist binding to wild type receptors to 
allow efficient transmission of a signal via activation of heterotrimeric G proteins 
[Lefkowitz etal, 1993]. There is strong correlation between the level of expression of the i
GPCR and the amount of effector regulation [Milano e/a/., 1994, Adie & Milligan, 1994,
Chidiac eta l, 1994] and this has indicated that GPCRs must have the capacity to exist and 
spontaneously interconvert between a minimum of two states, an inactive ground-state 
conformation R and an active confonnation R* [Milano et d ., 1994, Samama et al., 1994,
Milli gan et al., 1995, Gether et al., 1995].
Although the CAMaiB adrenergic receptor was inherently able to produce this 
effect, addition of agonist potentiated this effect greatly, indicating that this form of the 
receptor did not function in a fully agonist-independent manner [Allen et a l ,  1991]. 
Similarly, although the degree of agonist-independent inositol phosphate generation 
produced by the CAMaiB adrenergic receptor was markedly greater than by the wild type 
receptor, the CAM receptor produced a further robust stimulation upon addition of agonist 
[Cotecchiae/fl/., 1995].
I explored whether the CAMaiB adrenergic receptor had the capacity to act more 
effectively than the wild type receptor and whether this CAMaiB adrenergic receptor had 
greater ability to downregulate Gqa/Gna than the wild type receptor upon sustained 
agonist treatment of Rat 1 fibroblasts expressing each of the receptors. Addition of the a i  
agonist phenylephrine produced a markedly greater degree of G protein downregulation in 
the cells expressing the CAMaiB adrenergic receptor than in those expressing the wild
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type receptor, despite of the fact that the CAMaiB adrenergic receptor was expressed at 
somewhat lower steady-state levels than the wild type receptor.
The CAMaiB adrenergic receptor showed a higher level generation of inositol 
phosphates in the absence of agonist than the wild type receptor, this was also true in 
response to maximally effective concentrations of agonist. The same was also true when 
phosphatidylbutanol generation by phospholipase D was measured. By contrast, there was 
little difference in the maximal ability of endothelin 1 to stimulate inositol phosphate 
generation and phosphatidylbutanol generation in the two cell lines indicating that it is an 
inherent property of the CAMaiB adrenergic receptor, rather than some undefined element 
of clonal cell line variation, which was responsible for the greater response to a i  agonists.
Certainly, no higher steady-state levels of Gqx or G n a  were detected in the 
CAMaiB adrenergic receptor expressing cells and thus it seems likely that the CAM 
receptor activates these G proteins with higher stoichiometry than the wild type receptor. 
Although the EC50 for agonist stimulation of inositol phosphate generation was greater 
than 100  fold lower in the CAMaiB adrenergic receptor expressing cells compared to 
those expressing the wild type receptor this was not true when agonist-mediated Gqa/Gna 
downregulation was measured. I do not have a ready explanation for these differences.
From the analysis of p%]pulse-chase experiments on immunoprecipitated 
Gqa/Gna the aiB adrenergic receptors showed only limited signalling capacity in the 
absence of agonist and indicated that the half-life of these proteins was very similar in the 
two cell lines in the absence of agonist. Addition of a maximally effective concentration of 
phenylephrine during the chase phase of the experiments resulted in an acceleration in the 
rate of degradation of G q x /G u a  in cells expressing both the wild type and the CAM 
receptor. The acceleration in the rate of degradation of Gqa/Gna was more pronounced 
with agonist occupancy of the CAM receptor and this may be primarily responsible for the 
greater degree of Gqa/Gna downregulation produced by agonist treatment of the 
CAMaiB adrenergic receptor expressing cells. However, it must be stated that this
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difference seems too limited to account for the very marked differences in G protein 
regulation observed.
There has been considerable recent attention given to the concept of inverse 
agonism because such ligands may be useful therapeutic agents in a range of clinical 
conditions [Lefkowitz e/fl/., 1993; Bond a/., 1995; Milligan e?a/., 1995]. CAM variants 
of GPCRs have represented at least a partial model of the activated [R*] state of a receptor.
The activity of the a i  adrenergic inverse agonist phentolamine has assessed in cells 
expressing either the wild type or CAMaiB adrenergic receptor. The sustained presence of 
phentolamine in the CAMaiB adrenergic receptor expressing cells caused a dramatic
upregulation of levels of this receptor, but not those expressing the wild type receptor. An 
increase in levels of the CAMaiB adrenergic receptor was also observed in response to 
HV-723, YM 12617, corynanthine, 5 methyl urapidil and WB 4101 following sustained 
treatment of cells.
As it was expected, phentolamine-mediated upregulation of the CAMaiB 
adrenergic receptor levels was accompanied by a substantial increase in the maximal 
phosphoinositidase C as well as phospholipase D activity in response to agonist in a 
concentration-dependent manner. Unlike other effector enzymes, e.g. adenylyl cyclase, 
this may reflect that phosphoinositidase C and phospholipase D are not the quantitatively 
limiting protein components on these signalling cascades. This provided a useful system to 
overcome low basal enzyme activity for the detection of inverse agonists since the increase 
in the CAMaiB adrenergic receptor levels in response to phentolamine caused an increase 
in the basal level of phospholipase D activity. All of the tested a i  antagonists appeared to 
be clearly capable of acting as inverse agonists at this CAMaiB adrenergic receptor as 
measured by their ability to inhibit phentolamine-stimulated basal phospholipase D activity.
This study, therefore, provides a basis to suggest that upregulation of CAM GPCRs may 
be a simple approach for the screening and detection of novel inverse agonist ligands.
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